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Abstract 
 
Peptide YY (PYY) is a hormone produced by the enteroendocrine L cells in the gut. It is also 
expressed in the pancreatic islets and brainstem. PYY is secreted from the L cells in 
proportion to caloric intake and is involved in the regulation of satiety and energy 
homeostasis. The physiological role of PYY in the pancreatic islets and brainstem is not 
clear. 
In order to investigate the physiological role of PYY-expressing cells, I used a transgenic 
mouse model in which diphtheria toxin receptor (DTR) is expressed downstream of the PYY 
promoter. This enabled ablation of the PYY-expressing cells following administration of 
diphtheria toxin (DT) in adult mice. Intraperitoneal administration of DT at a dose of 40ng/g 
resulted in a significant loss of colonic, pancreatic and brainstem PYY (> 95%). 
Interestingly, ablation of PYY-expressing cells resulted in a significant loss of pancreatic 
insulin and hence severe hyperglycaemia in adult mice. In vitro administration of DT in 
cultured islets resulted in a significant dose-dependent loss of insulin, PYY and glucagon 
content. Immunohistochemical distribution of DTR was shown to be limited to the periphery 
of the islet, where PYY is also expressed. These experiments suggest that a product of the 
PYY-expressing cells may provide a paracrine factor essential for beta cell viability. 
Replacement of PYY using twice-daily subcutaneous injection of a long-acting PYY 
analogue (X-PYY) prevented the development of diabetes and reduced the loss of 
pancreatic insulin content.  Administration of the analogue also reduced insulin loss in 
streptozotocin-treated mice. These studies suggest that PYY may be an important signal for 
beta cell maintenance. These findings have important implications for identifying novel 
therapies for prevention of beta cell loss in diabetes mellitus. 
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1 General Introduction 
 
1.1 The Obesity Health Crisis 
Obesity constitutes a major global healthcare challenge. Obesity received epidemic status 
from the World Health Organisation in 2000 (WHO, 2000). The prevalence of obesity has 
increased significantly over the last two decades. It has been estimated that with the recent 
trends in adult obesity continuing, about a third of all adults in England (almost 13 million 
individuals) will be obese by 2012 (Zaninotto et al. 2009). 
The morbidity, mortality, and socioeconomic costs of obesity are considerable. Obesity is the 
most important risk factor for the development of type 2 diabetes, with its attendant 
microvascular and macrovascular risks (J. M. Chan et al. 1994). Overweight and obesity are 
independently linked to an increased risk of cardiovascular disease, as well as contributing 
to other established risk factors such as hypertension and dyslipidaemia (Dhaliwal and 
Welborn 2009; Dyer et al. 1990; Nieves et al. 2003).  
In addition, obesity has been linked to development of various malignancies, obstructive 
sleep apnoea, musculoskeletal disorders, infertility, depression and numerous other 
morbidities (Kopelman 2000). The economic costs of treating the obesity epidemic are 
substantial. In the UK, management of obesity and its associated conditions cost the NHS 
an estimated 1.2 billion pounds per year (House of Commons Health Committee, 2004). 
Currently there is only one anti-obesity drug available in the UK: orlistat, the clinical use of 
which is limited by adverse effects and modest efficacy (Thearle and Aronne 2003). 
Understanding the physiological systems regulating appetite and energy homeostasis may 
identify novel targets for treatment of obesity and its related co-morbidities. 
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1.2 Neuroendocrine Control of Appetite 
The hypothalamus and the brainstem are the main central nervous system regions 
responsible for the regulation of energy homeostasis.  These brain areas receive peripheral 
neural and hormonal signals that relay information about acute nutritional state and adiposity 
(Murphy and Bloom 2006).  Neural afferents and hormonal signals from the periphery are 
integrated with higher brain centre signals (e.g. relaying reward drive and mood) to regulate 
appetite and control energy expenditure (M. W. Schwartz et al. 2000). 
The arcuate nucleus (ARC) of the hypothalamus is believed to play a crucial role in the 
regulation of food intake and energy homeostasis. The ARC contains two populations of 
neurons with opposing effects on food intake. Medially located orexigenic neurons (i.e. those 
stimulating appetite) express neuropeptide Y (NPY) and Agouti-related protein (AgRP). 
Anorexigenic neurons (i.e. those inhibiting appetite) in the lateral ARC express alpha-
melanocyte-stimulating hormone (alpha-MSH) derived from pro-opiomelanocortin (POMC), 
and cocaine- and amphetamine-regulated transcript (CART).   
The ARC is adjacent to the median eminence, a ‘circumventricular organ’ with fenestrated 
capillaries and hence an incomplete blood brain barrier. Circulating hormones can therefore 
influence the activity of the arcuate nucleus neurons directly, after passing across the 
median eminence (M. W. Schwartz et al. 2000). Gut hormones, released from the 
gastrointestinal tract on a meal to meal basis, signal short term nutrient availability to the 
ARC (Chaudhri et al. 2008). Other circulating factors such as insulin and leptin (a circulating 
adipokine released from adipose tissue) relay information about long-term energy stores 
(Porte et al. 2002).  
Gastrointestinal vagal afferents are activated by mechanoreceptors and chemoreceptors, 
and converge in the nucleus of the tractus solitarius (NTS) of the brainstem. Neuronal 
projections from the NTS, in turn, carry signals to the hypothalamus. Circulating factors such 
19 
 
as gut hormones may influence the NTS neurons through the adjacent circumventricular 
organ, the ‘area postrema’ (AP). Gut hormones also alter the activity of the ascending vagal 
pathways from the gut to the brainstem (Jobst et al. 2004). The vagal efferents projecting 
from the NTS to the gastrointestinal tract, complete the gut-brain reflex circuit which 
modulates digestive functions (G. J. Schwartz 2000). 
Hence, the hypothalamic ARC orexigenic and anorexigenic neurons are influenced by 
numerous neuronal and endocrine inputs. These ARC neurons in turn project to a number of 
extra-hypothalamic and intra-hypothalamic regions, including in particular the hypothalamic 
paraventricular nucleus (PVN), where some of the important efferent pathways regulating  
energy expenditure arise. 
1.3 Bariatric Surgery 
The most effective treatment currently available for obesity is bariatric surgery. Bariatric 
surgery achieves substantial weight loss and a decrease in overall mortality (Adams et al. 
2007; Sjostrom et al. 2007). Several surgical procedures are used to achieve weight loss. 
The two most widely performed forms of bariatric surgery are illustrated in figure 1.1. Gastric 
banding restricts the amount of food that can be comfortably ingested and increases the 
satiating effect of food (Dixon et al. 2005). A more efficient reduction in appetite and weight 
loss is seen with surgical procedures that involve gastrointestinal bypass, such as Roux-en-
Y Gastric bypass (RYGB) (Adams et al. 2007; Kenler et al. 1990; Sjostrom et al. 2007).  
A significant difference in the effects of different forms of bariatric surgery on type 2 diabetes 
has been shown (Gan et al. 2007). RYGB ameliorates coexistent type 2 diabetes mellitus 
before substantial weight loss has occurred and more rapidly than gastric banding (Medeiros 
and Turner 1994).  
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Figure 1.1. A. Adjustable gastric banding: a rigid ring incorporating a fluid-filled reservoir is 
placed around the entrance to the stomach, which restricts gastric volume and outflow.  
B. Roux-en-Y gastric bypass (RYGB): A small stomach pouch is divided from the remainder 
of the stomach, with drainage of food to the rest of the gastrointestinal tract via a small 
gastrojejunal anastomosis and a Roux-en-Y small bowel arrangement. 
 
A 
   B 
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Weight loss is normally associated with reduced plasma levels of the adipocyte-derived 
anorectic hormone leptin, causing increased hunger (J. L. Chan et al. 2003). However, 
following RYGB, despite significant reductions in body weight and leptin levels, appetite is 
markedly reduced (Kenler et al. 1990). Determining the mechanisms behind this sustained 
reduction in appetite may identify pathways that can be targeted by anti-obesity agents. The 
differences between gastric banding and RYGB may be due to alterations in the anorectic 
and incretin gut hormone profile that is seen following RYGB, but not following gastric 
banding (Kellum et al. 1990; le Roux et al. 2006). Experimental evidence suggests that these 
anorectic gut hormones may mediate the effects of RYGB on appetite and body weight (le 
Roux et al. 2006; le Roux et al. 2007). Post-prandial PYY and GLP-1 levels begin to rise as 
early as 2 days following gastric bypass in humans (le Roux et al. 2007). Inhibiting gut 
hormone release with somatostatin analogue octreotide increases the food intake after 
gastric bypass surgery but not following gastric banding (le Roux et al. 2007).  
1.4 Anorectic Gut hormones 
The gastrointestinal tract is the body's largest endocrine organ and releases more than 20 
different regulatory peptide hormones that influence a number of physiological processes. 
Gut hormones act on tissues such as exocrine glands, smooth muscle and the peripheral 
nervous system (Murphy and Bloom 2006). The release of gut hormones such as peptide 
tyrosine tyrosine (PYY), glucagon-like peptide-1 (GLP-1), and oxyntomodulin (OXM) is 
stimulated by distension of the stomach and interactions between nutrients and the luminal 
wall of the intestine (Adrian et al. 1985b; Le Quellec et al. 1992).  
Gut hormones are believed to contribute to the short-term feelings of satiety and hunger 
(Badman and Flier 2005). These peptides may reduce food intake by decreasing 
hypothalamic orexigenic signalling, and increasing anorectic signalling (Batterham et al. 
2002; Jobst et al. 2004). Another effect of these peptides is to mediate inhibitory feedback 
mechanisms on intestinal transit, contributing to prolonged gastric distension, and increased 
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satiety between meals (H. C. Lin et al. 1996; Wen et al. 1995). The combined CNS effects 
and ‘intestinal brake’ mechanisms, mediated by gut peptides such as cholecystokinin (CCK), 
PYY, GLP-1 and OXM, facilitate the control of food intake and postprandial transit through 
the gastrointestinal tract. The possible mechanisms for the anorectic effects of gut hormones 
are summarized in Figure 1. 2. 
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Figure 1.2. PYY3–36, GLP-1 and OXM are released from gut L cells after a meal. They can 
directly stimulate anorectic pathways in the hypothalamus and brainstem, and may also act 
through the vagus nerve. The ARC is important in integrating gut hormone energy 
homeostasis signals. NPY/AgRP neurons and POMC neurons signal to the PVN and other 
hypothalamic nuclei to increase or decrease appetite, respectively. Adapted from (Murphy 
and Bloom 2006). 
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1.4.1 Peptide Tyrosine Tyrosine (PYY) 
 
PYY, like NPY and PP, belongs to the ‘PP-fold’ family of proteins. These peptides are 36 
amino acids in length and share a common tertiary structural motif known as the PP-fold. C-
terminal amidation of these proteins is a necessary requirement for biological activity. PYY 
exists endogenously in two forms: PYY1-36 and PYY3-36 (Grandt et al. 1994a). The enzymatic 
cleavage of secreted PYY1-36 at the amino terminal by the cell surface enzyme dipeptidyl 
peptidase IV (DPP-IV) gives rise to PYY3-36 (Medeiros and Turner 1994). Most circulating 
PYY immunoreactivity is in the form of PYY3-36. PYY1-36 and PYY3-36 exert their effects 
through the Y family of receptors (Larhammar 1996). PYY1-36 binds with similar affinity to all 
of the Y receptors. PYY3-36 is a selective high affinity agonist at the Y2 receptor subtype 
(Grandt et al. 1994b). 
Low levels of PYY are detected in the stomach, and levels increase distally along the small 
and large intestine, reaching their highest levels in the colon and rectum (Adrian et al. 
1985b). PYY is released post-prandially from enteroendocrine L cells lining the distal GI 
tract, in proportion to caloric intake (Adrian et al. 1985b). Endogenous concentrations of PYY 
levels are low in the fasting state and rise within 30 minutes of a meal. In humans, circulating 
levels plateau at 1-2 hours following a meal, and remain elevated for up to 6 hours 
(Batterham et al. 2003a).  
Peripheral administration of PYY3-36 reduces food intake and weight gain in rodents 
(Batterham et al. 2002; Challis et al. 2003; Chelikani et al. 2005; Vrang et al. 2006). Although 
there was initial controversy regarding the effects of PYY3-36 on food intake (Tschop et al. 
2004), many groups have subsequently validated its anorectic effects (Batterham et al. 
2002; Challis et al. 2003; Chelikani et al. 2005; Vrang et al. 2006). The demonstration of the 
anorectic effects is dependent upon the full acclimatization of the animals to the handling 
and injection procedures, and is lost in the presence of even mild stressors (Abbott et al. 
2006; Halatchev et al. 2004). This is because stress can reduce baseline food intake, 
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making it difficult for anorectic agents to further suppress appetite. Intravenous 
administration of PYY inhibits food intake in humans and it is equally effective in normal and 
obese subjects (Batterham et al. 2003a).  
The Y2R is an auto-inhibitory pre-synaptic receptor found on NPY neurons within the ARC 
(Broberger et al. 1997). PYY3–36 does not have an anorectic effect in Y2R deficient mice 
(Batterham et al. 2002) and the anorectic effects of PYY3–36 are attenuated by Y2R 
antagonists (Abbott et al. 2005a).  
Peripheral administration of PYY3–36 has been shown to increase c-fos expression in the 
ARC (Batterham et al. 2002). As discussed in section 1.2, the ARC contains two neuronal 
populations, orexigenic NPY/AgRP, and anorectic POMC/CART neurons. There is 
conflicting data regarding the effects of PYY3–36 on these neurons. Peripheral PYY3–36 has 
been reported to decrease expression and release of NPY whilst activating POMC neurons 
(Batterham et al. 2002). However, other investigators have reported that PYY3–36 inhibits 
POMC neurons via postsynaptic Y2 receptors (Ghamari-Langroudi et al. 2005). Moreover, 
Pomc knockout mice maintain their acute anorectic response to peripherally administered 
PYY3–36, suggesting that POMC is not critical to the inhibitory effects of PYY3–36 on feeding. 
PYY3–36 is thought to reduce food intake through activation of the Y2 receptor subtype (Y2R).  
PYY is present in myenteric nervous plexus neurons innervating the gastrointestinal tract 
and the Y2 receptor has been identified on the vagus nerve (Koda et al. 2005). A vagal 
brainstem mediated pathway may also be involved in the actions of circulating PYY3–36. The 
effects of peripheral administration of PYY3–36 on both food intake (Abbott et al. 2005b; Koda 
et al. 2005), and on the activation of ARC feeding neurons, are abolished following bilateral 
sub-diaphragmatic total truncal vagotomy or transectioning of the brainstem–hypothalamic 
pathway in rodents (Abbott et al. 2005b). 
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PYY has been shown to have an effect on intestinal motility. Close intra-arterial 
administration of PYY in cats causes an inhibition of jejunal and colonic motility (Lundberg et 
al. 1982). PYY also delays gastric emptying, decreases pancreatic secretions, and increases 
absorption of fluids and electrolytes from the ileum in humans (Savage et al. 1987; 
Symersky et al. 2005). It is possible that some of the anorectic effects of PYY may be 
mediated by the gastric distension secondary to delayed gastric emptying. 
Interestingly, it has recently been shown that acute effects of gastrointestinal bypass surgery 
on body weight are lost in PyyKO mice (Chandarana et al. 2011). Wild-type mice losing 
weight after gastrointestinal bypass surgery exhibit increased colonic Pyy expression and 
circulating fasting PYY levels (Chandarana et al. 2011). This suggests that PYY plays a key 
role in mediating the early weight loss that occurs following gastrointestinal bypass surgery. 
1.4.2 Glucagon-like peptide-1 (GLP-1) 
GLP-1 is a 30 amino acid peptide resulting from cleavage of the preproglucagon precursor 
molecule (Dhanvantari et al. 1996). The two bioactive forms of GLP-1, GLP-1 7-37 and GLP-1 
7-36 amide, are released into the circulation post-prandially from L cells of the gastrointestinal 
tract (Herrmann et al. 1995). Physiologically, GLP-1 is an important incretin, stimulating 
glucose-dependent insulin release (MacDonald et al. 2002). GLP-1 also inhibits the 
secretion of glucagon, thereby inhibiting endogenous glucose production (Willms et al. 
1996). The net effect is to reduce blood glucose following a meal. 
The GLP-1 receptor is present in a number of brain regions implicated in the control of 
appetite, including the ARC, PVN, SON, and AP (Shughrue et al. 1996). Both peripheral and 
central administration of GLP-1 reduce food intake in rats (Tang-Christensen et al. 2001; 
Turton et al. 1996). Chronic administration of GLP-1 reduces weight gain in rodents (Meeran 
et al. 1999). The intravenous administration of GLP-1 to normal and obese humans dose 
dependently decreases food intake (Verdich et al. 2001) and gastric emptying (Naslund et al. 
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1999; Nauck et al. 1997). These effects are thought to be mediated through vagal and 
brainstem pathways.  Peripheral administration of GLP-1 activates neurons within the 
brainstem in rats (Imeryuz et al. 1997). This increase in neuronal activity, and the anorectic 
effects of GLP-1, are abolished following vagotomy in rodents (Abbott et al. 2005b; Imeryuz 
et al. 1997). 
GLP-1 is rapidly degraded in the circulation, but longer acting GLP-1 mimetics have been 
developed as new treatments for type 2 diabetes (Joy et al. 2005). Exendin-4 is a naturally 
occurring GLP-1 mimetic isolated from the venom of Heloderma Suspectum, a lizard native 
to several southwestern American states (Eng et al. 1992). A truncated form of this peptide, 
exendin 9–39, acts as a competitive antagonist at the GLP-1 receptor. Acute 
intracerebroventricular administration of exendin 9–39 increases food intake, and chronic 
administration increases body weight in rats (Meeran et al. 1999; Turton et al. 1996). 
Endogenous peripheral GLP-1 may physiologically reduce appetite and food intake after a 
meal. However, GLP-1 receptor knockout mice do not have altered food intake or body 
weight (Drucker 2006). This may be because developmental changes compensate for the 
lack of GLP-1 signalling, or may reflect that GLP-1 has a more important physiological role in 
controlling blood glucose than in regulating food intake.  
The discovery of exendin-4 has led to the development of a synthetic version, exenatide. 
Exenatide has a much longer in vivo half-life than GLP-1 and is the first incretin mimetic 
approved for the treatment of type 2 diabetes (Drucker and Nauck 2006).  Exenatide is 
effective at stimulating insulin release, suppressing glucagon and lowering blood glucose. 
Clinical trials have demonstrated that exenatide (marketed as Byetta) is useful in the 
regulation of glucose homeostasis in patients with type 2 diabetes mellitus. Exenatide has 
also been shown to reduce body weight in treated diabetics in phase III clinical trials (Buse 
et al. 2004; DeFronzo et al. 2005; Kendall et al. 2005). The weight loss associated with 
exenatide is considered a significant advantage as many anti-diabetic treatments are 
28 
 
commonly associated with weight gain. Nausea is a relatively common side effect of the 
treatment. However, it does not seem to be intrinsically linked to the effects on appetite 
(Murphy and Bloom 2006). 
1.4.3 Oxyntomodulin (OXM) 
OXM is also a product of the preproglucagon precursor molecule.  It is a 37 amino acid 
peptide released post-prandially from L cells in proportion to caloric intake (Le Quellec et al. 
1992). OXM delays gastric emptying and gastric acid secretion (Schjoldager et al. 1989). 
Acute central and peripheral administration of OXM decreases food intake, and chronic 
administration decreases weight gain, in rodents (Dakin et al. 2001; Dakin et al. 2004). In 
addition, chronic administration of OXM causes rats to lose more weight than pair-fed 
controls, suggesting that it increases energy expenditure (Dakin et al. 2002). OXM also 
reduces food intake in normal weight human volunteers when administered intravenously or 
subcutaneously (Cohen et al. 2003). OXM given preprandially to obese subjects reduces 
both food intake and body weight (Wynne et al. 2005). As in rats, there is evidence that OXM 
increases energy expenditure in humans (Wynne et al. 2006).  
The anorectic effects of OXM are abolished in GLP-1 receptor knockout mice (Schjoldager 
et al. 1989) and in the presence of the GLP-1 receptor antagonist exendin 9-39 (Dakin et al. 
2004), suggesting that OXM acts via the GLP-1 receptor. However, OXM has a roughly 50-
fold lower affinity for the GLP-1 receptor than GLP-1, but reduces food intake with similar 
potency (Dakin et al. 2001). Furthermore, although the administration of exendin 9-39 
directly into the ARC blocks the anorectic effects of OXM, it does not block those of GLP-1 
(Dakin et al. 2004). Therefore, it is possible that OXM may act via an as yet unidentified 
receptor or a specific subpopulation of the GLP-1 receptor.  
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1.4.4 Cholecystokinin (CCK) 
CCK is released post-prandially from the small intestine (Murphy and Bloom 2006). 
However, CCK has also been shown to co-localise with PYY in L cells (Roth et al. 1992). 
Two types of CCK receptor have been identified in the CNS and peripheral tissues. CCK1 
receptors are present in peripheral tissues such as the pancreas, gallbladder, and on vagal 
afferent nerve fibres innervating the gut (Moran and Kinzig 2004). Within the CNS, CCK1 
receptors have been identified in areas involved in the regulation of food intake such as the 
NTS, AP, and dorsomedial hypothalamus (Moran et al. 1986). The CCK2 receptor has been 
identified in the cortex, hypothalamus, vagal afferents and gastric mucosa (Moran et al. 
1986). 
CCK is released post-prandially in response to saturated fat, long-chain fatty acids, and the 
amino acids and small peptides that would normally result from protein digestion (Liddle et 
al. 1985; Rehfeld et al. 2003). Postprandial secretion of CCK triggers the release of 
pancreatic enzymes, and of bile salts from the gallbladder, into the duodenum, promoting 
protein and fat digestion (Liddle et al. 1985; Rehfeld et al. 2003). CCK also regulates other 
gastrointestinal functions including gastric emptying. 
The effects of CCK on appetite are well documented. Peripheral administration of CCK in 
rodents results in a dose dependant reduction in food intake, decreasing both meal size and 
duration (Antin et al. 1975). The Otsuka Long-Evans Tokushima Fatty rat, which lacks the 
CCK1 receptor, is hyperphagic and obese, suggesting that CCK has a physiological role in 
the regulation of food intake (Bi and Moran 2002). However, CCK1 receptor knockout mice 
do not differ significantly in body weight from wild types (Kopin et al. 1999). It has been 
reported that endogenous circulating concentrations of CCK cannot activate the vagal 
circuits, suggesting that the actions of CCK on food intake might be paracrine or neurocrine 
rather than endocrine (Moran 2000). CCK administration is also associated with an increase 
in postprandial satiety behaviours such as increased grooming and decreased locomotor 
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activity (Antin et al. 1975). Intravenous administration of physiological doses of CCK reduces 
food intake and increases the perception of fullness in humans (Lieverse et al. 1995). 
However, the therapeutic potential of CCK as a treatment for obesity is limited by nausea 
and the decreased sensitivity to the anorectic effects associated with chronic administration 
(Covasa et al. 2001). 
1.4.5 Neurotensin (NT) 
Neurotensin (NT) is a 13 amino acid peptide first isolated from bovine hypothalamic extracts. 
NT is expressed in neurons throughout the central and peripheral nervous systems. 
However, the majority of NT is found within enteroendocrine cells of the GI tract (Carraway 
and Leeman 1976). NT has an important role in the structure and function of the GI tract. NT 
regulates a number of digestive processes, including gastric and small and large bowel 
motility, and pancreatic and biliary secretion (Kitabgi 2006). NT also has trophic effects on 
the pancreas, small intestine, and colon (Evers et al. 1992).  
Plasma levels of NT increase after meal, with intraluminal fat being the most potent stimulus 
(Rosell and Rokaeus 1979), suggesting that it may act as a satiety signal. However 
endogenous NT is rapidly degraded following its release. This suggests that physiological 
levels are unlikely to play a role in appetite regulation (Sandoval and Kulkosky 1992). 
Furthermore, although CNS administration of NT decreases food intake in rodents, only 
supraphysiological doses decrease food intake and grooming behaviour following peripheral 
administration (Sjolund et al. 1983). 
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1.4.6 Pancreatic polypeptide (PP) 
Pancreatic polypeptide (PP) is secreted mainly by a group of cells located at the periphery of 
the pancreatic islets of Langerhans (Adrian et al. 1976; Ekblad and Sundler 2002).  The 
functions of PP in regulating gallbladder motility and pancreatic secretions have been well 
characterized (Adrian et al. 1976; Adrian et al. 1979; Greenberg et al. 1979). PP has been 
shown to augmented basal insulin and glucagon release in rats (Szecowka et al. 1983). It 
has been suggested that PP may potentially exert direct paracrine effects on the pancreatic 
alpha and beta cells (Szecowka et al. 1983).  
PP binds to all the all members of the Y receptor family, but has the highest affinity for the Y4 
receptor subtype (Michel et al. 1998). PP has been implicated in the regulation of energy 
homeostasis. Similar to the anorectic intestinal peptides, PP is secreted in proportion to 
caloric intake and circulating levels remain elevated for up to 6 hours post-prandially (Adrian 
et al. 1976). PP also levels follow a circadian rhythm (Track et al. 1980). 
Intraperitoneal injection of PP acutely reduces food intake in fasted mice (Asakawa et al. 
2003). This effect remains apparent for 24 hours after injection. Furthermore, chronic 
administration of PP over 6 days in obese ob/ob mice significantly reduces body weight gain 
and improves glucose profile. Exogenous PP has also been shown to increase oxygen 
consumption (Asakawa et al. 2003), and thus part of the effect of PP on body weight may be 
due to increased energy expenditure. PP-over-expressing mice with supraphysiological PP 
concentrations have reduced food intake and are lean (Asakawa et al. 2003). 
The effects of PP are likely to be mediated by both the hypothalamus and brainstem 
(Asakawa et al. 2003). Y4 receptor mRNA has been shown to be present in the appetite-
regulating areas of the brainstem and in the ARC (Larsen and Kristensen 1997; Parker and 
Herzog 1999). It has been suggested that inhibition of food intake by PP may be secondary 
to an effect on gastric emptying. However, whilst some investigators have reported PP to 
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inhibit gastric emptying, others have failed to show this (Adrian et al. 1981; Batterham et al. 
2003b; P. T. Schmidt et al. 2005). Furthermore, the anorectic effects of PP in humans 
appear to be independent of changes in gastric motility (Batterham et al. 2003b). 
Patients with Prader-Willi syndrome, characterized by hyperphagia and morbid obesity, have 
abnormal patterns of PP secretion (Zipf et al. 1981). Administration of PP in both patients 
with Prader-Willi syndrome and healthy lean subjects reduces appetite (Batterham et al. 
2003b; Berntson et al. 1993). As seen in experiments with mice, the anorexigenic effects of 
PP in humans persist for 24 hours after intravenous infusion (Batterham et al. 2003b). 
1.4.7 Other gut peptides 
A number of other gut-derived peptides have been shown to reduce food intake. However, 
the physiological role of these peptides in the regulation of food intake and energy 
homeostasis remains unclear.  
ICV injection of glucagon-like peptide-2 (GLP-2) into rats inhibits food intake. In contrast, 
GLP-2 administered peripherally does not inhibit food intake in rodents or humans (P. T. 
Schmidt et al. 2003; Scott et al. 1998). GLP-2 appears to play a more important 
physiological role as an intestinal growth factor (Scott et al. 1998). 
Amylin is a peptide co-secreted with insulin by pancreatic beta cells. Injection of amylin or 
amylin agonist has been shown to reduce food intake in a number of species, including 
humans (Chance et al. 1993; Lutz et al. 1994; Ratner et al. 2005; Rushing et al. 2000; 
Whitehouse et al. 2002). The amylin agonist pramlintide has been shown to cause weight 
loss in diabetic humans (Ratner et al. 2005; Whitehouse et al. 2002). 
Vasoactive intestinal polypeptide (VIP) has been shown to reduce appetite, in addition to its 
well-characterized effects on the cardiovascular system and gastrointestinal motility and 
secretion. Peripheral administration of VIP into rodents suppresses food intake (Kulkosky et 
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al. 1989). ICV administration into mammals and chicks also reduces food intake (Olszewski 
et al. 2003; Tachibana et al. 2003). 
1.5 Enteroendocrine cells of the gastrointestinal tract 
There are at least 15 different types of enteroendocrine cells diffusely distributed throughout 
the gastrointestinal epithelium (Sjolund et al. 1983). These cells produce and release a 
variety of hormones and signalling molecules and together constitute the largest endocrine 
organ in the body (Cheng and Leblond 1974; Sjolund et al. 1983). The GI enteroendocrine 
cells are characterised by factors such as the morphology of secretary granules and the 
nature of their endocrine products. 
1.5.1 Enteroendocrine cell morphology 
The ultrastructure of enteroendocrine cells is characterised by the presence of dense 
hormone filled granules at the base of the cell. These cells are generally wider at the base 
than at the apex. Chemosensing of gut luminal contents by the enteroendocrine GI cells 
plays a critical role in the control of functions such as digestion, pancreatic secretion, food 
intake, and metabolic regulation. Evidence that endocrine cells can directly sense luminal 
contents has been demonstrated in PYY and GLP-1 expressing L cells. It has been shown 
that both human and rodent intestinal L cells express receptors previously identified in the 
oral epithelium for detecting sweet (T1R2 and T1R3) and bitter sensation (T2R), as well as 
amino acids (T1R1 and T1R3) (Jang et al. 2007; Rozengurt et al. 2006). The presence of 
these taste receptors may indicate that a molecular sensing mechanism, similar to that 
identified in the oral epithelium, exists in the GI tract, and that these cells detect changes in 
the chemical composition of luminal contents and react appropriately (Rozengurt et al. 
2006). The gustducin G protein associated with these taste receptors has also been 
identified in L cells of the gut (Jang et al. 2007; Rozengurt et al. 2006).  The activation of 
these receptors leads to an increase in intracellular calcium level (Rozengurt et al. 2006), 
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which is typically associated with vesicular movement and release of peptide containing 
vesicles from enteroendocrine cells (Rozengurt et al. 2006). The presence of the sweet taste 
receptor subunit T1R3 and gustducin may also underlie a luminal glucose sensing 
mechanism, since activation of these receptors mediates the postprandial release of GLP-1 
from intestinal L cells (Jang et al. 2007). The short-chain fatty acid receptors GPR43 and 
GPR41 have also been shown to be expressed in PYY-containing enteroendocrine L cells 
(Karaki et al. 2006; Tazoe et al. 2009). The enteroendocrine L cells therefore have the 
capacity to integrate complex nutrient sensing in the gut. 
In addition to chemical stimulation, the endocrine cells of the gut also respond to neural and 
physical stimulation of the cell by releasing peptide containing granules at the basolateral 
side of the cell (Cummings and Overduin 2007). These peptides can have an endocrine role, 
a local paracrine role, and/or activate receptors present on nerves innervating the GI 
mucosa (Cummings and Overduin 2007).  
1.5.2 Development of enteroendocrine L cells 
L cells are derived from multipotent stem cells, located towards the base of the intestinal 
crypts. These stem cells give rise to the four main types of epithelial cells: absorptive 
columnar enterocytes, mucus producing goblet cells, enteroendocrine cells, and lysozyme 
producing paneth cells (Cheng and Leblond 1974). The different enteroendocrine cell 
subpopulations are constantly re-established by the differentiation of enteroendocrine cells 
arising from the stem cells. The majority of enteroendocrine cells undergo terminal 
differentiation as they migrate up from the crypts to the epithelial surface (Tsubouchi and 
Leblond 1979). However, exactly how stem cells are committed to differentiate into a 
particular enteroendocrine cell is not completely understood (Potten and Loeffler 1990). The 
PYY progenitor cells can go through several rounds of cell division before terminally 
differentiating (Potten and Loeffler 1990). The migration, differentiation and exfoliation of 
enterocytes and goblet cells is completed in approximately three to five days (Tsubouchi and 
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Leblond 1979). Enteroendocrine cells in colonic crypts are bound to adjacent cells by 
junctional complexes. However, as the enteroendocrine cells migrate towards the epithelial 
surface these junctional connections are lost, leading to independent and slow migration of 
these cells. This prolongs enteroendocrine cell turnover to approximately 23 days 
(Tsubouchi and Leblond 1979).  
Immunohistochemical studies have shown that enteroendocrine cells frequently express two 
or more products. PYY has been shown to co-localise with GLP-1, NT, and CCK secreting 
cells in the colon (Roth et al. 1992). Approximately 50% of CCK, and NT cells co express 
PYY (Roth et al. 1992). Substance P/serotonin cells are commonly found in the same crypts 
as PYY/GLP-1/CCK/NT cells. Most of these substance P cells contain serotonin. However, 
co-expression of substance P/serotonin in the same cells as PYY/GLP-1/CCK/NT is only 
rarely observed (Roth et al. 1992). This suggests the existence of two separate branches of 
enteroendocrine L cell differentiation, with one branch resulting in cells producing substance 
P and serotonin, and the other resulting in GLP-1, PYY, NT, and CCK producing cells (Roth 
et al. 1992).  
1.6 PYY in the pancreatic islets of Langerhans 
In addition to the enteroendocrine L cells, PYY is also present in the pancreas in several 
mammals, as evident by immunochemical analysis and immunocytochemistry (Ali-Rachedi 
et al. 1984; Bottcher et al. 1989; Bottcher et al. 1993; el-Salhy et al. 1987; Miyachi et al. 
1986). 
The pancreas appears to be the major site of PYY expression in the foetus, where PYY 
mRNA expression exceeds colonic PYY expression (Krasinski et al. 1991). In rat foetuses, 
PYY-immunoreactive cells are first demonstrated at the seventeenth day of gestation (el-
Salhy et al. 1987). The abundance of PYY mRNA in the pancreas falls rapidly after birth 
(Krasinski et al. 1991). Similarly, the concentration of human foetal pancreatic PYY declines 
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with age, in contrast to glucagon levels which remain constant throughout the same foetal 
period (Ali-Rachedi et al. 1984).  
PYY immunoreactivity is present in all pancreatic endocrine cell types before birth (Jackerott 
et al. 1996). However, in the adult murine pancreas, PYY immunoreactivity has been 
demonstrated in a major subpopulation of alpha cells (glucagon-expressing), and in a 
subpopulation of the delta (somatostatin-expressing) and PP cells (Bottcher et al. 1989; 
Bottcher et al. 1993; Jackerott et al. 1996). PYY-expressing cells are usually located at the 
periphery of the islets (Bottcher et al. 1989).  
PYY administration has not been shown to influence basal plasma levels of insulin, 
glucagon, or glucose in in vivo experiments (Bottcher et al. 1989). However, insulin secretion 
stimulated by glucose or the cholinergic agonist carbachol is inhibited by PYY (Bottcher et al. 
1989). Similarly, at high doses PYY inhibits arginine-induced secretion of both insulin and 
glucagon in rats (Szecowka et al. 1983). PYY has been shown to antagonize beta-
adrenergic-stimulated release of insulin in dogs (Greeley et al. 1988). PYY also inhibits 
carbachol-induced glucagon secretion (Bottcher et al. 1989). In summary, PYY appears to 
inhibit stimulated insulin and glucagon secretion.  
1.7 PYY in the brainstem 
Neurons expressing PYY mRNA have been reported to be present in the brainstem. 
Specifically, PYY-immunoreactive cell bodies have been localized exclusively to the 
gigantocellular reticular nucleus (Gi) of the rostral medulla in the mouse, rat, and monkey 
(Glavas et al. 2008). PYY-immunoreactive fibres from these cells extend to the nucleus of 
the solitary tract and the dorsal motor nucleus of the vagus (Glavas et al. 2008). These 
regions play are important to regulation of food intake.  
Orexigenic orexin and melanin concentrating hormone (MCH) fibres make close appositions 
with PYY cell bodies in the Gi (Glavas et al. 2008). This distribution pattern suggests that 
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brainstem PYY neurons may play a role in energy homeostasis. However, the physiological 
role of PYY-expressing neurons in the brainstem is currently unclear. 
1.8 Summary of the thesis 
The physiological role of PYY in the gut and pancreas is not fully understood. The 
distribution and pharmacological effects of PYY in the gut and pancreas suggest that it may 
be involved in the regulation of energy homeostasis and pancreatic islet function. I used a 
transgenic mouse model expressing diphtheria toxin receptor (DTR) downstream of the PYY 
promoter. The purpose of developing this transgenic mouse was to specifically ablate PYY-
expressing cells in adult mice. Chapter 2 consists of the experiments investigating the 
phenotype of the transgenic mice before and after administration of diphtheria toxin. 
Interestingly, ablation of PYY-expressing cells resulted in hyperglycaemia caused by 
profound loss of insulin/beta cells. Chapter 3 includes the experiments performed to explore 
the reason for the development of diabetes after ablation of PYY-expressing cells.  
1.8.1 Hypothesis 
PYY physiologically regulates energy homeostasis and pancreatic islet function. 
1.8.2 Aims: 
1) To characterise the phenotype of transgenic mice in which PYY-expressing cells 
have been specifically ablated. 
2) To investigate the mechanisms by which ablation of PYY-expressing cells develop 
diabetes.  
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2 Investigation of the phenotype of transgenic mice expressing 
diphtheria toxin receptor in PYY-expressing cells 
 
2.1 Introduction 
 
2.1.1 Ablation of the L cells 
As discussed in chapter 1, PYY is released post-prandially from enteroendocrine L cells 
lining the distal GI tract (Adrian et al. 1985b). A model for ablation of PYY and other 
associated L cell products would facilitate the investigation of the physiological role of these 
cells in regulation of food intake and body weight. The diffuse nature of endocrine cells 
within the intestinal mucosa makes it impractical to surgically remove the source of a 
particular hormone and examine its absence without disrupting the gross anatomical 
structure of the GI tract. Pyy-knockout mice have disrupted energy homeostasis, suggesting 
a physiological role for the PYY system (Batterham et al. 2006; Boey et al. 2006). However, 
the ablation of peptides using germ line knockout approaches can lead to compensatory 
adaptive changes. The possibility of developmental compensation makes the interpretation 
of data from knockout animals difficult (Bewick et al. 2005).  
Expression of PYY mRNA is detected initially at day 17 of gestation in colonic extracts of 
rats (Gomez et al. 1995). Colonic PYY mRNA increases until 7 days of age and remains at 
its highest level through the end of the nursing period in rats. After weaning (21 days of age), 
PYY mRNA levels decline to adult levels (Gomez et al. 1995). Administration of PYY 
stimulates growth of the small intestine in nursing rats (Gomez et al. 1995), and growth of all 
bowel segments in adult mice (Gomez et al. 1995). The trophic effects of PYY on the 
developing and adult intestinal tract suggest that PYY plays a role in GI development. In 
addition to this developmental role, PYY also appears to have an embryonic role in the 
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development of the CNS (Yuzuriha et al. 2007). Chronic administration of PYY to normal 
pregnant mice, or transgenic over-expression of PYY is associated with neural tube defects 
and embryonic lethality (Yuzuriha et al. 2007). Mice surviving the germ line ablation of PYY 
may therefore have changes within the CNS from the embryo stage. The ablation of L cells 
in adult mice will enable the investigation of the role of L cell products following normal 
development of the CNS and GI tract.  
Cell ablation may be achieved by a variety of methods ranging from physical to 
pharmacological lesioning.  A greater selectivity of ablation has been achieved with the 
recent advances in genetic manipulation and transgenic approaches.  In order to ablate a 
particular tissue type, a tissue specific promoter may be used to drive a toxin gene. One 
approach utilizes constitutively active toxins such as diphtheria toxin (Palmiter et al. 1987), 
ricin (Landel et al. 1988), and ataxin-3 (Hara et al. 2001).  However, the early expression of 
a transgene may result in embryonic or early lethality, or compensatory changes by other 
genes may lead to the phenotype being obscured, limiting the usefulness of the transgenic 
model. Conditional transgenic approaches offer a major advantage over constitutively active 
systems as the ablation can be controlled temporally.  This temporal control allows 
phenotypic analysis after normal development, and negates the problem of compensation.  
The Herpes simplex virus thymidine kinase gene (HSVtk) has been used to achieve 
conditional ablation of dividing cells (Wallace et al. 1996).  HSVtk has no intrinsic toxicity but 
causes cell death by catalysing the incorporation of ganciclovir, an exogenously 
administered toxic nucleoside analogue, into DNA during replication (Wallace et al. 1996).  
Successful ablation of post-mitotic cells has been achieved using specific expression of the 
diphtheria toxin receptor (DTR) to confer sensitivity to the administration of diphtheria toxin 
(Saito et al. 2001). Administration of diphtheria toxin (DT) to transgenic mice expressing the 
diphtheria toxin receptor in a particular cell type may be used to specifically ablate those 
cells post-embryonically (Figure 2.1). 
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Figure 2.1. Schematic diagram illustrating how administration of diphtheria toxin (DT) to 
transgenic mice in which a particular cell type expresses the diphtheria toxin receptor results 
in targeted ablation of those cells. DT has no effect in the wild type mice. Adapted from 
(Saito et al. 2001). 
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2.1.2 Diphtheria Toxin (DT)  
Diphtheria toxin (DT) is a polypeptide produced by Corynebacterium diphtheriae. The in vitro 
trypsinisation and reduction of DT forms two components, fragment A (DT-A) and B (DT-B). 
In humans and primates the binding of DT-B to the DT receptor (DTR) leads to the receptor-
mediated endocytosis of DT-A into the cell.  DTR has been identified as a membrane-
anchored form of the heparin binding EGF-like growth factor (HB-EGF precursor) (Naglich et 
al. 1992).  
DT-A inactivates the polypeptide chain elongation factor 2 resulting in inhibition of protein 
synthesis and cell death. In rodents however, HB-EGF precursors do not recognise the DT-B 
component and are therefore at least 105 times more resistant to DT. Conditional ablation of 
murine cells may thus be achieved by the transgenic expression of primate/human DTR in 
mice, conferring sensitivity to DT.  
Transgenic mice expressing diphtheria toxin receptor in a particular cell type can be used for 
ablation of those cells upon administration of diphtheria toxin (DT). DT has no effect in wild 
type mice (Figure 2.1). Transgenic mice expressing the human DTR driven by the liver 
specific albumin promoter developed fulminant hepatitis after intramuscular administration of 
DT, without damage to surrounding cells (Saito et al. 2001). Only those cells expressing the 
DTR transgene were susceptible and DT did not affect wild type controls. DT has also been 
used to ablate Langerhans cells (Bennett et al. 2005), T cells and B cells in mice (Buch et al. 
2005). 
The advantage of this approach over other conditional ablation models is lack of ‘bystander 
effect’ with DT administration. No adverse effect is seen in wild type animals injected with 
doses 1000 times greater than those used to induce cell ablation (Saito et al. 2001). The 
toxic DT-A fragment cannot enter cells deficient in DTR as there is no recognition site for 
DT-B. 
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2.1.3 Generation of transgenic mice 
The most common way to generate transgenic mice is by injection of a ‘transgene’ into the 
pronucleus of fertilised oocytes. The ‘transgene’ may be a cDNA encoding all or part of a 
particular protein, a genomic fragment containing all or part of a gene, or an antisense 
fragment (Shuto et al. 2002).  The expression of the transgene relies on the presence of a 
suitable promoter. The promoter sequence also determines tissue specificity and temporal 
pattern of expression. Widespread expression of a transgene in multiple tissues may be 
achieved with non specific promoters such as the cytomegalovirus enhancer-promoter (E. V. 
Schmidt et al. 1990). Tissue specific expression can be driven with more tightly regulated 
promoters such as glial fibrillary acidic protein which promotes transgene expression in 
astrocytes within the CNS (Brenner et al. 1994). The gene’s own promoter may also be used 
to express the transgene in a pattern identical to that of the endogenous gene. 
The transgene integrates into the mouse genome as tandem repeats or is degraded by 
exonucleases. The exact mechanism of integration is not fully understood. Integration of the 
transgene often occurs during the single cell stage of the developmental process. Therefore, 
all or most of the cells in the adult mouse contain the transgene. Late integration results in 
‘mosaic’ adult mice in which the transgene is only present in a subset of cells. 
The transgene integrates randomly into the mouse genome.  The genomic sequences 
flanking the site of integration can enhance, reduce or abolish transgene expression 
completely. Even genes with small coding regions may have crucial regulatory sequences 
located at a considerable distance from the coding region. Integration of the transgene may 
also disrupt coding regions or endogenous promoter sequences, leading to spurious 
phenotypes (Cases et al. 1995).  
Following successful delivery of the transgene, the pronucleus is transplanted into a foster 
mother. The transgene will be transmitted to future generations of mice if it is present in cells 
44 
 
comprising the germ line.  Mice which are able to transmit the transgene are referred to as 
‘founder mice’. Founder mice derived from a pronuclear injection have a variable number of 
transgene copies ranging from 1 to greater than 50.  The expression of a transgene is 
influenced by the number of transgene copies integrated.  Founder mice with different copy 
numbers may be used in gene dosage studies (Koike et al. 1994). 
2.1.4 DTR-BAC mice 
The DTR-BAC transgenic mouse used in this work was generated by Dr. G. Bewick and Dr. 
David J L Gunner. These mice express the diphtheria toxin receptor (DTR) gene in PYY-
expressing cells.  The transgenic mouse was made by identifying a bacterial artificial 
chromosome (BAC) containing the PYY gene sequence near the centre of its DNA insert. 
Bacterial Artificial Chromosomes (BAC) are able to incorporate large genomic segments of 
DNA greater than 300 kilobase pairs (Shizuya et al. 1992). This increases the probability that 
all the upstream, and downstream regulatory elements necessary for the correct spatial and 
temporal expression of the gene will be present.  By using homologous recombination, 
driven by the pGETrec plasmid, the BAC was successfully modified to contain the diphtheria 
toxin receptor (DTR) gene (Figure 2.2). The successfully modified BAC was injected into the 
pronuclei of fertilised mouse eggs. The injected pronuclei were implanted into foster females. 
The male founder mice were then mated with female C57BL/6J mice and each line 
maintained separately.  
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Figure 2.2. The diphtheria toxin receptor (DTR) containing modification cassette with 
homology arms was constructed in a typical cloning vector by PCR and standard 
recombinant technology.  The modification cassette was isolated from the cloning vector by 
restriction digest and electroporated into the BAC host cell with the pGETrec plasmid which 
catalyses recombination between the homology arms and the BAC.  The modified BAC was 
isolated, purified and injected into the pronucleus to create a transgenic line. 
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2.1.5 Hypotheses 
The diphtheria toxin receptor (DTR) transgene will be expressed in DTR-BAC transgenic 
mice in a PYY-like manner, providing evidence that the modified BAC contains the 
necessary regulatory elements required to drive accurate and specific expression. The 
presence of the DTR transgene itself will not result in a phenotype and transgenic mice will 
have normal food intake, body weight and gut hormone levels prior to the administration of 
diphtheria toxin. Administration of diphtheria toxin to transgenic mice expressing diphtheria 
toxin receptor under the control of the PYY promoter will lead to ablation of PYY-expressing 
cells. 
2.1.6 Aims 
1. To investigate the expression pattern of the DTR transgene. 
2. To investigate the effect of DTR transgene on food intake, body weight and gut 
hormone levels (prior to administration of diphtheria toxin). 
3. To investigate the effect of diphtheria toxin administration on L cell survival in DTR-
BAC transgenic mice. 
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2.2 Materials and Methods 
 
2.2.1 Animals 
Transgenic mice from line DTR20 and 37 generated by Dr. D Gunner were used in this 
chapter.  Mice were maintained in cages under controlled temperature (21-23°C) and light 
(eleven hours light/thirteen hours dark) with ad libitum access to food (RM3 diet, SDS UK 
Ltd.) and water. Experiments were performed in 5-7 week old male mice unless otherwise 
specified. Animal procedures were approved by the British Home Office Animals Scientific 
Procedures Act 1986 (Project licence numbers 70/6270 and 70/6402). 
2.2.2 Genotyping of transgenic mice  
Materials  
Tail digestion buffer: 
    6.7mM Tris-HCl 
    0.67mM MgCl2 
    1.66mM (NH4)2 SO4 
    0.5% Triton X-100 
 1% β-mercaptoethanol 
 Proteinase K 20mg/ml in GDW 
 20µM oligonucleotide primers (Oswel DNA service, University of Southampton, 
Southampton, U.K.)   
10X Taq buffer (Sigma-Aldrich) 
Genomic Red Taq DNA polymerase (Sigma-Aldrich) 
Method 
Mice were weaned and genotyped by PCR at 4 weeks of age.  DNA was isolated from a 
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1mm tail biopsy by digestion in 100µl of tail digestion buffer.  The eppendorf tubes 
containing the reaction were incubated at 95oC for 10mins and then for 2 hours at 55oC 
supplemented with 1mg/ml proteinase K.  Proteinase K was inactivated with a final 10 
minutes at 95oC.  Digested tails were centrifuged for a few seconds to settle the debris and 
1µl of supernatant used to perform a 25µl PCR reaction. PCR was carried out in 1x Red Taq 
buffer, 0.2 mM dNTPs, 200 nM oligonucleotides with 3U of Genomic Red Taq per reaction. 
The PCR reaction was heated to 95oC for 15 minutes. It was then cycled 30 times through 
the following temperatures: 95oC for 40 seconds, 55oC for 40 seconds, 72oC for 40 seconds. 
Primers designed to amplify a cDNA fragment from the vector portion of the PYY BAC, 
pBeloBAC11, were used (Table 2.1). 
 
Primer  Oligonucleotide sequence 
BeloBAC 
5’ TCATTCTGCAATCGGCTTGC 
3’ GTGCCTGGAGAAATGCTCTT 
Table 2.1. Primers used for genotyping transgenic mice 
 
2.2.3 Agarose gel electrophoresis 
Materials 
  Agarose, type II-A medium (Sigma-Aldrich) 
  Ethidium bromide (10mg/ml) 
  50x TAE (see Appendix) 
     2M Tris-Acetate pH 8.5 
     0.05M EDTA pH 8.0 
  DNA marker (BRL 1Kb ladder, Invitrogen Life Technologies) 
  Gel loading buffer 
49 
 
Method 
A 1% (w/v) agarose gel was prepared by dissolving the agarose in 1x TAE in a microwave 
oven.  The gel was cooled to 45°C and ethidium bromide added to a final concentration of 
0.5 µg/ml.  The gel was placed into an electrophoresis tank containing 0.5x TAE with 0.5 
µg/ml ethidium bromide. One microlitre of DNA marker was added to 9µl of GDW and 3 µl of 
loading buffer. Samples were loaded onto the gel and electrophoresed at 130V.  The DNA 
was visualised by illumination with UV light at 300nm (Figure 2.3). 
 
 
 
 
1 kb 
          500 bp  
 
                                 L     C    wt   wt   wt   wt   wt   wt    tg    wt   wt    tg  
 
Figure 2.3. Identification of transgenic DTR-BAC mice by PCR. Representative 
electrophoresis of a PCR product of 600bp amplified using the BeloBAC primer set. L= 
ladder, C= positive control, wt= wild type, tg= transgenic. 
2.2.4 Total RNA extraction  
The Tri-reagent method was used to extract total RNA from the following tissues of wild type 
and transgenic male mice: hypothalamus, cortex, brainstem, heart, lung, stomach, liver, 
spleen, pancreas, kidney, jejunum and duodenum, ileum, colon, rectum, and testes. 
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Materials 
  Tri-Reagent (Helena Biosciences) 
  1-Bromo-Chloro-Propane (Sigma-Aldrich) 
  Ethanol  
  Isopropanol  
  Sterile distilled water (GDW) 
Method 
Total RNA was extracted using Tri-Reagent according to the manufacturer’s protocol. Tissue 
(up to 50mg) was homogenised in 1ml Tri-Reagent. The homogenized tissue was 
transferred to sterile 1.5ml eppendorf tubes and incubated at room temperature for 5 
minutes.  One hundred microlitres of bromo-chloro-propane was added and mixed 
thoroughly. The mixture was incubated at room temperature for 10 minutes, before being 
centrifuged at 12000g, 4oC for 15 minutes (centrifuge 5417 C/R, Eppendorf, Hamburg, 
Germany).  The upper, aqueous phase was transferred to a fresh eppendorf tube, 
precipitated with 0.5ml isopropanol for 10 minutes at room temperature, before being 
centrifuged at 12000g, 4oC for 10 minutes. After removing the supernatant, the pellet was 
washed with 75% ethanol (v/v), air-dried and resuspended in 400µl of GDW. 
Spectrophotometry was used to determine RNA concentration.  The RNA was diluted 1:100 
in GDW.  One ml was placed into a quartz cuvette and the absorbance was read at 260 and 
280nm.  The following formula was used to calculate the concentration: Concentration 
(g/ml) = (A260 x dilution factor) x 40. 
2.2.5 Reverse Transcription (RT) 
The expression of PYY and DTR in various tissues was investigated using RT-PCR analysis.  
Materials 
  RNA (5mg/ml) 
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  5x Reverse transcriptase buffer (Promega) 
      250mM Tris-HCl, pH 8.3 
      2560mM KCl 
      50mM Magnesium Chloride  
      2.5mM Spermidine 
    50mM Dithiothreitol (DTT) 
  10mM dNTPs (Amersham Biosciences) 
  Oligo dT (12-18) 200ng/µl (Amersham Biosciences) 
  Avian myoblastoma virus reverse transcriptase (RT) 10U/µl (Promega) 
Method 
The reaction was set up in a final volume of 20µl containing the following: 1x RT buffer, 
1mg/ml RNA, 10mg/ml oligo dT and 1mM dNTPs.  The solution was heated to 65oC for 5 
minutes and cooled to room temperature for 30 minutes.  Ten units of RT were added and 
the reaction incubated at 42oC for 1 hour, before being used in a polymerase chain reaction 
(PCR). 
2.2.6 Polymerase Chain Reaction (PCR) 
The expression pattern of PYY and DTR was investigated by PCR using primers 
corresponding to nucleotides 71-90 (5’primer) and 261-280 (3’primer) (210bp) of the PYY 
mouse gene (accession# NM145435) and primers corresponding to nucleotides 58-76 (5’ 
primer) and 663-682 (3’ primer) (625bp) of the DTR gene (accession# M93012) (Table 2.2).  
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PCR  Oligonucleotide sequence 
PYY 
5’ TCGCAATGCTGCTAATCCTG 
3’ CGTCTGTGAAGAGCAGTTTG 
DTR 
5’ GATCCAGCTGCTGCCGTCG 
3’ GTGGGAATTAGTCATGCCCA 
 
Table 2.2 Primers for PCR amplification of PYY and DTR. 
Materials 
  10x Taq Buffer (Sigma-Aldrich) 
      500mM Potassium Chloride 
    100mM Tris-HCl, pH 9.0 
      15mM Magnesium chloride 
      1% (v/v) Triton x100 
  Taq DNA polymerase (Sigma-Aldrich) 
  20mM oligonucleotide primers (Oswel DNA services) 
Method 
Ten microlitres of the reverse transcription reaction was added to a tube containing 1x Taq 
buffer, 200nM oligonucleotide primers and 0.2mM dNTPs.  The reaction was heated to 95oC 
for 5 minutes, before 5U of Taq DNA polymerase was added.  The reaction was cycled 30 
times through the following temperatures: 95oC for 40 seconds, 55oC for 40 seconds, 72oC 
for 1 minute.  Ten microlitres of the PCR product was analysed by gel electrophoresis on a 
1% TAE/agarose gel (Section 2.2.3). 
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2.2.7 Whole blood and tissue collection and peptide extraction 
The effect of diphtheria toxin (DT) administration on plasma and tissue peptide 
concentrations was determined in 7-week-old mice from lines DTR20 and 37. DT was 
dissolved in sterile injection water. Twelve wild type mice and 8 transgenic mice received DT 
intraperitoneally at a dose of 40 ng/g. Mice were killed by carbon dioxide inhalation 72 hours 
following DT injection. 
Cardiac puncture was used to collect blood into heparinised syringes. Blood was mixed with 
500 Kallikrein Inhibitor Units (20µl) of aprotinin (Trasylol, Bayer, Haywards Heath, UK) to 
prevent peptide degradation.  Plasma was separated by centrifugation at 4ºC 12000g for 15 
minutes and stored at -20°C until measurement of PYY by radioimmunoassay (section 
2.2.8).  
Colorectal tissues were dissected, cleaned, and wet tissue weights recorded prior to being 
snap frozen in liquid nitrogen.  Tissue samples were placed into preheated polypropylene 
tubes containing 0.5 M acetic acid. Ten millilitres of acetic acid solution was added per gram 
of colorectal tissue. The samples were boiled for 15 minutes in a water bath. The 
supernatant was used to measure peptide concentrations. The effect of DT administration on 
plasma PYY and colorectal tissue extract concentrations of PYY, GLP-1, CCK, neurotensin, 
substance P, glucose-dependant insulinotropic polypeptide (GIP) were determined by 
radioimmunoassay (section 2.2.8) or enzyme linked immunosorbent assay (section 2.2.9). 
Pancreata were dissected, weighed and immediately homogenized in acid-ethanol. Twenty 
millilitres of acid-ethanol was added per gram of pancreatic tissue. The acid-ethanol solution 
was made by adding 25 ml 2M HCl to 175 ml of 100% ethanol. After an overnight incubation 
at -4°C, the extracts were centrifuged at 10,000 rpm for 10 minutes at 4°C (centrifuge 5417 
C/R, Eppendorf, Hamburg, Germany). PYY, insulin and glucagon concentrations in the 
supernatant were measured by radioimmunoassay (RIA) (section 2.2.8).  
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2.2.8 Radioimmunoassay (RIA) 
The effects of the DTR transgene and DT administration on colorectal PYY, GLP-1, CCK 
and substance P and pancreatic PYY, insulin and glucagon were determined by 
radioimmunoassay (RIA). RIA is a technique for measuring low concentrations of biological 
substances in small volume plasma and tissue samples. The principle of RIA is competition 
between unlabelled antigen (in the sample) and radiolabelled antigen to bind to a fixed 
concentration of antibody.   
The number of binding sites available for the radiolabelled antigen decreases as the 
concentration of unlabelled antigen increases. The quantity of unlabelled antigen in a 
sample is therefore inversely proportional to the amount of radiolabelled antigen bound to 
the antibody. A ‘standard curve’ is constructed using known concentrations of peptide. The 
antibody-bound antigen is separated from the unbound antigen either by using a secondary 
antibody against the primary antibody (unbound antigen remains in the supernatant) or by 
the addition of dextran-coated charcoal (unbound antigen is adsorbed into the porous 
charcoal pellet). Dextran is added to the charcoal suspension to block the larger holes in the 
porous charcoal. In order to check for baseline drift, tubes with no sample (‘zero’ tubes) are 
placed at regular intervals throughout the assay and standard curves are performed at the 
beginning and end of each assay. 
After centrifugation and separation by aspiration, a gamma counter is used to measure the 
activity in the bound and free components. The concentration of the peptide is calculated by 
reference to the standard curve. 
2.2.8.1 Assay protocol 
Professor M. Ghatei iodinated all peptides used in the radioimmunoassay. Reaction products 
were purified by high performance liquid chromatography (HPLC) using a C18 column 
(Waters Corporation, Milford, Connecticut, U.S.A.) (Wood et al. 1981). The antisera used for 
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each assay are described below. The general structure of the RIA is outlined in table 2.3. 
Assays were performed in a total volume of 700l in 0.06M phosphate buffer (0.05M 
Na2HPO4.2H20, 0.006M KH2PO4, 0.01M disodium-EDTA.2H2O, 0.008M NaN3), at pH 7.3-7.4 
with 0.3% BSA, unless otherwise stated.  
Standard curves were generated using synthetic peptide in assay buffer, and added at 
volumes of 1, 2, 3, 5, 10, 15, 20, 30, 50 and 100l.  A second standard curve including 50µl 
of 0.5 M acetic acid or acid-ethanol per standard was added towards the end of the assay. 
All samples were assayed in duplicate. 
Samples were assayed neat, diluted 1 in 10, 1 in 100 and 1 in 1000 at a volume of 50µl. 
Radiolabelled peptide was diluted to 200-250 counts per 10 seconds per 100µl in assay 
buffer. The assays were incubated at 4°C for 3-5 nights.  Free and bound peptides were 
separated with either charcoal absorption or secondary antibody.    
For charcoal separation 2.4g charcoal and 0.24 g dextran were added to 100ml 0.06M 
phosphate buffer with gelatine and mixed for 20 minutes at 20ºC. Two hundred and fifty 
microlitres of the charcoal mixture was added to each sample. The samples were then 
centrifuged at 1500g, 4oC, for 20 minutes. For secondary antibody separation, samples were 
incubated for 1 hour with 100l of goat anti-rabbit solid phase secondary antibody 
(Pharmacia Diagnostics, Uppsala, Sweden) at room temperature.  One hundred microlitres 
of 10% polyethylene glycol and 500l of 0.01% Triton-X-100 solution were added to each 
sample prior to centrifugation at 1500g, 4°C, for 20 minutes.   
Free and bound label were separated using aspiration. A  counter (model NE1600, Thermo 
Electron Corporation) was used to count both the pellet and supernatant for 180 seconds.  
The concentration of peptides in the samples was calculated from the standard curve using 
a non-linear plot (RIA Software, NE Technology). 
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Tube 
Buffer 
(µl) 
 
Antibody 
(µl) 
 
Label 
(µl) 
 
Standard/sample 
(µl) 
 
Acetic acid or 
acid-ethanol 
(µl) 
Non-specific 
binding 
600 - 100 - - 
½ x label 550 100 50 - - 
2 x label 400 100 200 - - 
Zero 500 100 100 - - 
Standard  
1-15µl 
500 100 100 1-15 0/20 
Standard (20µl) 480 100 100 20 0/20 
Standard (30µl) 470 100 100 30 0/20 
Standard (50µl) 450 100 100 50 0/20 
Standard (100µ) 400 100 100 100 0/20 
Zero 500 100 100 - - 
Sample 450 100 100 50 - 
Excess Antibody - 600 100 - - 
Table 2.3. General plan of the radioimmunoassays carried out showing the volumes of 
radioimmunoassay constituents added to specific tubes 
2.2.8.2 PYY RIA 
An established in house radioimmunoassay was used to measure PYY immunoreactivity 
(PYY-IR) (Batterham et al. 2003a; Savage et al. 1987). This assay can detect changes of 0.2 
fmol/tube with 95% confidence. The antibody used in this assay was produced in a rabbit 
against synthetic porcine PYY (Bachem, UK) coupled to bovine serum albumin (BSA) and 
used at a final dilution of 1:50,000. This antibody cross-reacts fully with the biologically active 
forms of circulating PYY (full length PYY1-36 and the fragment PYY3-36), but not with 
neuropeptide Y, pancreatic polypeptide, or other known gastrointestinal hormones. 
Separation was performed by the secondary antibody method. The volumes required for all 
components in the RIA are shown in Table 2.3. 
2.2.8.3 GLP-1 RIA 
An established in house radioimmunoassay was used to measure GLP-1 immunoreactivity 
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(GLP-1-IR) (Kreymann et al. 1987). This assay detects concentration differences of 1.5 
fmol/tube with 95% confidence. GLP-1 assay was performed in a total volume of 700l of 
0·06 M Veronal buffer at pH 8·0 with 0·3% BSA. The GLP-1 antibody used in this assay was 
raised in a rabbit immunised with synthetic GLP-1 (7-36) amide conjugated to BSA. This 
antibody cross-reacts fully with GLP-11-36 amide, but not with glucagon, or other 
gastrointestinal hormones. Separation was performed by the charcoal absorption method. 
The volumes required for all components in the RIA are shown in Table 2.3. 
2.2.8.4 Substance P RIA 
An established in house radioimmunoassay was used to measure substance P 
immunoreactivity (substance P-IR) (McGregor and Bloom 1983). This assay detects 
concentration differences of 0.3 fmol/tube with 95% confidence. The substance P antibody 
used in this assay was raised in a rabbit immunised with synthetic bovine substance P 
conjugated to BSA. This antibody cross-reacts fully with substance P, but not with other 
gastrointestinal hormones. Separation was performed by the charcoal absorption method. 
The volumes required for all components in the RIA are shown in Table 2.3. 
2.2.8.5 CCK RIA 
An established in house radioimmunoassay was used to measure CCK immunoreactivity 
(CCK-IR) (Adrian et al. 1985a). This assay detects concentration differences of 0.25 
fmol/tube with 95% confidence. The CCK antibody used in this assay was raised in a rabbit 
immunised with synthetic porcine CCK-8 conjugated to BSA. This antibody cross-reacts fully 
with CCK, but not other gastrointestinal hormones. Separation was performed by the 
charcoal absorption method. The volumes required for all components in the RIA are shown 
in Table 2.3. 
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2.2.8.6 Insulin RIA 
An established in house radioimmunoassay was used to measure pancreatic insulin 
immunoreactivity (insulin-IR). Antisera were raised in rabbits immunized with synthetic 
insulin coupled to albumin. This antiserum is specific for pancreatic insulin and does not 
cross-react with other hormones. Separation was performed by the charcoal absorption 
method. The volumes required for all components in the RIA are shown in Table 2.3. 
2.2.8.7 Glucagon RIA 
An established in house radioimmunoassay was used to measure pancreatic glucagon 
immunoreactivity (glucagon-IR). The assay detects changes of 10 pg/ml between adjacent 
samples with 95% confidence. Antisera were raised in rabbits immunized with porcine 
glucagon coupled to albumin. This antiserum is specific for pancreatic glucagon and does 
not cross-react with other gut hormones. Separation was performed by the charcoal 
absorption method. The volumes required for all components in the RIA are shown in Table 
2.3. 
2.2.9 Enzyme Linked ImmunoSorbent Assay (ELISA)  
Enzyme-linked immunosorbent assay (ELISA), is a biochemical technique used to detect the 
presence of an antigen in a sample. There are a number of different types of ELISAs. One of 
the most common types of ELISA is the ‘sandwich ELISA’. In sandwich ELISA, the peptide in 
the sample binds to a specific capture antibody coating the wells of a microplate. Unbound 
materials from samples are washed away at each step. A biotinylated detection antibody is 
then added which binds to the captured peptide. The samples are incubated with 
streptavidin-Horseradish peroxidase (HRP) conjugate. Streptavidin binds to the biotin moiety 
of the detection antibody. A chromogenic substrate e.g. 3, 3', 5, 5'-tetramethylbenzidine 
(TMB) is then added which changes colour in the presence of the enzyme. The enzyme 
activity is measured spectrophotometrically. The increase in absorbency is proportional to 
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the amount of captured peptide in the sample. The amount of the antigen can be calculated 
from a standard curve constructed with reference standards of known concentrations of the 
peptide. 
Another form of ELISA employs the ‘competitive inhibition enzyme immunoassay’ technique. 
Biotinylated peptide and unlabeled peptide (standards or samples) compete for binding to an 
antibody. Streptavidin-Horseradish peroxidase (HRP) conjugate is then added which binds 
to the biotinylated peptide. The substrate solution is then added to the wells, which changes 
colour in the presence of the enzyme. The intensity of the color is measured 
spectrophotometrically. There is an inverse correlation between the assay signal intensity 
and peptide concentration in the sample. 
2.2.9.1 Glucose-dependant Insulinotropic Polypeptide (GIP) ELISA 
The concentration of Glucose-dependant Insulinotropic Polypeptide (GIP) in colorectal tissue 
extracts was measured using a commercially available kit and methods from LINCO 
research (St. Charles, USA). The lyophilised GIP standard was reconstituted by addition of 
the appropriate volume of deionised water. The manufacturer supplied all buffers ready to 
use. The stock solution was serially diluted to prepare standard GIP concentrations. Ninety 
microlitres of assay buffer was added to each well. Ten microlitres of sample or standard 
was added in duplicate.  The microplate was covered and incubated at room temperature on 
an orbital plate shaker at 500RPM.  After 90 minutes, the wells were aspirated and washed 3 
times with wash buffer. One hundred microlitres of biotinylated detection antibody was 
added to each well. The microplate was covered and incubated at room temperature on an 
orbital plate shaker.  After 1 hour, the wells were washed as previously described. One 
hundred microlitres of streptavidin-HRP was then added and incubated on an orbital shaker 
at room temperature.  After for 30 minutes the wells were washed as previously described, 
before the addition of 100µl enzyme substrate solution (TMB). The reaction was incubated at 
room temperature on an orbital plate shaker.  After 15 minutes, 100µl of 0.3M hydrochloric 
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acid was added to terminate the enzyme reaction. A Labsystems Multiskan RC plate reader 
was used to measure the absorbance at a wavelength of 450nm and read the background at 
590nm. 
2.2.9.2 Neurotensin (NT) ELISA 
A commercially available kit and methods from Bachem Ltd were used to measure the 
concentration of neurotensin (NT) in colorectal tissue extracts (San Carlos, CA, USA). The 
manufacturer supplied all the buffers ready to use. The lyophilised NT standard was 
reconstituted by addition of the appropriate volume of deionised water. The stock solution 
was serially diluted to prepare standard NT concentrations.  Twenty-five microlitres of 
peptide antibody and biotinylated peptide were added to each well. Fifty microlitres of 
sample or standard were then added in duplicate.  The microplate was covered and 
incubated at room temperature.  After 2 hours, the wells were aspirated and washed 5 times 
with wash buffer. One hundred microlitres of streptavidin-HRP was added to each well and 
incubated at room temperature for 1 hour.  The wells were then washed 5 times.  One 
hundred microlitres of enzyme substrate solution (TMB) was added and the reaction 
incubated at room temperature.  After 30 minutes, the enzyme reaction was terminated by 
the addition of 100µl of 2M hydrochloric acid. A Labsystems Multiskan RC plate reader was 
used to measure the absorbance at a wavelength of 450nm and read the background at 
650nm.    
2.2.10 Immunohistochemistry 
Immunohistochemistry (IHC) is a technique that enables identification and localization of 
proteins in tissue sections. IHC utilizes a primary antibody that is specific for the antigen of 
interest. Following an antigen-antibody reaction, an antibody-enzyme label is reacted with a 
substrate to produce a coloured product that can be visualized by light microscopy.  A three-
layer technique was performed, the third layer being an ABC-horse radish peroxidase (HRP) 
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reaction. The specificity of the primary antibody specificity was assessed by an overnight 
pre-incubation with a ten-fold excess of full length PYY at 4oC. The appropriate primary 
antibody dilutions were determined by titration experiments.  All antibody dilutions were done 
in 0.01M phosphate buffered saline (PBS)/0.1% bovine serum albumin.  
Materials  
   Methanol 
  Hydrogen peroxide 
  0.01M Citrate buffer pH 6 (see Appendix)  
  0.01M PBS (see Appendix)  
  PBS/0.05%Tween (see Appendix) 
  0.05 M Tris-buffered saline (TBS) pH 7.6: (see Appendix) 
  Antibodies: 
    Rabbit anti-PYY ab22663 (Abcam, Cambridge, UK) 
    Biotinylated donkey anti-rabbit (H+L) (Jackson, West Grove, PA)
 Normal donkey serum (Jackson, West Grove, PA) 
  ABC vectastain kit (Vector Laboratories, Burlingame, CA) 
  NovaRED substrate kit (Vector Laboratories, Burlingame, CA) 
  DPX mounting media 
Methods 
Carbon dioxide inhalation was used to sacrifice the mice. Colorectal tissue was dissected 
longitudinally, cleaned, and fixed in 10% formaldehyde overnight, before being processed 
and paraffin embedded (Histopathology, Hammersmith Hospital).   
Six-micrometer sections were cut with an AS500 microtome (Anglia Scientific, Cambridge, 
U.K.). Sections were mounted on poly-lysine slides and washed with xylene to remove the 
paraffin. The sections were then rehydrated by being washed in decreasing concentrations 
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of ethanol (100%, 70%, 50%) to 0.01M PBS.  The endogenous peroxidase activity was 
blocked by a 15-minute incubation with 0.6% H2O2 in methanol (v/v). The slides were then 
rinsed in distilled water. The sections were heated in a microwave in preheated citrate buffer 
(0.01M) for 10 minutes to permit antigen retrieval. Slides were gradually cooled in distilled 
water, rinsed in PBS/0.05%Tween and loaded into Sequenza immunostaining racks 
(Shandon, Pittsburgh, PA, USA). A 10-minute incubation with 100µl of 1:20 normal donkey 
serum at room temperature was used to block non-specific binding. Sections were then 
rinsed with PBS/0.05%Tween and incubated overnight with 100µl of primary antibody at 
1:10,000 dilution at 4ºC. Negative controls consisted of slides incubated with PBS.  
The sections were washed the following day in 0.01M PBS (1 x 5 minutes), and incubated 
with 100µl of secondary antibody at 1:50 dilution at room temperature.  After 30 minutes, 
sections were washed with 0.01M PBS (1 x 5 minutes) and incubated with ABC-HRP at the 
manufacturer’s recommended dilution for 30 minutes.   
Slides were then washed in 0.01M PBS (1 x 5 minutes) and developed by a 10-minute 
incubation with NovaRED substrate at the manufacturer’s recommended dilution.  The 
sections were rinsed in distilled water to stop the reaction. Slides were dehydrated by being 
washed in increasing concentrations of ethanol (50%, 70%, 100%) and mounted using DPX 
mounting media. 
2.2.10.1 Data analysis  
A Nikon Eclipse E800 microscope was used to visualize tissue sections.  The total number 
of PYY immunoreactive cells per slide was counted and expressed per centimetre of tissue.   
Representative photomicrographs were taken with a GXCAM-3 Tucsen camera and TSview 
V1.0 image capture software.   
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2.2.11 Blood collection and glucose measurement 
Blood was collected from the tail and plasma glucose was measured using the Acensia 
Contour blood glucose monitoring system (Bayer HealthCare, Newbury, U.K.). 
2.2.12 Statistical analysis 
Data are represented as the mean ± standard error of mean (SEM). Results were analysed 
using unpaired Student’s t-test. The threshold for statistical significance in all cases was 
conventionally set at p< 0.05. Analyses were performed using Prism version 5.1 software 
(GraphPad Software, San Diego, CA, USA). 
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2.3 Results 
 
2.3.1 Peptide YY (PYY) and diphtheria toxin receptor (DTR) expression 
The tissue expression pattern of PYY and DTR was assessed using RT-PCR analysis. PYY 
expression, identified by the presence of a 210bp PCR product, was observed in stomach, 
small intestine, colorectal tissue, and testes in both wild type and transgenic mice (Figure 2.4 
A). DTR expression was identified by the presence of a 625bp PCR product, which occurred 
in the same tissues in transgenic mice as wild-type mice with the exception of the stomach 
(Figure 2.4 B). This suggests that the expression of DTR driven by PYY BAC follows the 
same general pattern as that of endogenous PYY. 
2.3.2 Effects of the DTR transgene on food intake and body weight  
Mice from lines DTR20 and 37 were singly housed at weaning and body weight and food 
intake were measured weekly until seven weeks of age. Body weight and food intake 
measurements did not differ significantly between age matched wild type and transgenic 
mice (Figure 2.5). Mean body weight at 7 weeks of age was 25.97 ± 0.83 grams, n=12 for 
wild type mice and 26.10 ± 0.85 grams, n=9 for transgenic mice (p=0.92). Mean cumulative 
food intake at 7 weeks of age was 99.88 ± 4.41 grams, n=12 for wild type mice and 102.49 ± 
4.50 grams, n=9 for transgenic mice (p=0.69). 
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Figure 2.5 Effect of the DTR transgene on body weight and food intake in DTR20/37 
mice. The diphtheria toxin receptor (DTR) transgene had no effect on cumulative food intake 
(A) or body weight (B) comparing wild type (Wt) and transgenic mice (Tg). Wild type n=12, 
Transgenic n=9. 
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2.3.3 Effects of the DTR transgene on plasma and colorectal gut hormones 
The effect of the DTR transgene on plasma PYY-IR concentration, and colorectal PYY, GLP-
1 and CCK-IR concentrations was determined by radioimmunoassay (section 2.2.8). The 
concentration of NT in the colorectal tissue was determined by ELISA (section 2.2.9). Whole 
blood was collected as described in section 2.2.7. Colorectal tissues were dissected and 
peptide extracted as described in section 2.2.7. There were no differences between wild type 
and transgenic mice with regards to plasma or colorectal tissue concentrations of the gut 
peptides investigated. 
Plasma PYY-IR concentration did not statistically differ between wild type (Wt) and 
transgenic (Tg) mice (Wt 99.04 ± 14.64 pmoles/l, n=6 vs. Tg 85.97 ± 29.01 pmoles/l, n=3, 
p=0.66) (Figure 2.6 A). The colorectal PYY-IR concentration did not statistically differ 
between wild type (Wt) and transgenic (Tg) mice (Wt 421.82 ± 42.28 pmoles/g, n=6 vs. Tg 
456.09 ± 90.09 pmoles/g, n=3, p=0.70) (Figure 2.6 B). Wild type and transgenic mice had 
similar colorectal tissue GLP-1-IR concentrations (Wt 157.73 ± 15.24 pmoles/g, n=6 vs. Tg 
187.0 ± 47.30 pmoles/g, n=3, p=0.47) (Figure 2.7 A), CCK-IR concentrations (Wt 3.54 ± 0.43 
pmoles/g, n=6 vs. Tg 3.35 ± 0.86 pmoles/g, n=3, p=0.82) (Figure 2.7 B), and NT 
concentrations (Wt 62.79 ± 7.23 pmoles/g, n=6 vs. Tg 64.21 ± 12.70 pmoles/g, n=3, p=0.92) 
(Figure 2.8). 
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Figure 2.6 Effect of the DTR transgene on plasma and colorectal PYY-IR 
concentrations in DTR20/37 mice. Plasma (A) or colorectal tissue (B) PYY-IR 
concentrations were not different between wild type and transgenic mice (prior to 
administration of DT). Wild type n=6, Transgenic n=3. Results show mean ± SEM. 
A 
B 
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Figure 2.7. Effect of the DTR transgene on GLP-1 and CCK-IR concentrations in 
colorectal tissue from DTR20/37 mice. Colorectal GLP-1-IR (A) or CCK-IR (B) 
concentrations were not different between wild type and transgenic mice (prior to 
administration of DT). Wild type n=6, Transgenic n=3. Results show mean ± SEM. 
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Figure 2.8. Effect of the DTR transgene on neurotensin concentration in colorectal 
tissue from DTR20/37 mice. Colorectal neurotensin-IR concentration was not different 
between wild type and transgenic mice (prior to administration of DT). Wild type n=6, 
Transgenic n=3. Results show mean ± SEM. 
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2.3.4 Effects of diphtheria toxin on plasma and colorectal peptide concentration 
Diphtheria toxin (DT) was administered intraperitoneally (i.p.) at a dose of 40 ng/g. The 
animals were sacrificed 72 hours following DT injection. Whole blood was collected as 
described in section 2.2.7. Colorectal tissues were dissected and peptide extracted as 
described in section 2.2.7. The effects of DT administration on colorectal tissue extract 
concentrations of PYY, GLP-1, CCK, and substance P-IR were determined by 
radioimmunoassay (section 2.2.8). Colorectal tissue extract concentrations of NT and GIP 
were measured by ELISA (section 2.2.9).  
DT administration caused a significant 97.7% reduction in colorectal PYY-IR concentration in 
transgenic mice (Wt 231.59 ± 47.01 pmoles/g, n=12 vs. Tg 5.11 ± 1.22 pmoles/g, n=8, 
p<0.001) (Figure 2.9 A).  DT administration also caused significant decreases in the 
colorectal tissue concentrations of GLP-1-IR, CCK-IR, and NT in transgenic mice. GLP-1-IR 
was reduced by 95.9% (Wt 157.88 ± 12.86 pmoles/g, n=12 vs. Tg 6.39 ± 1.33 pmoles/g, 
n=8, p<0.001) (Figure 2.9 B), CCK-IR was reduced by 86.1% (Wt 2.44 ± 0.32 pmoles/g, 
n=12 vs. Tg 0.34 ± 0.04 pmoles/g, n=8, p<0.001) (Figure 2.10 A), and NT was decreased by 
42.2% (Wt 30.71 ± 2.98 pmoles/g, n=12 vs. Tg 17.74 ± 1.16, n=8, p<0.01) (Figure 2.10 B). 
Administration of DT did not affect colorectal substance P-IR and GIP concentrations. The 
substance P-IR concentration in wild type and transgenic mice after administration of DT 
was 191.97 ± 4.43 pmoles/g, n=10 vs. 198.85 ± 12.17 pmoles/g, n=6, p=0.54, respectively 
(Figure 2.11 A). Colorectal GIP concentration in wild type and transgenic mice was 21.82 ± 
4.56 pg/ml, n=12 and 25.27 ± 3.75 pg/ml, n=8, p=0.60, respectively (Figure 2.11 B). 
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Figure 2.9. Effect of diphtheria toxin (DT) administration on colorectal PYY and GLP-1-
IR concentration in DTR20/37 mice. Tissues were collected 72 hours after intraperitoneal 
administration of DT (40 ng/g). Colorectal PYY-IR concentration (A) was decreased by 
97.7% (***p<0.001). Colorectal tissue GLP-1-IR concentration (B) was decreased by 95.9% 
(***p<0.001). Wild type n=12, Transgenic n=8. Results show mean ± SEM. 
 
A 
B 
73 
 
 
 
 
Figure 2.10. Effect of diphtheria toxin administration on CCK-IR and neurotensin 
concentration in DTR20/37 mice. Tissues were collected 72 hours after intraperitoneal 
administration of DT (40 ng/g). Colorectal tissue CCK-IR concentration (A) was decreased 
by 86.3% (***p<0.001). Colorectal tissue neurotensin concentration (B) was decreased by 
42.2% (**p<0.01). Wild type n=12, Transgenic n=8. Results show mean ± SEM. 
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Figure 2.11. Effect of diphtheria toxin (DT) administration on substance P-IR and GIP 
concentration in DTR20/37 mice. Tissues were collected 72 hours after intraperitoneal 
administration of DT (40 ng/g). Colorectal tissue substance P-IR concentration (A) was 
unchanged following DT administration (p=0.54). Wild type n=10, Transgenic n=6. Colorectal 
tissue GIP concentration (B) was unchanged following DT administration (p=0.60). Wild type 
n=12, Transgenic n=8. Results show mean ± SEM. 
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2.3.5 PYY immunohistochemistry (IHC) 
 
2.3.5.1 Controls 
Colonic sections were incubated overnight with PYY primary antibody at a 1:10,000 dilution. 
Control sections were incubated with PYY primary antibody preabsorbed with a ten-fold 
excess of full length PYY peptide. Other control sections included replacement of the 
primary antibody incubation with PBS. No immunolabelling was seen in control sections 
incubated with preabsorbed PYY antibody or PBS (Figure 2.12 A and D). 
2.3.5.2 Effect of the DTR transgene on PYY cell number 
The effect of the DTR transgene on PYY-IR cell number was assessed in colorectal tissues 
from eight-week-old wild type and transgenic mice. There was no difference in PYY-IR cell 
numbers between wild type and transgenic mice prior to DT administration (wild type 59 ± 
4.50 cells/cm, n=3 vs. transgenic 56 ± 2.84 cells/cm, n=3 respectively, p=0.67) (Figure 2.12 
B-C and E-F, and Figure 2.14 A).  
2.3.5.3 Effect of diphtheria toxin administration on PYY cell number 
The effect of DT administration was investigated in 8-week-old wild type and transgenic 
mice. Intraperitoneal injection of DT (40 ng/g) resulted in a significant 95.9% reduction in 
PYY-IR cell numbers in transgenic mice (wild type 68 ±7.65 cells/cm, n=4 vs. transgenic 3 ± 
0.45 cells/cm, n=4 respectively, p<0.001) (Figure 2.13 and Figure 2.14 B). 
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Figure 2.14. Effect of diphtheria toxin receptor (DTR) transgene and diphtheria toxin 
(DT) administration on PYY-IR colorectal cell number. PYY-IR cell number, determined 
by immunohistochemistry, was not affected by the presence of the DTR transgene (A) 
(p=0.67). Wild type n=3, Transgenic n=3. DT administration (40ng/g, i.p.) reduced colorectal 
PYY-IR cell number by 95.9% in transgenic mice (B) (*** p<0.001). Wild type n=4, 
Transgenic n=4. Results show mean ± SEM. 
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2.3.6 Effects of diphtheria toxin on food intake and body weight 
Mice were singly housed.  Food intake and body weight were measured twice per week prior 
to administration of diphtheria toxin (DT). Body weight and food intake measurements were 
not significantly different between age matched wild type and transgenic mice prior to the 
administration of DT (Figure 2.15). Average body weight at day 25 was 25.97 ± 0.83 grams, 
n=12 for wild type mice and 26.10 ± 0.85 grams, n=9 for transgenic mice (p= 0.92). 
Cumulative food intake at day 25 averaged 99.88 ± 4.41 grams, n=12 for wild type mice and 
102.49 ± 4.50 grams, n=9 for transgenic mice (p= 0.68). 
DT (40 ng/g) was administered intraperitoneally (i.p.) on day 27. DT administration resulted 
in a significant reduction in body weight. Average body weight at day 32 was 26.06 ± 0.79 
grams, n=12 for wild type mice and 22.28 ± 1.42 grams, n=9 for transgenic mice (p < 0.05). 
Administration of DT (40 ng/g, i.p.) did not affect food intake during the 5-day period post 
injection.  Cumulative food intake at day 32 averaged 127.74 ± 5.11 grams, n=12 for wild 
type mice and 129.29 ± 5.28 grams, n=9 for transgenic mice (p= 0.84).  
It was noticed that the DT-treated transgenic mice had wet cage beddings consistent with 
polyuria. This along with the significant weight loss raised the possibility of diabetes in the 
transgenic mice treated with DT. In order to confirm this, plasma glucose concentration was 
measured in transgenic and wild type mice treated with DT (see below). 
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Figure 2.15. Effects of diphtheria toxin (DT) on body weight and cumulative food 
intake in transgenic DTR-BAC mice. Mice were 35 days old at the start of the experiment. 
Mice received DT (40 ng/g, i.p.) on day 27 (indicated by arrow). DT resulted in a significant 
reduction in body weight (A). Food intake (B) was not different between wild type (Wt) and 
transgenic (Tg) mice during the 5-day period post DT injection. Wt n=12, Tg n=9. *p<0.05. 
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2.3.7 Effect of diphtheria toxin on plasma glucose 
DT was administered i.p. at a dose of 40 ng/g. Plasma glucose concentration was measured 
as described in section 2.2.11. Plasma glucose concentrations were significantly higher on 
day 3 post DT injection in transgenic mice (Figure 2.16). The average plasma glucose on 
day 5 post injection was 8.48 ± 0.51 for wild type mice (n=5) and 31.2 ± 1.37 for transgenic 
mice (n=5, P < 0.001). Plasma glucose concentrations were above the upper limit of 
detection (i.e. ≥33 mmol/L) on day 7 and 10 post DT injection.  
 
 
 
Figure 2.16. The effect of diphtheria toxin (DT) on plasma glucose concentration in 
DTR mice. Mice received DT (40 ng/g, i.p.) on day 1. DT resulted in a significant increase in 
plasma glucose concentration in transgenic mice. The dotted line indicates the upper limit of 
detection. Wild type (wt) n=5; transgenic (tg) n=5. ***p < 0.001. 
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2.3.8 Effects of diphtheria toxin on pancreatic PYY, insulin and glucagon 
 
DT was injected i.p. at a dose of 40 ng/g. Mice were sacrificed 5 days after DT 
administration as significant hyperglycaemia was seen on day 5 in experiment 2.3.7. 
Pancreatic tissues were collected and peptide extracted as described in section 2.2.7.  
Pancreatic concentrations of PYY, insulin and glucagon-IR were determined by 
radioimmunoassay (section 2.2.8).  
 
Pancreatic PYY and insulin-IR concentrations did not statistically differ between wild type 
(Wt) and untreated transgenic (Tg) mice (i.e. prior to administration of DT). Wild type and 
untreated transgenic mice had similar pancreatic PYY-IR concentrations (Wt 31.53 ± 1.44 
pmoles/g, n=3 vs. Tg 29.54 ± 2.40 pmoles/g, n=3, p=0.51) (Figure 2.17 A) and insulin-IR 
concentrations (Wt 23.64 ± 4.44 nmoles/g, n=3 vs. Tg 21.93 ± 5.19 nmoles/g, n=3, p=0.81) 
(Figure 2.17 B). 
 
DT significantly reduced pancreatic PYY (Figure 2.18 A), insulin (Figure 2.18 B) and 
glucagon-IR (Figure 2.18 C). Pancreatic PYY-IR was decreased by 86.1% (Wt 35.07 ± 2.0 
pmoles/g, n= 5 vs. Tg 4.86 ± 0.61 pmoles/g, n=5, p<0.001). Pancreatic insulin-IR was 
decreased by 96.1% (28.31 ± 1.19 nmoles/g, n= 5 vs. Tg 1.09 ± 0.05 nmoles/g, n=5, 
p<0.001). Pancreatic glucagon-IR was decreased by 97.9% (Wt 1.910 ± 0.2 nmoles/g, n= 5 
vs. Tg 0.04 nmoles/g, n=5, p<0.001).  
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Figure 2.17 Pancreatic PYY (A) and insulin-IR (B) concentrations in wild type (Wt) and 
transgenic (Tg) mice prior to administration of diphtheria toxin. Pancreatic PYY-IR (A) 
and insulin-IR (B) concentrations were not different between wild type and untreated 
transgenic mice. Wild type n=3, Transgenic n=3. Results show mean ± SEM. 
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Figure 2.18. Effect of diphtheria toxin (DT) on pancreatic PYY (A), insulin (B) and 
glucagon-IR (C). DT (40 ng/g) was administered by intraperitoneal injection. Pancreatic 
tissue was collected 5 days post injection. Wild type n= 5, Transgenic n= 5. ***p<0.001. 
Results show mean ± SEM. 
85 
 
2.3.9 Effects of various doses of diphtheria toxin on colonic PYY and plasma glucose  
I investigated whether lower doses of DT can differentially affect PYY-IR levels in the colon 
and pancreas. DT was injected intraperitoneally (i.p.) at a range of doses (0.1, 0.2. 0.33 and 
1 ng/g). Mice were sacrificed 5 days after DT injection. Colonic tissue was collected and 
peptide extracted as described in section 2.2.7.  Colonic concentrations of PYY-IR were 
determined by radioimmunoassay as described in section 2.2.8. Plasma glucose 
concentration was measured as described in section 2.2.11. 
Colonic PYY-IR concentrations (Figure 2.19 A) were reduced by 23.3% and 35.3% following 
administration of 0.1 and 0.2 ng/g of DT respectively (n=5, p<0.05). Plasma glucose 
concentrations on day 5 post DT injection were not significantly different between transgenic 
and wild type mice receiving DT at these doses (Fig 2.19 B). 
As expected, higher doses of DT resulted in further reduction in colonic PYY-IR 
concentrations. Colonic PYY-IR concentrations (Figure 2.19 A) were reduced by 70.6% and 
78.3% following administration of DT at 0.33ng/g and 1ng/g of DT respectively (n=5, 
p<0.001). Plasma glucose concentrations on day 5 post DT injection (Fig 2.19 B) were 
significantly higher in transgenic mice receiving these doses (p<0.05). In mice receiving 0.33 
ng/g of DT, average plasma glucose was 7.96 ± 0.39 mmol/L for wild type mice (n=4) and 
11.48 ± 1.20 mmol/L for transgenic mice (n=4, p<0.05). In mice receiving 1 ng/g of DT, 
average plasma glucose was 8.2 ± 0.44 mmol/L for wild type mice (n = 4) and 15 ± 2.31 
mmol/L for transgenic mice (n = 4, p<0.05). 
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Figure 2.19. Dose response effect of diphtheria toxin (DT) on colonic PYY-IR 
concentration (A) and plasma glucose concentration (B) on day 5 post injection. DT 
was injected i.p. at a range of doses (0.1, 0.2. 0.33 and 1 ng/g). Mice were sacrificed 5 days 
after DT injection. Wild type n= 4, Transgenic n= 4. *p<0.05, ***p<0.001. Results show mean 
± SEM. 
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2.3.10 Effects of diphtheria toxin on colonic PYY and pancreatic PYY, insulin and 
glucagon in 5-week and 20-week-old mice 
I investigated whether the effect of diphtheria toxin (DT) on pancreatic hormones was 
different in 20-week-old mice compared to 5-week-old mice. DT was administered 
intraperitoneally (i.p.) at a dose of 40 ng/g. Mice were sacrificed 5 days after DT injection. 
Colonic and pancreatic tissues were collected and peptide extracted as described in section 
2.2.7.  Colonic concentrations of PYY-IR and pancreatic concentrations of PYY, insulin and 
glucagon-IR were determined by RIA (section 2.2.8). 
DT administration resulted in significant reductions in the colonic concentrations of PYY-IR in 
DTR mice of both age groups (Figure 2.20).  Colonic PYY-IR was decreased by 86.9% in 5-
week-old mice (n=5, p<0.01) and by 83.6% in 20-week-old mice (n=5, p<0.01).  
DT administration also resulted in significant reductions in pancreatic PYY, insulin and 
glucagon-IR concentrations in DTR mice of both age.  Pancreatic PYY-IR (Figure 2.21) was 
decreased by 92% in 5-week-old mice (n=5, p<0.01) and by 89.6% in 20-week-old mice 
(n=5, p<0.01). Pancreatic insulin-IR concentration (Figure 2.22 A) was decreased by 80.1% 
in 5-week-old mice (n=5, p<0.01) and by 83.7% in 20-week-old mice (n=5, p<0.01). 
Pancreatic glucagon-IR concentration (Figure 2.22 B) was decreased by 90.7% in 5-week-
old mice (n=5, p<0.01) and by 89.3% in 20-week-old mice (n=5, p<0.01). 
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Figure 2.20. Effect of diphtheria toxin (DT) on colonic PYY-IR concentration in 5-week 
and 20-week-old mice. DT (40 ng/g) was administered i.p. Colorectal tissue was collected 5 
days post injection. Wild type n= 5, Transgenic n= 5. **p<0.01. Results show mean ± SEM. 
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Figure 2.21. Effects of diphtheria toxin (DT) on pancreatic PYY-IR concentration in 5-
week-old and 20-week-old mice. DT (40 ng/g) was administered i.p. Pancreatic tissue was 
collected 5 days post injection. Wild type n=5, Transgenic n=5. **p<0.01. Results show 
mean ± SEM. 
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Figure 2.22. Effects of diphtheria toxin (DT) on pancreatic insulin (A) and glucagon-IR 
(B) concentrations in 5-week-old and 20-week-old mice. DT (40 ng/g) was administered 
i.p. Pancreatic tissue was collected 5 days post injection. Wild type (Wt) n=5, Transgenic 
(Tg) n=5. **p<0.01. Results show mean ± SEM. 
 
91 
 
2.4 Discussion  
The studies described in this chapter investigated the effect of using the PYY promoter to 
drive expression of a DTR transgene in mice.  
2.4.1 Tissue expression profile of DTR  
In order to understand the physiological role of PYY, a transgenic approach to specifically 
ablate PYY-expressing cells in adult mice was used. Prior to investigating the effects of 
ablation of PYY-expressing cells, it was important to demonstrate that the expression pattern 
of DTR transgene driven by the PYY promoter was similar to that of endogenous PYY. 
Transgenic mice from lines DTR20 and 37 were combined to provide adequate age- and 
sex-matched animals for these investigations.  
RT-PCR analysis confirmed that the expression profile of the DTR transgene was generally 
similar to that of PYY. This provides evidence that the full PYY expression domain was 
present in the BAC clone used to generate the transgenic DTR-BAC mice. The regulatory 
elements present in the BAC clone were capable of driving expression of the DTR transgene 
in tissues that express PYY. Although gastric PYY expression was identified by PCR 
analysis of both wild type and transgenic mice, DTR expression was not detected in the 
stomach tissue of transgenic mice. PYY expression is not particularly high in the stomach, 
and DTR expression may be below the detection limit of PCR in this tissue.  
2.4.2 The phenotype of transgenic mice prior to administration of diphtheria toxin  
The transgene integrates randomly into the mouse genome. It is possible that insertion of 
the transgene into the coding region or the regulatory sequences of a particular gene may 
disrupt its function. This may occasionally result in a spurious phenotype in the transgenic 
mice independent of diphtheria toxin (DT). Therefore it was important to ensure that the 
phenotype of the untreated transgenic mice was not different to that of wild type mice.  
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PYY is expressed most abundantly in the distal part of the GI tract (Adrian et al. 1985b). 
Colorectal tissue extracts were used to assess the effect of the DTR transgene on various 
gut hormones in wild type mice and ‘untreated’ transgenic mice (i.e. prior to administration of 
DT). Colorectal PYY, GLP-1, CCK and neurotensin levels were not significantly different 
between the wild type and untreated transgenic mice.  
Immunohistochemical analysis using a specific PYY primary antibody, also illustrated 
identical distribution of PYY in the colonic sections of wild type and untreated transgenic 
mice. Immunohistochemistry demonstrated that the presence of the DTR transgene did not 
affect PYY cell number in the colorectal region of the GI tract. The localisation of PYY in the 
colon was comparable to that reported in previous literature (Roth et al. 1992).  
It was also essential to determine that prior to the administration of DT, the transgenic and 
wild type mice had similar food intake and body weight gain. As expected food intake and 
body weight measured over 7 weeks did not differ between wild type and untreated 
transgenic mice. Together these studies suggest that the wild type and transgenic DTR-BAC 
mice had similar phenotypes with regards to gut hormone regulation of energy homeostasis. 
2.4.3 The effects of diphtheria toxin in DTR-BAC mice  
Ablation of PYY-expressing L cells was achieved by means of DT administration to 
transgenic mice expressing the DTR specifically in PYY-expressing cells, and the effects 
compared to those on wild type mice administered DT. Wild type mice exhibited significant 
resistance to the effects of DT (Saito et al. 2001). The expression of the human or primate 
DTR in mice confers sensitivity to DT.  
Mice received intraperitoneal DT at a dose of 40 ng/g. This dose has previously been 
demonstrated to enable the selective ablation of AgRP neurons (Gropp et al. 2005). As 
expected, administration of DT to DTR mice resulted in a significant (93%) reduction of 
colonic PYY concentration. Administration of diphtheria toxin resulted in a significant 
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reduction in PYY-positive cells visualized by immunohistochemistry. This supports the PCR 
analysis results that the PYY promoter drives colonic expression of diphtheria toxin receptor 
in a PYY-like manner.  
DT also induced 80% loss of colonic GLP-1. This was expected as GLP-1 is known to co-
localize with PYY in the L cells. L cell ablation also resulted in reductions in colonic CCK and 
neurotensin. Conditional ablation of secretin cells in transgenic mice expressing herpes 
simplex virus 1 thymidine kinase has been shown to induce complete ablation of 
enteroendocrine cells expressing CCK and peptide YY (L cells) as well as secretin cells 
(Rindi et al. 1999). This provides evidence for a close developmental relationship between 
these three cell types. At least 50% of CCK and neurotensin-expressing cells in the gut co-
express PYY (Roth et al. 1992). However CCK and neurotensin are produced mainly in the 
small intestine; the physiological relevance of the lower levels of CCK and neurotensin in the 
colon is unknown (Buchan et al. 1978b; Carraway and Leeman 1976).  
The enteroendocrine cell lineage is thought to have two major branches. One branch 
produces cells expressing PYY, GLP-1, CCK and neurotensin, while the other generates 
cells expressing substance P and serotonin (Roth et al. 1992). It has been shown that all L 
type enteroendocrine cells initially express PYY. However as cells differentiate, only one 
branch retains PYY. The PYY-producing cells have been shown to co-express CCK, GLP-1, 
and neurotensin (Roth et al. 1992). Co-expression of PYY with substance P/serotonin is only 
rarely reported (Roth et al. 1992). Administration of DT to transgenic mice did not affect 
colorectal concentrations of substance P, further supporting the lack of co-localisation of 
PYY with substance-P in the same enteroendocrine cells.  
GIP is produced by K cells, which have been identified mainly in the upper small intestine 
(Buchan et al. 1978a). Double immunohistochemistry and in situ hybridization studies have 
reported that GIP and PYY are rarely colocalized (Mortensen et al. 2003). Administration of 
94 
 
DT did not affect colorectal tissue concentrations of GIP. This provides further evidence for 
the specificity of L cell ablation in DTR-BAC mice.  
Interestingly, administration of DT also resulted in dramatic weight loss in the first week after 
DT injection. The weight loss observed in DTR mice could not be attributed to reduced food 
intake, which was not different between wild type and transgenic DTR mice during the first 
week post DT injection. The weight loss and the presence of wet beddings consistent with 
polyuria, raised the possibility of diabetes developing after DT injection. The development of 
diabetes was confirmed the severe hyperglycaemia noted from day 4 post-DT injection.  
2.4.4 Effect of DT on pancreatic hormones 
Administration of DT significantly reduced pancreatic PYY, glucagon and insulin content. 
The development of diabetes in these mice could therefore be attributed to the significant 
loss of pancreatic insulin. In the adult murine pancreas, PYY immunoreactivity has been 
demonstrated in alpha (glucagon-expressing), delta (somatostatin-expressing) and PP cells 
(Jackerott et al. 1996). The expression of DTR in PYY-expressing alpha cells likely accounts 
for the reduction in pancreatic glucagon following DT administration. 
However the near total loss of pancreatic insulin induced by DT was surprising since adult 
pancreatic beta cells have not been shown to contain immunoreactive PYY (Jackerott et al. 
1996). There is evidence that specific cell ablation with DT does not induce a bystander 
effect. DT has been shown to cause specific cell damage without any obvious abnormalities 
in nearby cells or tissues (Saito et al. 2001). DT has previously been demonstrated to 
specifically ablate pancreatic beta cells without inducing bystander death of adjacent cells 
observed with commonly used chemical agents such as streptozotocin (Kaestner 2007). It is 
therefore unlikely that ablation of PYY-expressing islet cells resulted in non-specific loss of 
beta cells.  
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PYY is the earliest peptide detectable in the developing murine pancreas and is present in 
all early appearing endocrine cell types. It has been suggested that PYY-positive endocrine 
cells may represent precursors for mature islet cells. PYY expression has been 
demonstrated in the developing murine pancreas as early as E11 (Jackerott et al. 1996). 
PYY is detectable in small endocrine cell clusters and found to be located in both insulin and 
glucagon cells. Insulin and glucagon co-localization is detected during early islet 
development. However by birth, insulin and glucagon are located in separate cell 
populations (Myrsen-Axcrona et al. 1997). PYY has been suggested to be a mediator of islet 
cell development, as well as a cofactor for growth factor responses, not only during foetal 
pancreas formation but also during regeneration in adult animals (Liu et al. 2006). Marked 
expansion of the PYY-expressing population has been shown during pancreatic 
regeneration (Liu et al. 2006). It is possible that PYY expressing cells maintain an important 
paracrine role in the maintenance of pancreatic islets and that their loss is detrimental to islet 
survival.  
Pancreatic beta cells comprise the centre of the pancreatic islets, whereas PYY-expressing 
cells are located around the periphery of the islets. It is possible that ablation of these 
surrounding cells can adversely affect the integrity of the islets, ultimately resulting in the 
loss of the central beta cells. However, it has previously been shown that beta-cells are able 
to survive when the neighbouring alpha-cells are destroyed (Skak et al. 2005). 
All the above experiments were performed in 5-7 week old mice. As PYY is expressed in the 
foetal beta cells, I hypothesized that the reduction in pancreatic insulin in DTR mice was due 
to residual beta cell expression of PYY in the first few weeks after birth. I therefore 
investigated the effect of DT administered to older (i.e. 20-week-old) mice, which would not 
be expected to express PYY in beta cells. Pancreatic beta cells in 20-week-old mice were 
also sensitive to DT, and DT administration resulted in 84% loss of pancreatic insulin in 
these mice. 
96 
 
Pancreatic beta cells have the potential to regenerate after an insult. However regeneration 
of beta cells occurs over a longer period than that of colonic L cells. Doxycycline-induced 
expression of diphtheria toxin in beta cells has been shown to result in the loss of 
approximately 80% of these cells (Nir et al. 2007). A significant regeneration of beta cell 
mass was seen twenty-three weeks after the withdrawal of doxycycline (Nir et al. 2007). 
Thus while many of the colonic PYY expressing cells killed by DT are replaced within days, a 
longer period would likely be required for the replacement of islet cells. It is possible, given 
the putative role of PYY in pancreatic regeneration, that the destruction of pancreatic PYY-
expressing cells is sufficient to irreversibly damage the pancreas.  
I investigated whether lower doses of DT could affect colonic PYY levels without causing 
diabetes. DT administered at a dose of 0.2 ng/g did not affect plasma glucose, but only 
resulted in a 35% reduction in colonic PYY. Administration of DT at 0.3 ng/g resulted in a 
statistically significant 71% reduction in colonic PYY in DTR mice. However these animals 
became hyperglycaemic 4-5 days post DT injection, indicating significant loss of pancreatic 
insulin. These studies suggested that it would be difficult to ablate the majority of L cells 
without affecting the pancreatic beta cells. In summary, the DTR-BAC mice expressed 
diphtheria toxin receptor in a pattern similar to that of endogenous PYY. The wild type and 
transgenic mice had similar phenotypes before administration of DT.  Administration of DT 
resulted in loss of colonic and pancreatic PYY as expected. The mice, however, developed 
severe hyperglycaemia due to loss of pancreatic insulin.  
The loss of pancreatic beta cells following ablation of PYY expressing cells in DTR mice is 
an intriguing finding and requires further investigation. The transgenic mouse was made by 
identifying a BAC containing the PYY gene sequence near the centre of its DNA insert. 
Although, this increases the probability that all the PYY transcriptional regulatory elements 
will be present, it is still possible that some regulatory sequences are missing. This may 
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result in some beta cell expression of DTR. Therefore it is important to clearly demonstrate 
the cellular localization of DTR within the islets. 
The possible explanations for loss of pancreatic insulin/beta cells also include removal of an 
important hormonal support from the PYY-expressing L cells in the gut such as GLP-1, or 
loss of a paracrine signal from the PYY-expressing cells within the pancreas. The possible 
effects of PYY loss in the gut and/or pancreas on beta cell viability are explored in chapter 3.  
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Chapter 3 
Investigation of the cause of 
diabetes associated with ablation 
of PYY-expressing cells in 
transgenic DTR-BAC mice 
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3 Investigation of the cause of diabetes associated with ablation of 
PYY-expressing cells in transgenic DTR-BAC mice 
 
3.1 Introduction 
The ablation of the PYY-expressing cells resulted in a dramatic loss of pancreatic insulin 
leading to diabetes in transgenic DTR-BAC mice. The work presented in this chapter aims to 
determine the underlying aetiology of pancreatic beta cell and insulin loss occurring after 
ablation of the PYY-expressing cells. 
3.1.1 Pancreatic islets of Langerhans 
Within the pancreas, the endocrine cells are organized in spherical clusters called ‘islets of 
Langerhans’. The endocrine pancreas of mammals consists of several thousand islets of 
Langerhans. These islets are scattered through the secretory acini and excretory ducts 
(Herrera 2002). There are four different endocrine cell types within the islets: insulin-
producing beta cells, glucagon-producing alpha cells, somatostatin-producing delta cells and 
PP-cells (Orci and Unger 1975; Orci 1982). Each of these four cell types has a characteristic 
distribution within the islet and comprises a characteristic proportion of the islet (Orci and 
Unger 1975; Orci 1982). During foetal development, cells containing more than one of these 
hormones are frequently observed. However, cell lineage studies using specific transgenes 
that ablate or mark islet cell precursors suggest that the alpha cells and beta cells 
differentiate from two independent cell lineages (Herrera et al. 1994; Herrera 2000).  
A neurovascular bundle consisting of sympathetic and parasympathetic nerves and 
arterioles enters the central beta cell-rich core of the islet. The capillaries formed from these 
arterioles pass through the periphery of the islet to reach the portal venous circulation. 
Pancreatic endocrine cells communicate with each other through gap junctions and 
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extracellular spaces. This organization of the cells within the islets allows cellular products 
released from one islet cell type to influence the function of the adjacent cells. For example, 
insulin released from beta cells suppresses glucagon secretion from the surrounding alpha 
cells. 
3.1.2 Morphogenesis and ontogeny of the endocrine pancreas 
Pancreatic morphogenesis starts during early gestation with evaginations of the embryonic 
foregut forming the ventral and dorsal buds of the pancreas. This begins at 28 days’ 
gestation in humans and at embryonic day (ED) 8 in mice (Peters et al. 2000). Both exocrine 
and endocrine cells originate from the primitive gut endoderm.  
Polyclonal endocrine cells aggregate to form islets (Deltour et al. 1991). This appears to 
occur when the endocrine cells start to express cell adhesion molecules such as neural cell 
adhesion molecule (N-CAM) (Lackie et al. 1994) and cadherins (Dahl et al. 1996). In 
humans, islet formation starts at gestational week 12 (Peters et al. 2000). Small aggregates 
of endocrine cells grow out from pancreatic ducts. Islets later lose their contact with ducts at 
around gestational week 17 to 20. Between gestational week 21 and 26, the average size of 
islets increases to 99um in diameter (Hahn von Dorsche et al. 1989). 
Studying mice with disrupted pancreatic regulatory genes in particular islet transcription 
factors, has enhanced our understanding of the genetic regulation of pancreatic endocrine 
cell development. Morphogenesis and differentiation of the pancreas is under the control of 
transcription factors including Pdx-1, Pax4 and pax6. Pdx-1 is a homeobox transcription 
factor, which is believed to be a key determinant of pancreatic development (McLin and Zorn 
2003). Knock-out mice homozygous for a pdx-1 gene mutation lack a pancreas (Jonsson et 
al. 1994). Targeted deletion of the Isl-1 gene has shown that it is necessary for the 
differentiation of islet cells (Ahlgren et al. 1997). Another key regulator of pancreatic 
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endocrine cell development is neurogenin 3 (ngn3), a basic helix-loop-helix transcription 
factor (Apelqvist et al. 1999; Gradwohl et al. 2000; Jensen et al. 2000).  
The order of appearance of different islet endocrine cells differs in humans and mice. 
Somatostatin- and PP-producing cells are the first endocrine cells identified by hormone 
content in the human embryonic pancreas. These cells are observed scattered among ductal 
cells from the 7th gestational week (Bocian-Sobkowska et al. 1997).  Glucagon-producing 
cells appear one week later, and insulin-producing cells are detectable by the beginning of 
gestational week 9 (Peters et al. 2000). In mice, however, insulin and glucagon-expressing 
cells are first detected between days 9.5 and 10.5 of embryonic development (Herrera et al. 
1991; Teitelman et al. 1993), and somatostatin is expressed by embryonic day 15.5.  
3.1.3 Gastrointestinal peptides and pancreatic beta cell mass 
A number of gastrointestinal hormones have been reported to affect beta cell mass. Gut 
peptides may affect beta cell mass by influencing beta cell proliferation, beta cell apoptosis 
and islet neogenesis. 
Glucagon-like peptide 1 (GLP-1) has been shown to promote beta cell proliferation and islet 
neogenesis, and to inhibit beta cell apoptosis (Lavine and Attie 2010). Exogenous GLP-1 
administration promotes beta cell proliferation in models of beta cell mitogenesis in rodents. 
GLP-1 stimulates beta cell proliferation in normoglycaemic rats and mice (Lavine and Attie 
2010) and GLP-1 receptor agonists activate beta cell mitogenesis in non-obese diabetic 
(NOD) mice which are susceptible to development of autoimmune insulin dependent 
diabetes mellitus (Zhang et al. 2007). GLP-1 receptor agonism also enhances beta cell 
replication following caspase 8-mediated beta cell ablation (Wang et al. 2008) and partial 
pancreatectomy (Kwon et al. 2009; Xu et al. 1999). Exogenous GLP-1 administration also 
promotes beta cell replication in models of obesity-induced diabetes. For example, GLP-1 
receptor agonism has been shown to increase beta-cell mass and islet size in obese diabetic 
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(ob/ob) mice (Green et al. 2006). GLP-1 receptor activation regulates beta-cell mitogenesis 
through activation of protein kinase A (PKA) signaling and transactivation of the epidermal 
growth factor receptor (EGFR). The signaling cascades downstream of these receptors 
stimulate beta cell replication through activation of transcription factors such as pdx-1 and 
CREB (cyclic AMP response element-binding) (Lavine and Attie 2010). GLP-1 receptor 
knock-out mice have reduced beta cell regeneration following partial pancreatectomy, 
suggesting that this is a physiological role, and not just a pharmacological effect (De Leon et 
al. 2003). 
GLP-1 has also been shown to stimulate islet neogenesis in several models of beta-cell 
regeneration. GLP-1 receptor agonism increases markers of islet neogenesis in diabetic 
NOD mice (De Leon et al. 2003; Suarez-Pinzon et al. 2008) and in rats following 
streptozotocin treatment (Tourrel et al. 2001) or partial pancreatectomy (Kwon et al. 2009; 
Xu et al. 1999). 
There is also evidence that GLP-1 receptor agonism reduces beta-cell apoptosis. GLP-1 
receptor knockout mice exhibit increased beta cell apoptosis (Li et al. 2003). GLP-1 receptor 
agonism also reduces beta cell apoptosis in streptozotocin-induced diabetes (Li et al. 2003; 
Maida et al. 2009), and GLP-1 prevents beta-cell apoptosis in the NOD mouse (Suarez-
Pinzon et al. 2008; Zhang et al. 2007). 
The small intestinal hormone cholecystokin (CCK) has also been shown to increase beta cell 
mass. CCK is synthesized and released by I-cells in the duodenum in response to fat and 
protein (Dufresne et al. 2006). CCK regulates gallbladder contraction and pancreatic 
exocrine secretion through binding to the CCKA receptor (Dufresne et al. 2006). In addition, 
CCK is a neuropeptide that regulates behaviours such as satiety and anxiety through the 
CCKB receptor (Dufresne et al. 2006). CCK stimulates beta-cell proliferation in rats via the 
CCKA receptor. CCK-8 has been shown to increase islet cell replication during the 
regenerative phase following partial pancreatectomy in rats (Chen et al. 2007). 
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Administration of CCK-8 increases beta-cell mass via proliferation in streptozotocin-treated 
rats (Kuntz et al. 2004). Over-expression of the CCK gene (Cck) in isolated rat islets has 
been shown to stimulate islet cell proliferation (Lavine et al. 2010). However, Cck over-
expression in mouse and human islets has no effect on replication (Lavine et al. 2010).   
Gastrin is a peptide hormone produced and released from G cells in the gastric antrum that 
stimulates gastric acid secretion by binding to the CCKB receptor (Dufresne et al. 2006).  
Gastrin stimulates islet neogenesis by acting on the CCKBR (Lavine and Attie 2010). CCK 
binds to the CCKB receptor with similar affinity to gastrin. Therefore it is possible that CCK 
also promotes islet neogenesis. 
Glucose-dependent Insulinotropic peptide (GIP) is another gut peptide that promotes beta-
cell survival in vivo (Lavine and Attie 2010). GIP receptor agonism has been shown to 
reduce beta cell apoptosis in streptozotocin-treated mice (Maida et al. 2009; Widenmaier et 
al. 2010). 
Ghrelin is a peptide initially isolated from rat and human stomach and is an endogenous 
ligand of the growth hormone secretagogue receptor type 1a (Kojima et al. 1999). The 
ghrelin gene peptides include acylated ghrelin, unacylated ghrelin, and obestatin (Granata et 
al. 2010). The ghrelin gene peptides are expressed in rodent and human pancreatic islets 
during both foetal period and adulthood. Ghrelin is expressed in epsilon cells and also 
colocalizes with glucagon in alpha cells (Granata et al. 2010). In addition to regulation of 
insulin secretion, the ghrelin gene peptides are reported to promote beta cell proliferation 
and regeneration, inhibit beta cell apoptosis, and modulate the expression of genes 
important to islet cell function (Granata et al. 2010). 
3.1.4 PYY-expressing cells in pancreatic islets of Langerhans 
Peptide YY immunoreactivity has been identified in the earliest endocrine cells in the foetal 
pancreas in mice (Upchurch et al. 1994). PYY has been shown to be co-expressed in all 
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pancreatic islet cell types during development (Upchurch et al. 1994). Co-expression of 
peptide YY in all islet cell types as they first emerge raises the possibility that all islet cell 
types may originate from a common, peptide YY-producing progenitor cell (Upchurch et al. 
1994).  However, pancreatic endocrine cells have been shown to develop normally in the 
absence of peptide YY, with the exception of pancreatic polypeptide (PP) cell (Schonhoff et 
al. 2005). Nevertheless, it is possible that during development, other factors could 
compensate for the loss of PYY. 
PYY administration does not appear to influence basal plasma levels of insulin, or glucagon 
in vivo (Bottcher et al. 1989). However, PYY has been reported to inhibit stimulated insulin 
and glucagon secretion. Insulin secretion stimulated by glucose or the cholinergic agonist 
carbachol is inhibited by PYY (Bottcher et al. 1989). Similarly, at high doses PYY inhibits 
arginine-induced secretion of both insulin and glucagon in rats (Szecowka et al. 1983). PYY 
also inhibits carbachol-induced glucagon secretion (Bottcher et al. 1989).  
The number of PYY immunoreactive cells increases in pancreatic islets following beta cell 
death in alloxan-treated hyperglycemic mice (Bottcher et al. 1994). The concentration of 
pancreatic PYY significantly increases in the splenic portion of the pancreas in these mice 
(Bottcher et al. 1994). Pancreatic glucagon concentrations, however, were not significantly 
changed in these studies (Bottcher et al. 1994). It is tempting to hypothesize that increased 
PYY expression following beta cell death may present a compensatory mechanism 
stimulating beta cell proliferation or islet neogenesis. 
In the adult murine pancreas, PYY is expressed in less than half of the glucagon-producing 
alpha cells (Upchurch et al. 1994). In addition to playing a role in glucose homeostasis, 
glucagon also participates in the regulation of the number of islets per pancreas and the 
proportion of the different endocrine cell types in islets (Vuguin et al. 2006). Ablation of the 
glucagon receptor has been shown to delay beta-cell differentiation and perturb the 
proportion of beta to alpha cells in embryonic islets (Vuguin et al. 2006). In adults, deletion of 
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the glucagon receptor affected the expression of several beta cell specific genes, inhibited 
the progression of alpha cells to maturity, and increased alpha, beta and delta cell mass 
(Vuguin et al. 2006). 
It has recently been shown that the adult pancreas can generate new beta cells after their 
near total loss, mainly by the spontaneous reprogramming of alpha-cells (Thorel et al. 2010). 
Alpha cells were able to transdifferentiate into beta cells in a transgenic model of diphtheria-
toxin-induced acute, selective and near-total beta-cell ablation (Thorel et al. 2010).  
A marked expansion of the PYY-expressing cells has been observed during pancreatic 
regeneration in interferon-gamma (IFN-γ) transgenic mice (Liu et al. 2006). In IFN-γ 
transgenic mice, the islet cells constitutively express IFN-γ under the control of the insulin 
promoter (Liu et al. 2006). This mouse model has been used to study islet neogenesis 
during pancreatic regeneration. It has been shown that during pancreatic regeneration in 
these mice, PYY, as well as GLP and GIP, is strongly expressed in the ducts and in 
periductal regions (Liu et al. 2006). Furthermore, PYY and insulin-like growth factor 1 (IGF-1) 
have been shown to act in concert to promote cellular responses in pancreatic epithelial 
cells. Activation of phosphorylated mitogen-activated protein kinase (pMAPK) is significantly 
increased following IGF-I treatment in PYY-transfected pancreatic epithelial cells (Liu et al. 
2006). These studies suggest that PYY mediates islet cell development, during pancreatic 
regeneration in adult animals as well as during foetal pancreatic formation. 
PYY is also co-expressed with pancreatic polypeptide in most PP-cells (Upchurch et al. 
1994). PP expression has been detected in foetal murine pancreas at embryonic day 10.5 
(Herrera et al. 1991). The very early expression of the PP gene and its co-localization with 
other pancreatic hormones during islet formation has led to suggestions that that PP cells 
may play a role in the development of endocrine pancreas. 
Somatostatin-producing delta cells have been shown to co-express PYY from their first 
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appearance in foetal pancreas and through adulthood (Upchurch et al. 1994). Delta cells 
comprise 5–10% of the islet endocrine cells (Hauge-Evans et al. 2009). About half of the 
somatostatin cells display PYY immunoreactivity in adult rat pancreas (Jackerott et al. 1996). 
In addition to the delta cells in the pancreatic islets, somatostatin is also produced and 
secreted by neuroendocrine cells in the gastrointestinal tract and the central nervous 
system.  Gut-derived somatostatin contributes to most of the circulating somatostatin 
(Reichlin 1983b, 1983a). Somatostatin is predominantly a negative regulator of endocrine 
systems.  Exogenous administration of somatostatin inhibits stimulated insulin and glucagon 
secretion (Strowski et al. 2000).  
In conclusion, PYY is expressed in a number of endocrine cells in the pancreas as well as 
the enteroendocrine L cells. PYY and other products of PYY-expressing cells in the gut and 
pancreas appear to be involved in the regulation of islet cell development and regeneration, 
as well as in glucose homeostasis. 
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3.1.5 Hypothesis 
The insulin loss and subsequent hyperglycaemia that occurs with ablation of PYY-
expressing cells is secondary to removal of L cell products (such as PYY), and/or paracrine 
signals from pancreatic PYY-expressing cells. PYY plays an important role in beta cell 
viability and maintenance. 
3.1.6 Aims 
To determine: 
1. The effects of specific ablation of enteroendocrine L cells by local intestinal 
administration of diphtheria toxin (DT) in transgenic DTR-BAC mice. 
2. The effects of specific ablation of PYY-expressing cells in cultured islets. 
3. The cellular localization of DTR in pancreatic islets. 
4. The effects of replacement of PYY, GLP-1 and PP on pancreatic islets following 
ablation of PYY-expressing cells in vivo. 
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3.2 Methods 
 
3.2.1 In vivo administration of diphtheria toxin 
Diphtheria toxin (DT) was diluted in sterile water to the desired concentration. Transgenic 
and wild type mice received 40ng/g of DT intraperitoneally (i.p.) unless otherwise specified. 
DT was also administered into the terminal ileum following laparotomy under isofluorane 
inhalation anaesthesia. Mice were allowed to recover from the anaesthetic before being 
returned to their home cage. Rectal DT was administered under isofluorane inhalation 
anaesthetic using an 18G cannula. Mice were killed by cervical dislocation 5 days after DT 
administration unless otherwise specified. Colonic and pancreatic tissues were collected and 
peptide extracted as in section 2.2.7. Colonic and pancreatic peptide concentrations were 
measured using radioimmunoassay as described in section 2.2.8. 
3.2.2 Isolation of islets of Langerhans  
Materials 
Collagenase (1 mg/ml; type XI; Sigma, St. Louis, MO) 
RPMI 1640 (10% FBS, 2% glutamine, 100 units/ml penicillin/0.1 mg/ml streptomycin,   
Gibco) 
MEM (Gibco) 
Foetal calf serum (FCS) (Gibco) 
Histopaque 1077 (Sigma) 
Methods 
Islets from 5 to 8-week-old male mice were isolated by collagenase digestion. Mice were 
injected with 50 µl of Nembutal (2 μl/g) intraperitoneally and placed under a dissecting 
microscope. The duodenum was clamped at the ampulla of Vater where the bile and 
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pancreatic ducts empty into the duodenum. Between 2 and 3 millilitres of collagenase (1 
mg/ml; type XI; Sigma, St. Louis, MO) were injected into the bile duct (using a bent 29G 
needle and 2cc syringe) to expand the pancreas. The heart was then clipped to sacrifice the 
mouse. Pancreata were removed and placed in a 50ml conical plastic tube on ice.  
Pancreata were then incubated at 37oC for about 20 minutes. Twenty-Five millilitres of ice-
cold MEM (Gibco, UK) plus 10% foetal calf serum (FCS) (Gibco) were added to the tubes to 
stop reaction. The tubes were shaken vigorously for 10 sec and centrifuged for 2 minutes at 
290g. The supernatant was discarded and the pellet resuspended with MEM and centrifuged 
for 90 seconds at 290g. The supernatant was discarded and the pellet again resuspended 
with 10 ml of MEM and centrifuged for 90 seconds at 290g. The supernatant was discarded, 
pellet resuspended in MEM and filtered through 425μm stainless steel mesh into a new 50 
ml tube. The tube was then centrifuged at 290g for 2 minutes, supernatant discarded and 
drops of MEM removed from tube with Kimwipe.  
The pellet was resuspended in 15 ml Histopaque 1077 (Sigma) by vortexing. Ten millilitres 
of MEM were added and centrifuged at 1750g for 18 minutes with slow acceleration and no 
brake. The islets were removed at the interface, placed in a new 50ml tube and resuspended 
in 25ml total media and allowed to sit for 4 minutes on ice. The top 10ml were removed and 
10 ml of new media was added. This was repeated 4 times to further purify the islets. The 
islets were pelleted, resuspended in media and placed into a 60 ml Petri dish. 
The plate was swirled so that the islets coalesced in the centre. The desired number of islets 
was placed into a microcentrifuge tube containing 1ml of MEM. The islets were washed 
(pelleted, supernatant removed and resuspended) three times with cold PBS. Four millilitres 
of room temperature RPMI 1640 (10% FBS, 2% glutamine, 100 units/ml penicillin/0.1 mg/ml 
streptomycin) were added into 60 mm Petri dish. One millilitre of the same was added to the 
microtube with islets. Islets were pipetted into a Petri dish and incubated at 37oC (5% CO2). 
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3.2.3 The effect of diphtheria toxin on hormone content, cell morphology and viability 
in cultured islets  
Pancreatic islets were isolated from 4 wild type and 4 transgenic mice. Four groups of wild 
type and four groups of transgenic islets were placed into small Petri dishes and exposed to 
standard culture medium (RPMI 1640), 50ng/ml DT, 150ng/ml DT or 750ng/ml DT. One 
hundred and sixty five islets were in each group shown in table 3.1. Various concentrations 
of DT were prepared in culture medium with 10% FCS. 
Genotype Treatment 
Wt RPMI 
Wt 50ng/ml DT 
Wt 150ng/ml DT 
Wt 750ng/ml DT 
Tg RPMI 
Tg 50ng/ml DT 
Tg 150ng/ml DT 
Tg 750ng/ml DT 
 
Table 3.1 In vitro treatment of cultured pancreatic islets from wild type (Wt) and transgenic 
(Tg) mice with increasing concentrations of diphtheria toxin (DT). 
 
The islets were maintained in culture for four days. Photographs of cultured islets were taken 
on days 1, 2 and 3 following addition of DT to the medium. On day 4 post-DT treatment, 
groups of 5 islets were placed into eppendorf tubes for hormone content (n=6). Groups of 5 
islets were placed into eppendorf tubes for ATP assay (n=8) as described in section 3.2.3.1.  
For measurement of hormone content, islets were picked into eppendorf tubes and 
resuspended in 50 l of 10mM HCl. After 20 minutes, HCl was neutralised by addition of 200 
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l 0.5M PO4 buffer (+ 0.5mg/ml BSA). The samples were then sonicated on ice and frozen at 
-20C until hormone contents were measured using radioimmunoassay (section 2.8.8). 
3.2.3.1 Assessment of islet cell viability 
Islet cell viability was assessed using the CellTiter-Glo Luminescent Cell Viability Assay 
(Promega, Madison, WI). The CellTiter-Glo® Luminescent Cell Viability Assay is a 
homogeneous method to determine the number of viable cells in culture. This assay is 
based on quantity of the ATP present, which indicates the presence of metabolically active 
cells. The CellTiter-Glo® Assay relies on the properties of a thermostable luciferase (Ultra-
Glo™ Recombinant Luciferase), which generates a luminescent signal in the presence of 
ATP. The luminescent signal is proportional to the quantity of ATP present. The amount of 
ATP is proportional to the number of cells present in culture (Crouch et al. 1993). 
The assay was performed according to the manufacturer’s protocol. The ‘CellTiter-Glo® 
Reagent was prepared by addition of the CellTiter-Glo® buffer to the CellTiter-Glo® 
substrate. One hundred microlitres of CellTiter-Glo® Reagent was added to 100μl of 
medium containing cells in each well of a 96-well plate. The contents were mixed for 2 
minutes on an orbital shaker to induce cell lysis. The plate was incubated at room 
temperature for 10 minutes and luminescence recorded. Control wells contained medium 
without cells to obtain a value for background luminescence. 
3.2.4 Immunohistochemical localization of pancreatic insulin and PYY in DTR-BAC mice 
Immunohistochemistry was used to determine cellular co-localization of diphtheria toxin 
receptor with PYY and insulin in pancreatic islets of transgenic DTR-BAC mice.  
Materials  
Methanol 
  Hydrogen peroxide 
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  0.01M Citrate buffer pH 6 (see Appendix) 
  0.01M PBS (see Appendix) 
  PBS/0.05%Tween: (see Appendix) 
  0.05 M Tris-buffered saline (TBS) pH 7.6: (see Appendix) 
  Antibodies: Insulin (C27C9) rabbit mAb (Cell Signalling Technology, MA, USA) 
    Rabbit anti-PYY ab22663 (Abcam, Cambridge, UK) 
    Biotinylated donkey anti-rabbit (H+L) (Jackson, West Grove, PA) 
  Normal donkey serum (Jackson, West Grove, PA) 
  Vector® Avidin/Biotin Blocking Kit (Cat. No. SP-2001). 
  ABC vectastain kit (Vector Laboratories, Burlingame, CA) 
  NovaRED substrate kit (Vector Laboratories, Burlingame, CA) 
  DPX mounting media 
Methods 
Carbon dioxide inhalation was used to sacrifice the mice. Pancreatic tissue was dissected 
and fixed in 10% formaldehyde overnight, before being processed and paraffin embedded 
(Histopathology, Hammersmith Hospital).   
Five-micrometer sections were cut using an AS500 microtome (Anglia Scientific, Cambridge, 
U.K.). Sections were mounted on poly-lysine slides and washed with xylene to remove the 
paraffin. The sections were then rehydrated by being washed in decreasing concentrations 
of ethanol (100%, 70% and 50%). Sections were washed in 0.01M PBS for two minutes. 
Endogenous peroxidase enzyme activity was blocked by incubation with 0.6% H2O2 in 
methanol (v/v) for 15 minutes. The slides were gradually rinsed in distilled water.  
The sections were heated in a microwave in preheated 0.01M citrate buffer for 10 minutes to 
permit antigen retrieval. Slides were gradually cooled in distilled water, rinsed in 0.01M 
PBS/0.05%Tween and loaded into Sequenza immunostaining racks (Shandon, Pittsburgh, 
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PA, USA). A 10-minute incubation with 100µl of 1:20 normal donkey serum at room 
temperature was used to block non-specific binding. Avidin/Biotin blocking was performed 
using Vector® Avidin/Biotin Blocking Kit (Cat. No. SP-2001). Sections were incubated with 
100 µl of Avidin for 15 minutes at room temperature. Sections were then washed with 0.01M 
PBS/0.05%Tween and incubated with 100 µl of Biotin for 15 minutes at room temperature.   
Sections were then rinsed with 0.01M PBS/0.05%Tween. Serial sections were incubated 
overnight at 4ºC with either 100µl of a primary antibody specific for insulin (at 1:800 dilution 
in 0.1% BSA in 0.01M PBS) or PYY (at 1:10,000 dilution in 0.1% BSA in 0.01M PBS). 
Negative controls consisted of sections incubated with PBS.  
The sections were washed the following day in 0.01M PBS/0.05%Tween (1 x 5 minutes), 
and incubated with 100µl of secondary antibody (goat anti-Rabbit IgG) at 1:50 dilution in 
0.1% BSA in 0.01M PBS at room temperature. A working solution of ABC/HRP was 
prepared by diluting (1:50) reagents from the ABC/HRP kit using Tris/HCl solution. After 30 
minutes of incubation with the secondary antibody, sections were washed with 0.01M PBS 
(1 x 5 minutes) and incubated with ABC-HRP for 30 minutes.  
Slides were then washed in 0.01M PBS (1 x 5 minutes) and developed by incubation with 
NovaRED substrate at the manufacturer’s recommended dilution (3 drops of reagent 1, 2 
drops of reagent 2, 2 drops of reagent 3 and 2 drops of H2O2 per 5ml GDW). The slides were 
rinsed in distilled water to stop the reaction. Sections were dehydrated by being washed in 
increasing concentrations of ethanol (50%, 70%, 100%) and mounted using DPX mounting 
media. 
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3.2.5 Immunohistochemical localization of DTR in colon an pancreatic islets in DTR-
BAC mice 
Diphtheria toxin receptor (DTR) is a membrane-anchored form of the heparin binding EGF-
like growth factor (HB-EGF). Immunohistochemical localization of DTR within the colon was 
performed using an antibody against human HB-EGF. Tyramide Signal Amplification (TSA) 
was used for detection of lower levels of DTR in islet cells. TSA is a technology that 
enhances sensitivity for localization of low abundance proteins. HRP converts the TSA 
reagent to a highly reactive free radical that binds covalently to electron-rich amino acids 
such as tryptophan and tyrosine. The amplification reagent is labeled with biotin. Therefore 
the reaction results in the deposition of numerous biotin labels immediately adjacent to the 
immobilized HRP enzyme. These labels can then be indirectly detected using a streptavidin-
enzyme conjugate. 
Materials 
  Methanol 
  Hydrogen peroxide 
  0.01M Citrate buffer pH 6 (see Appendix)  
  0.01M PBS (see Appendix) 
  PBS/0.05%Tween: (see Appendix) 
  0.05 M Tris-buffered saline (TBS) pH 7.6: (see Appendix) 
  Normal donkey serum (Jackson, West Grove, PA) 
  Vector® Avidin/Biotin Blocking Kit (Cat. No. SP-2001) 
  Anti-HB-EGF antibody (Abcam, Cambridge, UK) 
  Biotinylated donkey anti-rabbit (H+L) (Jackson, West Grove, PA) 
  ABC vectastain kit (Vector Laboratories, Burlingame, CA) 
  TSA PLUS Biotin Kit (PerkinElmer, Waltham, MA, USA) 
  NovaRED substrate kit 
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  (Vector Laboratories, Burlingame, CA) 
  DPX mounting media 
Methods 
A mouse monoclonal anti-HB-EGF antibody (Abcam, Cambridge, UK) was used to detect 
expression of the product of the DTR transgene in DTR-BAC mice. A major problem with 
using mouse primary antibodies on mouse tissues is the inability of the anti-mouse 
secondary antibody to distinguish between endogenous mouse immunoglobulins in the 
tissue and the mouse primary antibody. This can result in high background staining which 
obscures the specific staining. In order to overcome this problem, I used the Vector® M.O.M. 
Immunodetection Kit (Vector Labs, Burlingame, CA). This kit is designed specifically to 
localize mouse primary monoclonal and polyclonal antibodies on mouse tissues. It utilizes a 
novel blocking agent and special detection methodology to significantly reduce undesired 
background staining. 
Pancreatic sections were fixed, cut, deparaffinized, rehydrated, endogenous peroxidase 
activity quenched, antigen unmasking and Avidin/Biotin blocking performed as described in 
section 3.2.4. Sections were incubated for 1 hour in working solution of M.O.M. Mouse Ig 
Blocking Reagent. M.O.M. Mouse Ig Blocking Reagent was prepared by addition of 2 drops 
of stock solution to 2.5 ml of 0.01M PBS. Sections were washed with 0.01M PBS for 2 
minutes twice and incubated for 5 minutes in working solution of M.O.M. Diluent. M.O.M. 
Diluent was prepared by addition of 600 μl of Protein Concentrate stock solution to 7.5 ml of 
0.01M PBS. 
Excess of M.O.M. Diluent was tipped off sections. Primary anti-DTR antibody was diluted 1: 
250,000 in M.O.M. Diluent. The appropriate primary antibody dilution was determined by a 
series of titration experiments. Sections were incubated in primary antibody for 30 minutes at 
room temperature. Sections were washed 3 x 5 minutes in 0.01M PBS and incubated with 
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M.O.M. Biotinylated Anti-Mouse IgG Reagent (diluted 1:1000 in M.O.M. diluent) for 10 
minutes. The appropriate secondary antibody dilution was determined by a series of titration 
experiments. Sections were washed 3 x 5 minutes in 0.01M PBS and incubated with ABC-
HRP for 30 minutes at room temperature. ABC-HRP was prepared by diluting (1:50) 
reagents from the ABC-HRP kit using Tris/HCl solution. Sections were washed 3 x 5 minutes 
in 0.01M PBS. Colonic sections were at this point developed by incubation with NovaRED 
substrate as described in section 3.2.4. TSA was used for Immunohistochemical detection of 
DTR in pancreatic islets as described below.  
The Biotin Amplification Reagent was reconstituted in 300 μl of dimethyl sulfoxide.  The 
Biotin Stock solution was stored at 4oC and diluted each time to 1:50 using the Amplification 
Diluent provided by the manufacturer to make the working solution. 
Pancreatic sections were incubated in Biotin Amplification Reagent working solution for 3 
minutes. The sections then washed 3 x 5 minutes in 0.01M PBS and incubated with ABC-
HRP for 30 minutes at room temperature. Sections were washed 3 x 5 minutes in 0.01M 
PBS and developed by incubation with NovaRED substrate as described in section 3.2.4. 
The slides were rinsed in distilled water to stop the reaction. Sections were dehydrated by 
being washed in increasing concentrations of ethanol (50%, 70%, 100%) and mounted using 
DPX mounting media. 
3.2.6 Investigating the effect of PP and long-acting PYY and GLP-1 analogues on beta cell 
survival after ablation of PYY-expressing cells 
The investigations in this section aimed to determine whether pancreatic beta cell loss could 
be prevented by chronic replacement of gut/pancreatic peptides that are lost with ablation of 
PYY-expressing cells in the transgenic DTR-BAC mice. 
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3.2.6.1 Animals 
All mice were singly housed prior to the studies. Mice were maintained in cages under 
controlled temperature (21-23°C) and light (eleven hours light/thirteen hours dark) with ad 
libitum access to food (RM3 diet, SDS UK Ltd.) and water. Experiments were performed in 
5-7 week old male mice unless otherwise specified. Animal procedures were approved by 
the British Home Office Animals Scientific Procedures Act 1986 (Project licence numbers 
70/6270 and 70/6402). 
3.2.6.2 Peptide Synthesis and purification 
 
All peptides and analogues were synthesized by and purchased from Bachem, Ltd. All 
peptides used in the following studies are based on the human sequence. Peptides 
synthesis was carried out using an automated fluorenylmethoxycarbonyl solid phase peptide 
synthesis methodology with amino acids added sequentially from the C to the N terminus.  
All peptides used in these studies had a purity > 95%. Peptides were purified by Bachem, 
Ltd. using reverse phase preparative high performance liquid chromatography (HPLC) 
followed by lyophilisation.  The purified product was analysed by reverse phase HPLC and 
matrix-assisted laser desorption ionization mass spectroscopy (MALDI-MS). 
3.2.6.3 Administration of PP via Alzet® Osmotic Minipumps 
There are no known long acting PP analogues. To determine whether chronic PP 
replacement could ameliorate the effect of ablating PYY-expressing cells on the pancreas, 
PP was administered continuously for 5 days using Alzet® Osmotic Minipumps (Durect 
Corporation). PP was injected into a flexible central reservoir within the pump before 
implantation. An impermeable membrane separates this reservoir from an outer chamber 
with high salt concentration.  After implantation into the animal, fluid enters via a semi-
permeable cellulose outer membrane due to the high osmotic pressure of the salt.  This 
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mechanically compresses the central reservoir and leads to delivery of the peptide at a fixed 
rate via a stainless steel flow moderator.   
The pumps utilised in the experiments were 1007D (length 150 mm, circumference 0.6 mm, 
weight 0.4 g, release rate 0.5 µl/hour). Pumps were loaded with PP reconstituted in sterile 
water (5%), 0.1M acetic acid (18%) and saline (77%) or vehicle control. After filling, each 
Alzet pump was submersed in 0.9% saline at 37°C overnight. 
Mice were anesthetised with 4% inhaled isoflurane (Abbott Laboratories Limited) and 
osmotic pumps implanted subcutaneously below the scapulae. Surgical staples were used to 
close the incision.  Following surgery, mice received antibiotic Baytril (enrofloxacil 5mg/kg 
intraperitoneally (Bayer Healthcare)) and analgesic Rimadyl (carprogen 4mg/kg 
subcutaneously (Pfizer Animal Health)).  Peptide delivery was confirmed by measuring PP-
immunoreactivity (PP-IR) concentrations in plasma obtained by cardiac puncture at the end 
of the study. An established in-house radioimmunoassay was used to measure pancreatic 
polypeptide (Adrian et al. 1976). The principles of radioimmunoassay are described in 
section 2.8.8. Antisera against human pancreatic polypeptide were raised in rabbits. This 
antiserum is specific for PP and does not cross-react with other hormones. Separation was 
performed by the charcoal absorption method. The volumes required for all components in 
the RIA are shown in Table 2.3. 
3.2.6.4 Administration of long-acting PYY and GLP-1 analogues  
X-PYY is a PYY3-36 analogue, developed in the section of Investigative Medicine at Imperial 
College London, with rational amino acid substitutions aimed at improving its 
pharmacokinetic profile. Unpublished data kindly provided by Professor S. R. Bloom have 
demonstrated that plasma levels of X-PYY remain elevated 24 hours following injection; an 
equivalent dose of PYY3-36 is no longer detectable after 4 hours. Furthermore, the feeding-
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inhibitory effects of X-PYY last significantly longer than PYY3-36. We therefore used X-PYY 
as a model of chronic replacement of PYY bioactivity. 
Exendin-4 is a long-acting GLP-1 analogue. It has previously been used to investigate the 
effects of GLP-1 on regeneration of β-cell mass in streptozotocin-treated neonatal rats 
(Tourrel et al. 2001). 
Subcutaneous (SC) injections of X-PYY and exendin-4 were administered twice daily using a 
0.5ml insulin syringe with a 29-gauge needle. The maximum volume injected was 100µl. 
Food intake, body weight and plasma glucose were measured daily. 
3.2.7 Investigating the effects of long-acting PYY and GLP-1 analogues in streptozotocin-
treated diabetic mice 
GLP-1 and exendin-4 (long-acting GLP-1 analogue) have been shown to stimulate beta-cell 
neogenesis in streptozotocin-treated newborn rats (Tourrel et al. 2001). I investigated 
whether chronic replacement of long-acting PYY analogue (X-PYY) would have an effect on 
pancreatic insulin concentration in a streptozotocin-induced model of beta cell injury. 
A 2% (w/v) solution of streptozotocin (Sigma) was made by adding 100mg of streptozotocin 
to 5ml of citrate buffer. Citrate buffer was made by dissolving 0.21g citric acid (Sigma) in 100 
ml of 0.9% sodium chloride. The pH was adjusted to 4.5. The buffer was filtered through a 
0.22m filter into a sterile bottle. Streptozotocin was dissolved in citrate buffer and injected 
intraperitoneally a dose of 180mg/kg. Blood glucose, body weight and food intake were 
measured daily over 4 days. 
3.2.8 Statistical analysis 
Data are represented as the mean ± standard error of mean (SEM). Unpaired Student’s t-
test was used for studies with 2 variables and one-way ANOVA for those with more than 2 
variables. Post hoc analysis was performed using Bonferroni test for comparison between 
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various groups and Dunnett’s test for comparing treatment groups with the control group. 
Analyses were performed using Prism version 5.1 software (GraphPad Software, San Diego, 
CA, USA). Cumulative food intake data were analysed using a Generalized Estimation 
Equations (GEE), and if significantly different further analysed by a non-parametric two-
sample Wilcoxon rank-sum (Mann-Whitney U) test comparing the control group to the 
treatment groups. Stata Intercooled, version 9 (Statacorp Ltd, College Station, Texas) was 
used for GEE. The threshold for statistical significance in all cases was conventionally set at 
p< 0.05. 
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3.3 Results 
 
3.3.1 Effects of local administration of diphtheria toxin into terminal ileum on 
colonic PYY, pancreatic PYY and insulin  
Diphtheria toxin (DT) was injected into the terminal ileum at a dose of 700 ng/g. Mice were 
sacrificed 5 days after DT administration. Colonic and pancreatic tissues were collected and 
peptide extracted as described in section 2.2.7.  Colonic concentrations of PYY-IR and 
pancreatic concentrations of PYY and insulin-IR were determined by radioimmunoassay 
(section 2.2.8). 
DT administration into the terminal ileum significantly reduced the colonic concentration of 
PYY-IR (Figure 3.1). Colonic PYY-IR was decreased by 60.7% (Wt 251.4 ± 64.88 pmoles/g, 
n= 4 vs. Tg 98.82 ± 33.96 pmoles/g, n=4, p<0.05).  
DT administration into the terminal ileum also significantly reduced the pancreatic 
concentrations of PYY-IR (3.2 A) and insulin-IR (3.2 B). Pancreatic PYY-IR was decreased 
by 80.2% (Wt 56.08 ± 8.45 pmoles/g, n=4 vs. Tg 11.11 ± 4.88 pmoles/g, n=4, p<0.01). 
Pancreatic insulin-IR was decreased by 57.4% (Wt 24.94 ± 2.75 nmoles/g, n=4 vs Tg 10.63 
± 3.77 nmoles/g, n=4, p<0.05).  
 
 
 
 
 
 
122 
 
 
 
 
Figure 3.1. Effect of local administration of diphtheria toxin (DT) into terminal ileum on 
colorectal PYY-IR content. DT (700 ng/g) was injected into terminal ileum. Colorectal 
tissue was collected 5 days post injection. Wild type n= 4, Transgenic n= 4. *p<0.05. Results 
show mean ± SEM. 
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Figure 3.2. Effects of local administration of diphtheria toxin (DT) into terminal ileum 
on pancreatic PYY (A) and insulin-IR (B) content. DT (700 ng/g) was injected into 
terminal ileum. Pancreatic tissue was collected 5 days post injection. Wild type n= 4, 
Transgenic n= 4. *p<0.05, **p<0.01. Results show mean ± SEM. 
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3.3.2 Effects of rectal administration of diphtheria toxin on colorectal PYY, and 
pancreatic PYY, insulin and glucagon 
In order to investigate the effects of local administration of diphtheria toxin (DT) further, I 
administered DT rectally at a dose of 100 ng/g. Mice were sacrificed 5 days after DT 
administration. Colorectal and pancreatic tissues were collected and peptide extracted as 
described in section 2.2.7.  Colorectal concentrations of PYY-IR and pancreatic 
concentrations of PYY, insulin and glucagon-IR were determined by radioimmunoassay 
(section 2.2.8). 
Rectal DT administration significantly reduced the colorectal concentration of PYY-IR (Figure 
3.3). Colorectal PYY-IR was decreased by 40.1% (Wt 457.4 ± 50.71 pmoles/g, n=4 vs. Tg 
273.9 ± 38.77 pmoles/g, n=4, p<0.05).  
Rectal DT administration also significantly reduced the pancreatic concentrations of PYY, 
insulin and glucagon-IR. Pancreatic PYY-IR (Figure 3.4) was decreased by 46.2% (Wt 62.74 
± 5.01 pmoles/g, n=4 vs. Tg 26.59 ± 7.285 pmoles/g, n=4, p<0.05). Pancreatic insulin-IR 
(Figure 3.5 A) was decreased by 63.1% (Wt 22.0 ± 3.33 nmoles/g, n= vs. Tg 8.11 ± 1.83 
nmoles/g, n=4, p<0.05). Pancreatic glucagon-IR (Figure 3.5 B) was decreased by 37.9% (Wt 
1.607 ± 0.16 nmoles/g, n=4 vs. Tg 0.915 ± 0.18 nmoles/g, n=4, p<0.05).  
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Figure 3.3. Effect of rectal administration of diphtheria toxin (DT) on colorectal PYY-IR 
content. DT was administered rectally at a dose of 100 ng/g. Colorectal tissue was collected 
5 days post injection. Wild type n=4, Transgenic n=4. *p<0.05. Results show mean ± SEM. 
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Figure 3.4. Effect of rectal administration of diphtheria toxin (DT) on pancreatic PYY-
IR content. DT was administered rectally at a dose of 100 ng/g. Pancreatic tissue was 
collected 5 days post injection. Wild type n=4, Transgenic n=4. *p<0.05. Results show mean 
± SEM. 
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Figure 3.5. Effects of rectal administration of diphtheria toxin (DT) on pancreatic 
insulin (A) and glucagon-IR (B) content. DT was administered rectally at a dose of 100 
ng/g. Pancreatic tissue was collected 5 days post injection. Wild type n=4, Transgenic n=4. 
*p<0.05. Results show mean ± SEM. 
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3.3.3 Effects of ablation of PYY-expressing cells in cultured islets 
Intraperitoneal injection of DT results in ablation of PYY in both colorectal and pancreatic 
tissue extracts as shown in sections 2.3.4 and 2.3.8. The loss of pancreatic insulin 
associated with ablation of PYY-expressing cells may, at least in part, be secondary to loss 
of L cells, pancreatic PYY-expressing cells or both. The following in vitro experiments were 
performed to specifically determine the effect of ablation of pancreatic PYY-expressing cells 
on pancreatic islets. 
3.3.3.1 Concentration of insulin, glucagon and PYY in cultured islets at baseline 
Islets were isolated and cultured from wild type and transgenic mice as described in section 
3.1.2. Pancreatic islet insulin, glucagon and PYY-IR concentrations were measured using 
radioimmunoassay (section 2.8.8). 
The pancreatic islet concentration of insulin-IR did not statistically differ between wild type 
(Wt) and transgenic (Tg) mice (Wt 33.42 ± 4.54 ng/islet, n=6 vs. Tg 24.73 ± 4.15 ng/islet, 
n=6, p: 0.20) (Figure 3.6 A). The pancreatic islet concentration of glucagon-IR did not 
statistically differ between wild type (Wt) and transgenic (Tg) mice (Wt 0.37 ± 0.11 ng/islet, 
n=6 vs. Tg 0.42 ± 0.17 ng/islet, n=6, p: 0.79) (Figure 3.6 B). The pancreatic islet 
concentration of PYY-IR did not statistically differ between wild type (Wt) and transgenic (Tg) 
mice (Wt 10.22 ± 0.99 fmoles/islet, n=6 vs. Tg 10.26 ± 1.50 fmoles/islet, n=6, p: 0.98) 
(Figure 3.6 C).  
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Figure 3.6 Pancreatic islet insulin, glucagon and PYY-IR content in cultured islets 
prior to administration of diphtheria toxin. Pancreatic islet insulin-IR (A), glucagon-IR (B) 
and PYY-IR (C) concentrations were not different between wild type (Wt) and transgenic 
(Tg) mice. Wild type n=6, Transgenic n=6. Results show mean ± SEM. 
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3.3.3.2 Effects of ablation of pancreatic PYY-expressing cells on pancreatic PYY content 
Islets were isolated and cultured from wild type and transgenic mice as described in section 
3.1.2. Diphtheria toxin was added to the cultured islets at the following doses: 50ng/ml, 150 
ng/ml and 750 ng/ml. PYY-IR content (Figure 3.7) was measured in cultured islets after 4 
days of incubation with DT using radioimmunoassay (section 2.8.8).  
There was no difference in PYY-IR content of islets between wild type and transgenic mice 
in the absence of DT (Wt 10.22 ± 0.99 fmoles/islet, n=6 vs. Tg 10.26 ± 1.50 fmoles/islet, 
n=6, p: 0.98). Incubation with DT at 50 ng/ml, 150ng/ml and 750ng/ml for 4 days resulted in 
statistically significant reductions in PYY-IR content in islets isolated from transgenic mice.  
Addition of 50 ng/ml of DT reduced pancreatic PYY-IR by 51.3 % after a 4-day incubation 
period (Wt 9.63 ± 0.51 fmoles/islet, n=6 vs Tg 4.70 ± 0.66 fmoles/islet, n=6, p<0.0001). 
Addition of 150 ng/ml of DT reduced pancreatic PYY-IR by 63.4 % after a 4-day incubation 
period (Wt 9.65 ± 0.88 fmoles/islet, n=6 vs. Tg 3.53 ± 0.47 fmoles/islet, n=6, p<0.0001). 
Addition of 750 ng/ml of DT reduced pancreatic PYY-IR by 75.3% after a 4-day incubation 
period (Wt  11.49 ± 0.34 fmoles/islet, n=6 vs. Tg 2.84 ± 0.18 fmoles/islet, n=6, p< 0.0001).  
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Figure 3.7. Effect of diphtheria toxin (DT) on PYY-IR content in cultured islets from 
wild type (Wt) and transgenic (Tg) mice. Cultured islets were incubated with culture 
medium (RPMI) and DT at 50 ng/ml, 150 ng/ml and 750 ng/ml. Pancreatic islet PYY-IR 
content was measured on day 4 post-incubation. Wild type n= 6, Transgenic n= 6, 
***p<0.0001. Results show mean ± SEM. 
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3.3.3.3 Effects of ablation of pancreatic PYY-expressing cells on pancreatic insulin content 
Islets were isolated and cultured from wild type and transgenic mice as described in section 
3.1.2. Diphtheria toxin was added to the cultured islets at the following doses: 50ng/ml, 150 
ng/ml and 750 ng/ml. Insulin-IR content (Figure 3.8) was measured in cultured islets after 4 
days of incubation with DT using radioimmunoassay (section 2.8.8). 
There was no difference in insulin-IR content of islets between wild type and transgenic mice 
in the absence of DT (Wt 33.42 ± 4.54 ng/islet, n=6 vs. Tg 26.60 ± 3.88 ng/islet, n=6, p: 
0.28). There was also no difference in insulin-IR content of islets from wild type and 
transgenic mice after a 4-day incubation period with 50ng/ml of DT (Wt 32.13 ± 2.34 ng/islet, 
n=6 vs. Tg 38.34 ± 3.25 ng/islet, n=6, p: 0.15). 
Incubation with DT at 150ng/ml and 750ng/ml for 3 days resulted in statistically significant 
reductions in insulin-IR content in islets isolated from transgenic mice. Addition of 150 ng/ml 
of DT reduced pancreatic insulin-IR by 31.6% after a 4-day incubation period (Wt 31.35 ± 
2.99 ng/islet, n=6 vs Tg, 21.44 ± 2.47 ng/islet, n=6, p< 0.05). Addition of 750 ng/ml of DT 
reduced pancreatic insulin-IR by 64.3% after a 4-day incubation period (Wt 39.63 ± 2.93 
ng/islet, n=6 vs Tg 14.17 ± 1.78 ng/islet, n=6, p<0.0001).  
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Figure 3.8. Effect of diphtheria toxin (DT) on insulin-IR content in cultured islets from 
wild type (Wt) and transgenic (Tg) mice. Cultured islets were incubated with culture 
medium (RPMI) and DT at 50 ng/ml, 150 ng/ml and 750 ng/ml. Pancreatic islet insulin-IR 
content was measured on day 4 post-incubation. Wild type n=6, Transgenic n=6, *p<0.05, 
***p<0.0001. Results show mean ± SEM. 
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3.3.3.4 Effects of ablation of pancreatic PYY-expressing cells on pancreatic ATP content 
Pancreatic ATP content, a marker of islet cell viability, was measured as described in section 
3.2.3.1. Islets were isolated and cultured from wild type and transgenic mice as described in 
section 3.1.2. Diphtheria toxin was added to the cultured islets at the following doses: 
50ng/ml, 150 ng/ml and 750 ng/ml. ATP content (Figure 3.9) was measured in cultured islets 
after 4 days of incubation with DT using radioimmunoassay (section 2.8.8). 
There was no difference in the ATP content of islets between wild type and transgenic mice 
in the absence of DT (Wt 2.2 x 106 ± 0.1 x 106 RLU, n=8 vs. Tg 2.4 x 106 ± 0.2 x 106 RLU, 
n=8, p: 0.53). A trend was seen towards reduced ATP content in islets from transgenic mice 
incubated with 50ng/ml of DT for 4 days (Wt 2.3 x 106 ± 0.3 x 106 RLU, n=8 vs Tg 1.6 x 106 ± 
0.7 x 106 RLU, n=8, p: 0.05). 
Incubation with DT at 150ng/ml and 750ng/ml for 4 days resulted in statistically significant 
reductions in islet ATP content in transgenic mice. Addition of 150 ng/ml of DT reduced islet 
ATP content by 51% after a 4-day incubation period (Wt 2.6 x 106 ± 0.3 x 106 RLU, n=8 vs 
Tg, 1.2 x 106 ± 0.9 x 106 RLU, n=8, p< 0.001). Addition of 750 ng/ml of DT reduced islet ATP 
content by 41% after a 4-day incubation period (Wt 2.3 x 106 ± 0.3 x 106 RLU, n=8 vs. Tg 1.4 
x 106 ± 0.1 x 106 RLU, n=8, p <0.01).  
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Figure 3.9. Effect of diphtheria toxin (DT) on ATP content in cultured islets from wild 
type (Wt) and transgenic (Tg) mice. Cultured islets were incubated with culture medium 
(RPMI) and DT at 50 ng/ml, 150 ng/ml and 750 ng/ml. Pancreatic islet ATP content was 
measured on day 4 post-incubation. Wild type n=8, Transgenic n= 8, **p<0.01, ***p<0.001. 
Results show mean ± SEM. 
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3.3.3.5 Effects of ablation of pancreatic PYY-expressing cells on islet morphology  
Islets were isolated and cultured from wild type and transgenic mice as described in section 
3.1.2. Islets were isolated and cultured from wild type and transgenic mice as described in 
section 3.1.2. Diphtheria toxin was added to the cultured islets at the following doses: 50 
ng/ml, 150 ng/ml and 750 ng/ml. Photographs of islets were taken on day 1, 2 and 3 days 
after incubation with DT.  
No difference in islet morphology was observed between wild type and transgenic mice prior 
to administration of DT (Figure 3.10). Figure 3.11 shows the altered morphology of the 
cultured islets from the transgenic mice treated with 50 ng/ml (Figure 3.11 B), 150 ng/ml 
(Figure 3.11 D) and 750 ng/ml (Figure 3.11 F) after a 2-day incubation with DT. Islets from 
transgenic mice developed blurred indistinct outlines compared to those from wild type mice 
(Figure 3.11 A, C and E). This is consistent with loss of PYY-expressing cells, which are 
located around the periphery of the islets. 
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Figure 3.10. Representative light-field photomicrographs of cultured islets from wild 
type and trandgenic DTR-BAC mice. There was no difference in islet morphology between 
wild type (A) and transgenic (B) islets prior to treatment with diphtheria toxin. x 4 
magnification 
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Figure 3.11. Representative light-field photomicrographs of cultured islets from wild 
type and transgenic DTR-BAC mice after a 2-day incubation with diphtheria toxin. 
Cultured islets from the transgenic mice were treated with 50 ng/ml (Figure 3.11 B), 150 
ng/ml (Figure 3.11 D) and 750 ng/ml of DT (Figure 3.11 F). Cultured islets from wild type 
mice were treated with the same doses respectively (Figure 3.11 A, C and E). 4x 
magnification. 
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3.3.4 Cellular localization of DTR in pancreatic islets 
Immunohistochemistry was used to determine the cellular localization of diphtheria toxin 
receptor (DTR) within pancreatic islets. Colonic and pancreatic tissues were dissected and 
prepared as described in sections 2.2.10 and 3.2.4. Immunohistochemistry for colonic PYY, 
and pancreatic PYY and insulin was performed as described in section 2.2.10 and 3.2.4. 
Immunohistochemistry for DTR localization in islet cells was performed using Tyramide 
Signal Amplification (TSA) to increase the sensitivity of detection as described in section 
3.2.5. For DTR immunohistochemistry in pancreatic sections, the optimal concentrations of 
primary and secondary antibodies were determined using a series of experiments with 
various dilutions of the antibodies. A primary antibody dilution of 1:250,000 and secondary 
antibody dilution of 1:1000 was found to yield the highest sensitivity with lowest background 
signal. Immunohistochemical localization of DTR in the colon is shown in Figure 3.12. The 
pattern of distribution DTR in the colon is similar to that observed for PYY (see Figure 2.12).  
Immunohistochemical localization of insulin and PYY in serial 5µm pancreatic sections from 
transgenic mice are shown in Figure 3.13 A and 3.13 B, respectively. As expected, PYY was 
found to be localized in peripherally located cells, which did not stain for insulin. Insulin 
positive beta cells comprised the core of the islets. There was no DTR immunolabelling 
detected in wild type mice (Figure 3.14). Immunohistochemical localization of insulin, PYY 
and DTR in serial 5µm pancreatic sections from transgenic mice is illustrated in Figure 3.15 
A, 3.15 B and 3.15 C, respectively. DTR and PYY immunolabelling was localized in 
peripherally located cells, which did not stain for insulin. Insulin positive beta cells comprised 
the core of the islets.  
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Figure 3.12. Representative light-field photomicrograph of diphtheria toxin receptor 
(DTR) immunohistochemistry in colonic tissue of transgenic DTR-BAC mouse. Arrow 
indicates a DTR positive cell. 5x magnification. 
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Figure 3.13. Representative light-field photomicrographs of insulin (A) PYY (B) 
immunohistochemistry in serial pancreatic sections of transgenic DTR-BAC mouse. 
Insulin positive beta cells (A) comprise the core of the islet. PYY (B) is localized in 
peripherally located cells, which do not stain for insulin.  Scale bar = 50 µm. 
 
 
 
 
 
 
 
142 
 
 
 
 
 
 
 
Figure 3.14. Representative light-field photomicrograph of diphtheria toxin receptor 
(DTR) immunohistochemistry in pancreatic tissue from a wild type mouse. No DTR 
immunolabelling was detected. Scale bar = 50 µm. 
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3.3.5 Effects of replacement of PP via Alzet osmotic minipump following ablation of 
PYY-expressing cells in DTR-BAC mice 
PP co-localizes with PYY in pancreatic islet cells. PP-containing cells have been suggested 
to play a role in endocrine pancreas development (Herrera et al. 1991). I hypothesized that 
PP is required for maintenance of adult islets and that loss of PP following ablation of PYY-
expressing cells contributes to loss of pancreatic beta cells. Alzet osmotic minipumps were 
prepared and implanted as described in section 3.2.6.3. PP was replaced in DT-treated 
transgenic mice continuously via Alzet osmotic minipumps at a dose of 250 nmol/kg/day for 
4 days starting from the day of DT injection (40ng/g, i.p.). The control groups were wild type 
and DT-treated transgenic mice receiving vehicle control via Alzet osmotic minipumps. 
Colorectal and pancreatic tissues were collected 4 days post DT injection and PYY and 
insulin-IR concentrations measured using radioimmunoassay as described in section 2.2.8.  
There was no significant difference in the baseline body weight (Figure 3.16) of the three 
groups (Wt/vehicle 21.67 ± 0.67 g, Tg/vehicle 23.23 ± 1.15 g, Tg/PP 23.49 ± 0.79 g, n=6, p: 
0.59). There was no significant difference in food intake (Figure 3.17) between the three 
groups at any of the time points during the study as shown by GEE analysis and Mann 
Whitney U test.  
In order to confirm PP delivery, blood was obtained from wild type and transgenic mice 
receiving vehicle or PP via cardiac puncture and plasma PP-IR measured using 
radioimmunoassay as described in section 3.2.6.3. As expected, transgenic mice treated 
with PP had significantly higher plasma PP-IR concentrations compared to wild type and 
transgenic mice that received vehicle (p <0.0001) (Figure 3.18). 
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Figure 3.16. Baseline body weight in wild type (Wt) mice receiving vehicle and DT-
treated transgenic (Tg) mice receiving vehicle or PP via Alzet osmotic minipumps. 
There was no significant difference in the baseline body weight of the three groups. n=6, p 
0.59. Results show mean ± SEM. 
 
Figure 3.17 Cumulative food intake in wild type (Wt) mice receiving vehicle and DT-
treated transgenic (Tg) mice receiving vehicle or PP via Alzet osmotic minipumps 
over 4 days. Data represented as mean ± SEM. Statistics: GEE with Mann-Whitney U test. 
There was no significant difference in food intake between the three groups at any time point 
investigated during the study. n=6. 
146 
 
 
 
 
 
 
Figure 3.18. Plasma PP-IR concentration in wild type (Wt) and DT-treated transgenic 
(Tg) mice receiving vehicle or PP via Alzet osmotic minipumps. Blood was obtained 
using cardiac puncture and plasma PP-IR measured using radioimmunoassay. Transgenic 
mice treated with PP have significantly higher plasma PP-IR concentrations compared to 
mice that received vehicle. Wild type (Wt) n=6, Transgenic (Tg) n=6. ***p <0.0001. Results 
show mean ± SEM. 
 
 
 
 
147 
 
DT resulted in a significant reduction in colorectal PYY-IR content (Figure 3.19 A) in DT-
treated transgenic mice (receiving vehicle or PP) compared to wild type mice as shown by 
Bonferroni’s multiple comparison test (p<0.0001). Pancreatic PYY-IR concentration (Figure 
3.19 B) was also significantly reduced in DT-treated transgenic mice (receiving vehicle or 
PP) compared to wild type mice (p<0.0001).  
Pancreatic insulin-IR concentration (Figure 3.19 C) was significantly reduced in DT-treated 
transgenic mice (receiving vehicle or PP) compared to wild type mice (p<0.0001). PP 
replacement via Alzet osmotic minipumps at a dose of 250 nmol/kg/day had no effect on 
pancreatic insulin-IR content in DT-treated transgenic mice (Tg/Vehicle 2.25 ± 0.42 nmoles/g 
vs Tg/PP 3.25 ± 0.73 nmoles/g, n=6). 
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Figure 3.19. Colorectal PYY-IR (A), and Pancreatic PYY (B) and insulin-IR (C) 
concentrations in wild type (Wt) mice receiving vehicle and transgenic DTR-BAC mice 
receiving either vehicle or PP (250nmol/kg/day) via Alzet osmotic minipumps. 
Colorectal PYY-IR, and pancreatic PYY and insulin-IR concentrations were significantly 
reduced in DT-treated transgenic mice receiving vehicle or PP. PP replacement had no 
effect on pancreatic insulin-IR content in DT-treated transgenic mice. Wild type (Wt) n=6, 
Transgenic (Tg) n=6. ***p<0.0001. Results show mean ± SEM. 
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3.3.6 Effects of replacement of long-acting PYY and GLP-1 analogues following ablation 
of PYY-expressing cells in DTR-BAC mice 
A long-acting PYY analogue (X-PYY) and exendin-4 were administered subcutaneously 
twice daily for 4 days at 250nmol/kg and 5 nmol/kg respectively. The first dose of analogue 
or saline was given at the time of injection of DT (40ng/g, i.p.). Colorectal and pancreatic 
tissues were collected 4 days post DT injection and PYY and insulin-IR concentrations 
measured using radioimmunoassay as described in section 2.2.8.  
There was no significant difference in the baseline body weight (Figure 3.20) of the three 
groups (p 0.6561, n=8). GEE analysis followed by Mann-Whitney U test showed that DT-
treated transgenic mice receiving exendin-4 or X-PYY consumed significantly less food than 
transgenic mice receiving saline in the first 48 hours following injection (p<0.05, n=8) (Figure 
3.21). Wild type mice receiving exendin-4 or X-PYY consumed significantly less food than 
the transgenic mice receiving saline on days 1-4 (p<0.05, n=8). Transgenic mice receiving 
X-PYY consumed less food than transgenic mice receiving exendin-4 on days 1 and 2 
(p<0.05, n=8). 
DT significantly reduced colorectal PYY-IR concentration (Figure 3.22) in all transgenic DTR-
BAC mice (treated with saline, exendin-4 or X-PYY) compared to wild type mice (treated with 
exendin-4 or X-PYY) (p <0.0001). Pancreatic PYY-IR concentration (Figure 3.23 A) was also 
significantly reduced in all transgenic DTR-BAC mice (treated with saline, exendin-4 or X-
PYY) compared to wild type mice (treated with exendin-4 or X-PYY) (p <0.0001). Compared 
to DT-treated transgenic mice receiving saline, DT-treated transgenic mice receiving X-PYY 
had a significantly higher pancreatic insulin-IR concentration (Figure 3.23 B) (Tg/Saline 1.90 
± 0.52 nmol/g, n=8 vs Tg/X-PYY 5.30 ± 0.74 nmol/g, n=8, p<0.05). There was a trend 
towards increased pancreatic insulin-IR concentration in DT-treated transgenic mice 
receiving exendin-4 compared to DT-treated transgenic mice receiving saline (Tg/Saline 
1.90 ± 0.52 nmol/g vs Tg/exendin-4 4.51 ± 0.68 nmol/g, n=8). 
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Figure 3.20. Baseline body weight in wild type (Wt) and DT-treated transgenic DTR-
BAC mice receiving saline, X-PYY (250 nmol/kg bd, s.c.) or exendin-4 (Ex4, 5 nmol/kg 
bd, s.c.) There was no difference in baseline bodyweight between any of the groups. Wild 
type (Wt) n=8, Transgenic (Tg) n=8. P=0.66. Results show mean ± SEM. 
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Figure 3.21. Cumulative food intake over 4 days in wild type (Wt) and DT-treated 
transgenic DTR-BAC mice receiving saline, X-PYY (250 nmol/kg bd, s.c.) or exendin-4 
(Ex4, 5nmol/kg bd, s.c.). Transgenic mice receiving exendin-4 or X-PYY consumed 
significantly less food than transgenic mice receiving saline in the first 48 hours after DT 
injection (p< 0.05, n=8). Wild type mice receiving exendin-4 or X-PYY consumed significantly 
less food than the transgenic mice receiving saline on days 1-4 (p<0.05, n=8). Transgenic 
mice receiving X-PYY consumed less food than transgenic mice receiving exendin-4 on 
days 1 and 2. Wild type (Wt) n=8, Transgenic (Tg) n=8. p<0.05. 
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Figure 3.22. Colorectal PYY-IR concentrations in wild type (Wt) and DT-treated 
transgenic DTR-BAC mice receiving saline, exendin-4 (Ex4, 5nmol/kg bd, s.c.) or X-
PYY (250 nmol/kg bd, s.c.). Colorectal PYY-IR concentrations were significantly reduced in 
DT-treated transgenic mice receiving exendin-4, X-PYY and saline compared to wild type 
mice receiving exendin-4 or X-PYY. Wild type (Wt) n=8, Transgenic (Tg) n=8. ***p<0.0001. 
Results show mean ± SEM. 
 
 
 
 
153 
 
 
 
Figure 3.23. Pancreatic PYY (A) and insulin-IR (B) concentrations in wild type (Wt) and 
DT-treated transgenic DTR-BAC mice receiving saline, exendin-4 (Ex4, 5nmol/kg bd, 
s.c.) or X-PYY (250 nmol/kg bd, s.c.). Pancreatic PYY-IR (A) and insulin-IR (B) 
concentrations were significantly reduced in DT-treated transgenic mice receiving exendin-4, 
X-PYY or saline compared to wild type mice receiving exendin-4 or X-PYY (***p<0.0001 
indicates significant difference compared to both wild type groups shown by Bonferroni’s 
multiple comparison test). Transgenic mice receiving X-PYY had a significantly higher 
pancreatic insulin-IR concentration than transgenic mice receiving saline. Wild type (Wt) 
n=8, Transgenic (Tg) n=8. *p<0.05. Results show mean ± SEM. 
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3.3.7 Effects of combination of long-acting PYY and GLP-1 analogues following ablation 
of PYY-expressing cells in DTR-BAC mice 
I also investigated the effect of combination treatment with X-PYY and exendin-4 on 
pancreatic insulin-IR concentration following ablation of PYY-expressing cells in transgenic 
DTR-BAC mice. X-PYY and exendin-4 were administered subcutaneously twice daily over 4 
days at 250nmol/kg and 5 nmol/kg respectively. The first dose of analogue or saline was 
given at the time of injection of DT (40ng/g, i.p.). Colorectal and pancreatic tissues were 
collected 4 days post DT injection and PYY and insulin-IR concentrations measured using 
radioimmunoassay as described in section 2.2.8.  
There was no significant difference in the baseline body weight (Figure 3.24) of the three 
groups (p: 0.13). DT-treated transgenic mice receiving combination of X-PYY and exendin-4 
had a significantly lower food intake than DT-treated transgenic mice receiving saline, at all 
time points (Figure 3.25) (p< 0.05, n=5). There was no significant difference in food intake 
between wild type mice receiving a combination of X-PYY and exendin-4 and transgenic 
mice receiving a combination of X-PYY and exendin-4 as shown by GEE analysis and Mann 
Whitney U test.  
DT (40 ng/g, i.p.) significantly reduced colorectal PYY-IR (Figure 3.26A) and GLP-1-IR 
(Figure 3.26 B) concentrations in transgenic mice receiving saline or combination of the two 
analogues compared to wild type mice receiving the analogues (P<0.0001, n=5).  
Pancreatic PYY-IR (Figure 3.27 A), glucagon-IR (Figure 3.27 B) and insulin-IR (Figure 3.27 
C) concentrations were also significantly reduced in the transgenic mice receiving saline or 
combination of X-PYY and exendin-4 compared to wild type mice receiving a combination of 
X-PYY and exendin-4. Compared to DT-treated transgenic mice receiving saline, DT-treated 
transgenic mice receiving a combination of X-PYY and exendin-4 had a significantly higher 
pancreatic insulin-IR concentration (Figure 3.27 C) (Tg/Saline 4.22 ± 1.42 nmol/g, n=5 vs 
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Tg/X-PYY/exendin-4 10.92 ± 1.668 nmol/g, n=5, p<0.05). Pancreatic insulin-IR loss in DT-
treated transgenic mice receiving X-PYY/exendin-4 was 51.8% compared to an 81.4% 
reduction in pancreatic insulin-IR observed in transgenic mice receiving saline. 
 
 
Figure 3.24 Baseline body weight in wild type (Wt) and DT-treated transgenic (Tg) 
mice receiving combination of X-PYY (250 nmol/kg bd, s.c.) and exendin-4 (Ex4, 5 
nmol/kg bd, s.c.) and transgenic mice receiving saline over 4 days after DT injection. 
There was no difference in baseline body weight between any of the groups. Wild type (Wt) 
n=5, Transgenic (Tg) n=5. p=0.13. Results show mean ± SEM. 
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Figure 3.25. Cumulative food intake over 4 days in wild type (Wt) and DT-treated 
transgenic (Tg) mice receiving combination of X-PYY (250 nmol/kg bd, s.c.) and 
exendin-4 (Ex4, 5nmol/kg bd, s.c.) and transgenic mice receiving saline. Wild type and 
DT-treated transgenic mice receiving combination of X-PYY and exendin-4 had a 
significantly lower food intake than DT-treated transgenic mice receiving saline, at all time 
points. Wild type (Wt) n=5, Transgenic (Tg) n=5. p<0.05. 
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Figure 3.26 Colorectal PYY (A) and GLP-1-IR (B) concentrations in wild type (Wt) and 
DT-treated transgenic (Tg) mice receiving combination of X-PYY (250 nmol/kg bd, s.c.) 
and exendin-4 (Ex4, 5nmol/kg bd, s.c.) and transgenic mice receiving saline. Colorectal 
PYY-IR and GLP-1-IR concentrations were significantly reduced in DT-treated transgenic 
mice receiving combination of X-PYY/exendin-4 or saline compared to wild type mice 
receiving the analogues. Wild type (Wt) n=5, Transgenic (Tg) n=5. ***p<0.0001. Results 
show mean ± SEM. 
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Figure 3.27. Pancreatic PYY (A), glucagon (B) and insulin-IR (C) concentrations in wild 
type (Wt) and transgenic (Tg) mice receiving combination of X-PYY and exendin-4 or 
saline. Pancreatic PYY, glucagon and insulin-IR concentrations were reduced in both 
groups of transgenic mice compared to wild type mice. Transgenic mice receiving 
combination treatment with X-PYY and exendin-4 had a significantly higher pancreatic 
insulin-IR concentration than transgenic mice receiving saline. Wild type (Wt) n=5, 
Transgenic (Tg) n=5. ***p<0.0001, **p<0.001, *p<0.05. Results show mean ± SEM. 
 
159 
 
3.3.8 Effects of long-acting PYY and GLP-1 analogues in streptozotocin-treated diabetic 
mice 
Streptozotocin was injected intraperitoneally at a dose of 180mg/kg (Gonzalez et al. 2003). 
X-PYY and exendin-4 were administered subcutaneously twice daily over 4 days at 
250nmol/kg and 5 nmol/kg respectively. The first dose of analogue or saline was given at the 
time of injection of DT (40 ng/g, i.p.). Colorectal and pancreatic tissues were collected 4 days 
post DT injection and PYY and insulin-IR concentrations measured using radioimmunoassay 
as described in section 2.2.8.  
There was no significant difference in the baseline body weight (Figure 3.28) between the 4 
groups (buffer/saline: 26.52 ± 1.613 g, streptozotocin/saline: 25.73 ± 1.61 g, 
streptozotocin/exendin-4: 26.55 ± 1.60 g, streptozotocin/X-PYY: 26.57 ± 1.90 g, n=6, p 
=0.98) 
There was no significant difference in the baseline plasma glucose (Figure 3.29 A) between 
the 4 groups (buffer/saline: 5.9 ± 0.6 mmol/l, streptozotocin/saline: 6.9 ± 0.4 mmol/l, 
streptozotocin/exendin-4: 5.9 ± 0.3 mmol/l, streptozotocin/X-PYY: 6.6. ± 0.3 mmol/l, n=6, p 
=0.23). On day 4 post streptozotocin injection, the streptozotocin/saline group had a 
significantly higher average plasma glucose than the buffer/saline group (Figure 3.29 B) 
(streptozotocin/saline: 17.7 ± 3.9, buffer/saline: 6.6 ± 0.42, n=6, P<0.05). There was no 
statistically significant difference in plasma glucose between the streptozotocin-treated mice 
receiving exendin-4 or X-PYY and mice receiving buffer/saline (Figure 3.29 B) 
(streptozotocin/exendin-4: 13.4 ± 3.7 mmol/l, streptozotocin/X-PYY: 9.7 ± 2.3, buffer/saline: 
6.6  ± 0.4, n=6).  
The cumulative food intake for the four groups is shown in Figure 3.30. The 
streptozotocin/saline group consumed significantly less food than the buffer/saline group on 
days 1 and 2 (p< 0.01). The streptozotocin/exendin-4 group consumed significantly less food 
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than the buffer/saline group on days 1 to 3 (p< 0.01). The streptozotocin/X-PYY group 
consumed significantly less food than the buffer/saline group on days 1 to 4 (p< 0.01). The 
streptozotocin/X-PYY group consumed significantly less food than the streptozotocin/saline 
group on days 1 to 4 (p< 0.01). The streptozotocin/X-PYY group consumed significantly less 
food than the streptozotocin/exendin-4 group on days 1 to 4 (p< 0.01).  
 
 
Figure 3.28. Baseline body weight in buffer- or streptozotocin (STZ)-treated mice 
receiving saline, exendin-4 (Ex4) or X-PYY over 4 days. There was no significant 
difference in the baseline body weight between the 4 groups. n=6. p=0.98. Results show 
mean ± SEM. 
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Figure 3.29. Plasma glucose in buffer- or streptozotocin (STZ)-treated mice receiving 
saline, exendin-4 (Ex4) or X-PYY before (A) and 4 days after STZ administration (B). 
There was no significant difference in the baseline plasma glucose between the 4 groups, 
p=0.23. n=6. On day 4 post streptozotocin injection, the streptozotocin/saline group had a 
significantly higher average plasma glucose than the buffer/saline group. n=6. *p<0.05. 
Results show mean ± SEM. 
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Figure 3.30. Cumulative food intake over 4 days in buffer- or streptozotocin (STZ)-
treated mice receiving saline, exendin-4 (Ex4) or X-PYY before (A). The STZ/Ex4 group 
consumed significantly less food than the buffer/saline group on days 1 to 3 (p<0.01). The 
STZ/X-PYY group consumed significantly less food than the buffer/saline group on days 1 to 
4 (p<0.01). The STZ/X-PYY group consumed significantly less food than the STZ/Ex4 group 
on days 1 to 4 (p<0.01). Data represented as mean ± SEM. n=6. 
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There was no statistically significant difference in colorectal tissue PYY-IR concentration 
(Figure 3.31 A) between any of the four groups (buffer/saline: 324.4 ± 46.82 pmoles/g, 
streptozotocin/saline: 260.6 ± 32.60 pmoles/g, streptozotocin/exendin-4: 368.9 ± 71.40 
pmoles/g, streptozotocin/X-PYY: 356.0 ±79.31 pmoles/g, n=6, p=0.70) 
Similarly, pancreatic PYY-IR concentration (Figure 3.31 B) did not differ significantly 
between the 4 groups (buffer/saline: 25.92 ± 2.43 pmoles/g, streptozotocin/saline: 33.97 ± 
6.26 pmoles/g, streptozotocin/exendin-4: 21.79 ± 2.80 pmoles/g, streptozotocin/X-PYY: 
35.82 ± 7.19 pmoles/g, n=6, p=0.26) 
Pancreatic insulin-IR concentration (Figure 3.31 C) was significantly reduced in all 
streptozotocin-treated mice (receiving saline, exendin-4 or X-PYY) compared to the 
buffer/saline group (buffer/saline: 13.38 ± 1.82 nmoles/g, streptozotocin/saline: 1.670 ± 0.66 
nmoles/g, streptozotocin/exendin-4: 2.46 ± 1.22 nmoles/g, streptozotocin/X-PYY: 4.97 ± 1.72 
nmoles/g) 
There was a trend towards increased pancreatic insulin-IR concentration (Figure 3.31 C) in 
streptozotocin/X-PYY group compared to the streptozotocin/saline group (streptozotocin/X-
PYY: 4.97 ± 1.72 nmoles/g vs streptozotocin/saline: 1.67 ± 0.66 nmoles/g). A trend was also 
observed towards increased pancreatic insulin-IR concentration in streptozotocin/exendin-4 
group compared to the streptozotocin/saline group (streptozotocin/exendin-4: 2.46 ± 1.22 
nmoles/g vs streptozotocin/saline: 1.670 ± 0.66 nmoles/g). 
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Figure 3.31. Colorectal PYY-IR (A), pancreatic PYY (B) and insulin-IR (C) 
concentrations in buffer- or streptozotocin (STZ)-treated mice receiving saline, 
exendin-4 (Ex4) or X-PYY. X-PYY and exendin-4 were injected subcutaneously twice daily 
at 250nmol/kg and 5nmol/kg respectively for 4 days post DT administration (40ng/g, i.p.). 
n=6. ***p<0.0001,**p<0.001. Results show mean ± SEM. 
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3.4 Discussion 
The experiments described in this chapter aimed to determine the cause of the 
hyperglycaemia that occurs following the ablation of PYY-expressing cells in transgenic 
DTR-BAC mice. 
3.4.1 Effects of local gastrointestinal administration of diphtheria toxin on pancreatic 
hormones 
Intraperitoneal injection of diphtheria toxin results in a global ablation of PYY in transgenic 
DTR-BAC mice. In the first set of experiments presented in this chapter I investigated the 
effect of local gastrointestinal administration of DT on colonic PYY and pancreatic islet 
hormones. I hypothesized that local administration of DT in the gut would avoid the effects 
on the pancreas observed following systemic administration. Administration of DT into the 
terminal ileum significantly reduced colonic PYY concentrations. This effect of DT may be 
mediated by binding to DTR on the apical surface of the L cell. However, it is unclear 
whether DTR localizes on the apical surface of PYY-expressing enteroendocrine cells. DT 
administration into the terminal ileum also significantly reduced pancreatic PYY and insulin 
concentrations. DT may have also reached the systemic circulation through absorption or 
leakage from the injection site into the peritoneal cavity.  
In order to eliminate the risk of DT leaking through the injection site, I administered DT 
rectally. Rectal administration of DT significantly reduced colonic PYY. Interestingly, rectal 
administration of DT also significantly reduced pancreatic insulin concentrations. DT may 
have reached the pancreatic islet cells via absorption in the distal colon. However, the 
possibility that loss of colonic PYY and other L cell products may have an adverse effect on 
pancreatic beta cells cannot be excluded.  
Several gastrointestinal hormones including GLP-1, GIP, CCK and gastrin have been shown 
to influence beta cell mass (Lavine and Attie 2010). PYY has been shown to co-localise with 
166 
 
GLP-1 and CCK-producing cells in the colon (Roth et al. 1992). GLP-1 promotes beta cell 
proliferation in several experimental models of beta cell injury/regeneration (Kwon et al. 
2009; Wang et al. 2008; Xu et al. 1999; Zhang et al. 2007). GLP-1 has also been shown to 
stimulate islet neogenesis and reduce beta-cell apoptosis (Lavine and Attie 2010). However, 
the normal islet has only a low basal rate of apoptosis (Scaglia et al. 1997). It is not known 
whether GLP-1 and other gut hormones provide an essential trophic support for the 
maintenance of the islets in the absence of beta cell injury. 
Reduced beta cell regeneration following partial pancreatectomy in GLP-1 receptor knock-
out mice (De Leon et al. 2003) suggests that GLP-1 may have a physiological role in the 
regulation of beta cell mass. PYY has been shown to co-localise with GLP-1 in the colon 
(Roth et al. 1992).  In accord with this data, ablation of the enteroendocrine L cells in 
transgenic DTR-BAC mice results in the loss of more than 95% of the colorectal GLP-1 
content. It is therefore possible that loss of GLP-1 contributes, at least in part, to the loss of 
pancreatic beta cells following L cell ablation. However, my experiments do not conclusively 
prove a physiological role for GLP-1 in maintaining the viability of adult beta cells.  
Oxyntomodulin is a peptide hormone also derived from the proglucagon gene and binds to 
both the glucagon and GLP-1 receptor (Maida et al. 2008). Oxyntomodulin has been shown 
to ameliorate hyperglycemia and reduce streptozotocin-induced apoptosis in murine beta-
cells (Maida et al. 2008). Another gut peptide shown to affect beta cell mass is GIP. GIP and 
PYY are rarely colocalized (Mortensen et al. 2003), and indeed, colorectal GIP levels were 
not affected following L cell ablation in our transgenic model. However, GIP is also 
expressed in the pancreatic islets. GIP has been shown to be expressed in alpha-cells in 
adult pancreatic islets (Fujita et al. 2010). A truncated, bioactive form of GIP is generated 
from proGIP by prohormone convertase (PC) 2 in the pancreas that is different from the 
PC1/3 generated form that is produced by K-cells in the gut (Fujita et al. 2010). Therefore it 
is possible that loss of pancreatic GIP, rather than gut-derived GIP, contributes to loss of 
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beta cells following ablation of pancreatic PYY-expressing cells.  
Interestingly, GIP has been suggested to play a role in the embryonic pancreas 
differentiation, which forms beta cells (Prasadan et al. 2011). Inhibition of GIP or its receptor 
results in a reduction in the number of developing pancreatic beta cells. Furthermore, GIP 
receptor agonism has been shown to reduce beta cell apoptosis in streptozotocin-treated 
mice (Maida et al. 2009; Widenmaier et al. 2010). The effects of pancreatic GIP on beta cell 
maintenance in adult islets thus require further investigation. 
Cholecystokin (CCK) and gastrin are other gut hormones that may affect beta cell mass. 
PYY has been shown to co-localise with CCK in the colon (Roth et al. 1992). CCK stimulates 
beta-cell proliferation in rats via the CCKA receptor (Lavine and Attie 2010). Gastrin 
promotes islet neogenesis by acting on the CCKB receptor (Lavine and Attie 2010). CCK 
binds to the CCKB receptor with similar affinity as gastrin. Thus it is possible that CCK also 
stimulates islet neogenesis. 
3.4.2 Effect of ablation of pancreatic PYY-expressing cells on beta cells in cultured islets 
Intra-ileal and intra-rectal administration of DT could not reliably ablate intestinal L cells 
without influencing pancreatic islets due to putative leakage and systemic absorption of DT. 
In order to investigate the effects of specific ablation of pancreatic PYY-expressing cells I 
studied the effects of incubation of pancreatic islet cells with DT in vitro. Prior to investigating 
the effects of ablation of PYY in cultured islets from transgenic mice, it was important to 
demonstrate that the islets from these mice were not different to those from wild type mice at 
baseline (i.e. prior to administration of DT). Islets cultured from transgenic and wild type mice 
had similar insulin, glucagon and PYY levels at baseline. Furthermore, there was no 
difference in the morphology of cultured islets. It therefore appeared likely that the transgenic 
mice had normal pancreata before they were subject to experimental intervention. 
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Administration of DT had no effect on pancreatic hormone levels or morphology of wild type 
islets, ruling out a non-specific toxic effect of DT on the islet cells. Incubation with DT 
resulted in a significant loss of pancreatic PYY as expected. Ablation of PYY-expressing 
cells resulted in a significant loss of pancreatic insulin.  
Loss of pancreatic insulin, however, does not necessarily equate with loss of beta cells. ATP 
content was therefore measured as a marker of islet cell viability. Incubation with DT 
resulted in loss of approximately half of islet ATP content. The amount of ATP has been 
shown to be directly proportional to the number of cells present in culture (Crouch et al. 
1993).  Beta cells constitute approximately 80% of the endocrine pancreas (Bonal et al. 
2008). PYY has been shown to be expressed in a sub-population of glucagon-, 
somatostatin- and PP-producing cells, which together comprise approximately 20% of the 
islet. Loss of 50% of the transgenic islet cells after a 4-day incubation period with DT, as 
suggested by the reduction in ATP content, is more than would be expected from the loss of 
PYY-expressing cells alone, which comprise less than 20% of endocrine pancreas. Although 
reductions in pancreatic insulin and ATP content are consistent with loss of beta cells, 
further studies are required to assess the degree and mechanisms of beta cell death in DT-
treated DTR-BAC mice. 
Interestingly, incubation of islets with DT at 50ng/ml resulted in loss of half of pancreatic 
PYY, without a significant effect on pancreatic insulin or ATP content. However treatment 
with DT at larger doses, which caused a greater reduction in pancreatic PYY (> 60%) was 
associated with a significant loss of pancreatic insulin and ATP content. Together, these 
studies suggest that the PYY-expressing cells provide important paracrine signal(s) essential 
for beta cell viability.  
In addition to PYY itself, a number of peptides co-expressed in PYY cells may be important 
for maintaining beta cell viability. For example, delayed beta cell differentiation during 
development and alpha cell maturation in adults (Vincent et al. 2003), has been observed in 
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mice lacking prohormone convertase 2, which are not able to convert proinsulin, 
proglucagon and prosomatostatin to the mature forms (Furuta et al. 1997). 
PYY is co-expressed with PP in most PP cells. PP is detected during early formation of 
islets, and is co-expressed with other pancreatic hormones in islet cells (Herrera et al. 1991). 
It has therefore been suggested that PP may play a role in islet cell development. 
Another pancreatic hormone that may play a role in islet cell development and survival is 
ghrelin. The ghrelin gene peptides are expressed in rodent and human pancreatic islets in 
both foetal period and adult life. Ghrelin colocalizes with glucagon in alpha cells and is also 
expressed in epsilon cells (Granata et al. 2010). The ghrelin gene peptides are reported to 
inhibit beta cell apoptosis and promote beta-cell proliferation and regeneration, and to inhibit 
beta cell apoptosis (Granata et al. 2010). 
It is possible that a number of paracrine factors released by the PYY-expressing cells, for 
example PP, somatostatin, GIP and ghrelin may act together to maintain beta cell viability. 
3.4.3 Cellular localization of DTR in pancreatic islets  
One possible explanation for the loss pancreatic beta cells in DTR-BAC mice is non-specific 
expression of the DTR transgene in the beta cell, which would confer sensitivity to diphtheria 
toxin in these cells. However, this is unlikely for a number of reasons.  The pattern of 
expression of the DTR transgene is very similar to that of endogenous PYY in the DTR-BAC 
transgenic mouse. Although insulin-producing cells express PYY in early pancreatic 
development, PYY is no longer expressed in beta cells in adult mice (Upchurch et al. 1994). 
Furthermore, it has been shown that most beta cells are not descendants of the 
PYY/glucagon/ insulin-positive cells that appear during early pancreatic formation (Schonhoff 
et al. 2005).  
As expected, immunohistochemical analysis of localization of PYY in the pancreatic islets 
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confirmed the presence of PYY in peripherally located cells, which did not stain for insulin. 
The diphtheria toxin receptor is a membrane-anchored heparin-binding epidermal growth 
factor-like growth factor (HB-EGF). A mouse monoclonal antibody against human HB-EGF 
was used to determine the cellular localization of DTR. Colocalization of DTR with PYY cells 
and lack of DTR colocalization with insulin makes non-specific beta cell expression of the 
DTR transgene unlikely. It is possible that DTR is expressed below the detection limit of 
immunohistochemistry. However, the immunohistochemistry technique used for DTR 
detection employed tyramide signal amplification, which greatly enhances the sensitivity of 
antigen detection and enables identification of peptides that are present at low 
concentrations.  
3.4.4 Effects of chronic replacement of PP, GLP-1 and PYY following ablation of PYY-
expressing cells 
Beta cell loss is the underlying cause of type 1 diabetes mellitus and plays an important role 
in the progression of type 2 diabetes mellitus. Reduction of beta cell mass to below a certain 
threshold results in hyperglycaemia (Ritzel et al. 2006). Identification of the products of PYY-
expressing cells that may be essential for beta cell maintenance can provide novel targets 
for treatment of both type 1 and type 2 diabetes.  
As described above, PP has been implicated in pancreatic islet development. However, the 
role of PP in the maintenance of beta cells in adult pancreas is unknown. Chronic 
administration of PP via Alzet osmotic minipumps did not rescue beta cells following ablation 
of PYY-expressing cells. This reduces the possibility that loss of PP alone is the underlying 
reason for beta cell death in our mouse model.  
Pancreatic beta cell renewal after injury may occur through three mechanisms: proliferation 
of pre-existing beta cells, neogenesis from undefined adult progenitor cells, or as a product 
of stem cells and transdifferentiation from differentiated cells (Bonal et al. 2008). As 
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described above, a number of gut peptides, including GLP-1, GIP, gastrin, CCK and ghrelin, 
have been shown to affect beta cell survival through these processes. 
A trend towards increased pancreatic insulin was observed with chronic administration of 
exendin-4, a long-acting GLP-1 analogue, following ablation of PYY-expressing cells. This 
effect did not reach statistical significance. However, the dose and duration of exendin-4 
administration in our experiments were lower than that used in studies where exendin-4 was 
shown to reduce apoptosis in streptozotocin-induced cell death (Li et al. 2003).  
Pancreatic insulin content was significantly higher when X-PYY, a long acting PYY 
analogue, was administered following ablation of PYY expressing cells, suggesting the 
analogue rescued the beta cell to some extent. The number of PYY immunoreactive cells 
has been shown to increase in pancreatic islets following beta cell death in alloxan-treated 
hyperglycaemic mice (Bottcher et al. 1994). Similarly, a marked expansion of the PYY-
expressing cells occurs during pancreatic regeneration in interferon-gamma (IFN-γ) 
transgenic mice (Liu et al. 2006). These studies raise the possibility that PYY may play an 
important role during pancreatic regeneration. However, the physiological role of PYY in the 
maintenance of beta cells in adult pancreas has not previously been explored.  
PYY1-36 binds with similar affinity to all of the Y receptors including Y1 and Y2 receptor 
subtypes. However PYY3-36 is a selective high affinity agonist at the Y2 receptor subtype 
(Grandt et al. 1994b). It has been suggested that the 'active' form of PYY in the pancreas is 
PYY1-36 (Chandarana  2009). Incubation of pancreatic islets with PYY1-36 has been shown to 
decrease insulin secretion while incubation with PYY3-36 has no effect (Chandarana  2009). 
Y1 receptors are expressed in pancreatic islets (Cho and Kim 2004). The long-acting PYY 
analogue used in my experiments has a high affinity for the Y1 receptor subtype, comparable 
to that of endogenous PYY1-36 (unpublished data from Professor S.R. Bloom’s group). The 
paracrine effects of PYY released from islet cells may be mediated via the Y1 receptor. 
Interestingly, NPY has been shown to promote beta-cell replication via the Y1 receptor (Cho 
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and Kim 2004). Further investigations are required to determine whether the beta cell 
sparing effects of X-PYY observed in my studies are mediated via the stimulation of 
proliferation, islet neogenesis or the inhibition of beta cell apoptosis. 
One potential limitation of the analogue replacement studies was lack of a ‘pair-fed’ control 
group. It may be argued that reduced food intake caused by the long-acting GLP-1 and PYY 
analogues indirectly increased pancreatic insulin content, rather than through a direct effect 
on the beta cells. Future studies should address this question. In addition, direct assessment 
of beta cell mass, and the use of apoptosis markers are necessary to confirm that the loss of 
pancreatic insulin indeed indicates ‘beta cell death’. 
A significantly higher pancreatic insulin content was observed in mice receiving combination 
treatment with X-PYY and exendin-4 compared to those that received saline following 
ablation of the PYY-expressing cell. This suggests that the combination of X-PYY and 
exendin-4 can rescue beta cells in our transgenic model. Further studies should compare 
whether combination of X-PYY and exendin-4 has a greater effect on beta cells than the 
individual analogues. It is possible that a range of growth factors released from PYY-
expressing cells act in concert to maintain the adult beta cells. 
PYY appears to inhibit stimulated insulin and glucagon secretion. However, PYY does not 
affect basal plasma levels of insulin in in vivo experiments (Bottcher et al. 1989). Therefore it 
is unlikely that the increase in pancreatic insulin content in X-PYY-treated mice was caused 
by reduced insulin secretion. Nevertheless, further studies are necessary to confirm that 
increased pancreatic insulin content was indeed due to increased beta cell mass. 
Finally, the effect of PYY on prevention of beta cell loss in a different streptozotocin-induced 
experimental model of diabetes was also investigated. Streptozotocin is a glucose-
conjugated nitrosourea. The uptake of streptozotocin into beta cells is mediated by the 
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glucose transporter 2 (GLUT 2) (Schnedl et al. 1994). Streptozotocin induces DNA damage 
by the formation of free radicals (alkylating agent) (Bolzan and Bianchi 2002). 
A trend towards increased pancreatic insulin was observed in streptozotocin-treated mice 
receiving X-PYY or exedin-4. Exendin-4 has been shown to reduce streptozotocin-induced 
beta-cell apoptosis (Li et al. 2003). However, the dose and duration of administration of 
exendin-4 in this previously published study was greater than that used in our experiments. 
Further dose response experiments are necessary to elucidate the potential beneficial 
effects of both analogues on beta cell recovery in streptozotocin-treated mice. 
GLP-1 receptor agonists reduce graft beta cell apoptosis in streptozotocin-induced diabetic 
mice receiving islet transplants (C. C. Lin and Anseth 2009; Merani et al. 2008; Toyoda et al. 
2008). GLP-1 receptor agonism has also been reported to reduce both the number of 
required islets and to prolong the duration of insulin independence after islet transplantation 
(Faradji et al. 2008; Froud et al. 2008; Gangemi et al. 2008). Further studies should 
investigate the use of PYY to promote islet survival prior and to augment islet cell mass after 
islet cell transplantation.  
In summary, the experiments presented in this chapter suggest that PYY may play an 
important role in maintenance and viability of adult pancreatic beta cells. PYY, as well as 
other putative hormones/growth factors released from the PYY-expressing cells in the 
pancreas may provide an essential trophic support to keep pancreatic beta cells alive.  
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4 General discussion and future works 
 
Obesity is associated with considerable morbidity, mortality, and socioeconomic costs. 
Understanding the physiology of appetite and energy homeostasis may reveal novel targets 
for the development of safe and effective anti-obesity drugs. The enteroendocrine L cells 
within the gastrointestinal tract release a number of peptide hormones that may play an 
important part in the regulation of energy and glucose homeostasis (Murphy and Bloom 
2006). These anorectic gut hormones present an attractive target for the development of 
new treatments for obesity.  
PYY is secreted from the enteroendocrine L cells in the distal GI tract in response to food 
intake. Exogenous administration of PYY3-36 has been shown to reduce food intake in 
humans (Batterham et al. 2003a). PYY is also expressed in the pancreatic islet cells 
(Upchurch et al. 1994) and may influence stimulated insulin and glucagon release (Bottcher 
et al. 1989). These pharmacological effects of PYY and its distribution in the gastrointestinal 
tract and pancreas suggest that it may be involved in the regulation of energy homeostasis 
and in islet cell function. The aim of this thesis was to investigate the physiological role of the 
PYY-expressing cells in the gut and pancreas.  
4.1 The phenotype of the transgenic DTR-BAC mouse  
I used a transgenic mouse expressing diphtheria toxin receptor (DTR) downstream of the 
PYY promoter. This transgenic mouse had been generated by modifying a bacterial artificial 
chromosome (BAC) containing the PYY gene sequence near the centre of its DNA insert. 
Bacterial Artificial Chromosomes (BAC) are capable of carrying large genomic DNA 
fragments of greater than 300 kilobase pairs (Shizuya et al. 1992). This increases the 
probability that all the regulatory elements necessary for the correct spatial and temporal 
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expression of DTR were present. Indeed, RT-PCR analysis showed that the expression 
profile of the DTR transgene was generally similar to that of PYY. This suggests that the 
modified BAC contains the regulatory elements necessary for accurate and specific 
expression. 
Pyy-knockout mice have disrupted energy homeostasis (Batterham et al. 2006; Boey et al. 
2006). However, the possible occurrence of compensatory adaptive changes makes the 
interpretation of data from embryonic knockout animals difficult. The transgenic approach 
used in my experiments enabled post-embryonic ablation of the L cells, negating the 
problem of developmental compensation.  The analysis of the phenotype resulting from loss 
of PYY after normal development is particularly important as PYY may play a role in 
embryonic GI and CNS development (Gomez et al. 1995; Yuzuriha et al. 2007).  
The presence of the DTR transgene itself did not result in a phenotype with regards to food 
intake and energy homeostasis. Prior to the administration of diphtheria toxin, transgenic 
mice had normal food intake, body weight and gut hormone levels. However, administration 
of a single dose of diphtheria toxin to transgenic mice expressing DTR under the control of 
the PYY promoter resulted in a significant reduction (>90%) of colorectal PYY concentration 
and number of PYY-expressing cells as shown by immunohistochemistry.  
Our data suggests only PYY-expressing enteroendocrine cells were being lost, as no 
change in colorectal substance P or GIP concentrations were seen. Unlike substance P and 
GIP, which are rarely colocalized with PYY in the enteroendocrine L cells, GLP-1, CCK and 
neurotensin have been shown to be co-expressed with PYY in the these cells (Roth et al. 
1992). Accordingly, loss of PYY in DT-treated transgenic DTR-BAC mice was accompanied 
by a significant reduction in colorectal GLP-1, CCK and neurotensin concentrations. 
Interestingly, ablation of PYY-expressing cells was associated with dramatic weight loss and 
wet beddings consistent with polyuria. These observations raised the possibility of diabetes 
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developing following administration of DT. Transgenic mice were indeed severely 
hyperglycaemic from day 4 post-DT injection. The hyperglycaemia observed in the 
transgenic mice was shown to be secondary to a near total loss of pancreatic insulin. As 
expected, DT administration also resulted in a significant loss of pancreatic PYY and 
glucagon in the transgenic DTR-BAC mice. In the adult murine pancreas, PYY 
immunoreactivity has been shown in alpha (glucagon-expressing), delta (somatostatin-
expressing) and PP cells (Jackerott et al. 1996).  
The significant loss of pancreatic insulin induced by DT was surprising as PYY is not 
expressed in adult beta cells (Upchurch et al. 1994). DT has been reported to cause specific 
cell damage with no obvious abnormalities observed in nearby cells or tissues (Saito et al. 
2001). Unlike chemical agents such as streptozotocin, DT has been shown to specifically 
ablate pancreatic beta cells without causing bystander death of adjacent cells (Kaestner 
2007). Non-specific beta cell death secondary to loss of the adjacent PYY-expressing cells is 
therefore an unlikely explanation for the severe diabetes in DT treated transgenic mice.  
4.2 The cause of diabetes associated with ablation of PYY-expressing cells 
I subsequently investigated the reason for the development of diabetes after ablation of 
PYY-expressing cells.  
In order to determine the contribution of a possible trophic effect of the enteroendocrine L 
cells on pancreatic beta cell, I attempted to specifically ablate PYY expressing cells in the 
gut, without affecting pancreatic PYY, by local injection of DT into the terminal ileum or intra-
rectal administration. However, local gastrointestinal administration of DT resulted in a 
significant loss of both colonic PYY and pancreatic PYY. It is possible that the DT reached 
the pancreatic islets via absorption through the intestinal mucosa or following inadvertent 
leakage into the peritoneum via the injection site. Similarly, reduced colonic PYY and 
pancreatic PYY and insulin concentrations were observed after rectal administration of DT. 
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Although this approach eliminates the risk of absorption of DT through leakage into the 
peritoneum, the possibility of DT absorption by colonic mucosal cells persists using this route 
of administration. Another intriguing possibility is the loss of trophic support from the L cells 
necessary for maintaining beta cell viability.  
In fact several gastrointestinal hormones have been shown to influence beta cell mass. Beta 
cell renewal following injury may occur through stimulation of beta cell proliferation, 
increased islet neogenesis or reduced beta cell apoptosis. There is evidence that gut 
peptides such as GLP-1, GIP, gastrin and CCK affect some or all of these processes (Lavine 
and Attie 2010). For example, reduced beta cell regeneration following partial 
pancreatectomy has been reported in GLP-1 receptor knock-out mice (De Leon et al. 2003) 
suggesting that GLP-1 may have a physiological role in the regulation of beta cell mass. It is 
therefore possible that the enteroendocrine L cells release hormones/growth factors that are 
necessary for beta cell maintenance and that their loss is the underlying cause of beta cell 
loss following L cell ablation. However, this could not be proved in these sets of experiments, 
as the possibility of DT reaching the systemic circulation and hence the pancreas could not 
be ruled out. 
Ablation of PYY-expressing cells in cultured pancreatic islets resulted in a significant loss of 
pancreatic insulin. In addition, DT resulted in a significant loss of pancreatic ATP content, 
which is a marker of cell viability. Interestingly, incubation of islets with a low dose of DT 
(50ng/ml), causing an approximately 50% loss of islet PYY content, did not have a significant 
effect on pancreatic insulin. However, larger doses of DT leading to a PYY loss of >60% 
caused significant beta cell loss. This suggests that loss of pancreatic PYY is only 
detrimental to islet survival if levels drop below a certain threshold. These studies suggest 
that ablation of PYY-expressing cells in the pancreas is the major cause of beta cell loss 
seen after ablation of PYY-expressing cells. Further studies measuring markers of apoptosis 
are required to confirm that loss of pancreatic insulin and ATP are due to beta cell death. 
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PYY is co-expressed with PP in most PP cells in the islets. Therefore, ablation of PYY would 
be expected to result in a significant loss of pancreatic PP. Pancreatic PP levels were not 
measured due to lack of a sensitive assay for rodent PP. Future studies using quantitative 
PCR are required to confirm that pancreatic PP levels are reduced following ablation of 
pancreatic PYY. 
GIP and ghrelin are peptide hormones co-expressed with glucagon in alpha cells. Pancreatic 
GIP and ghrelin levels would therefore be expected to be affected by loss of PYY-expressing 
alpha cells in DT-treated transgenic mice. Ghrelin has been reported to promote beta cell 
proliferation and regeneration, and to inhibit beta cell apoptosis (Granata et al. 2010). GIP 
receptor agonism has been shown to reduce beta cell apoptosis in streptozotocin-treated 
mice (Maida et al. 2009; Widenmaier et al. 2010). 
Further in vitro islet experiments are required to assess the effect of replacement of 
glucagon, somatostatin, PP, GLP-1, GIP and ghrelin on beta cell survival following 
incubation of the islet cells with DT.  
As described above, the pattern of DTR expression closely resembled that of PYY. Since 
PYY has not been shown to be expressed in adult beta cells, one would not expect DTR 
expression to be seen in beta cells. This was indeed the case as immunohistochemical 
analysis of serial pancreatic sections showed DTR and PYY to be localized in the periphery 
of the islets within cell populations that did not stain for insulin. The tyramide signal 
amplification technique used in these immunohistochemical analyses greatly enhances the 
sensitivity of detection of very low levels of antigen. No DTR immunoreactivity was observed 
in insulin staining cells, which comprised the core of the islets. 
Beta cell loss is the underlying cause of type 1 diabetes and an important component of the 
pathogenesis of type 2 diabetes mellitus. Identification of the potential products of pancreatic 
and/or gastrointestinal PYY-expressing cells that may be necessary for beta cell 
180 
 
maintenance may provide novel targets for the treatment of diabetes. Interestingly, 
pancreatic insulin content in DT-treated transgenic mice was significantly higher when a 
long-acting PYY analogue or combination of long-acting PYY and GLP-1 analogues were 
administered. This suggests that chronic replacement of PYY, alone or in combination with 
GLP-1, may rescue pancreatic beta cells following ablation of the PYY-expressing cells. 
Further work is required to determine the effects of chronic replacement of pancreatic 
hormones such as glucagon, somatostatin, GIP and ghrelin on beta cells following ablation 
of the PYY-expressing cells. Further studies are also required to investigate the effects of 
chronic replacement of other gut peptides such as CCK and oxyntomodulin, and the effect of 
a combination of these peptides with X-PYY and exendin-4 in DT-treated transgenic DTR-
BAC mice. 
The Y1 receptor has been shown to be expressed in the islets (Cho and Kim 2004). NPY, a 
Y1 receptor agonist, has been shown to promote beta cell replication (Cho and Kim 2004). 
The possible effects of PYY in the pancreas should be explored with the use of specific Y1 
receptor agonists and antagonists and transgenic models with specific loss of the Y1 
receptor in the pancreas. Future studies should also assess the potential beneficial effects of 
PYY on pancreatic islet cells in the context of pancreatic islet transplantation. It is tempting 
to speculate that PYY might improve islet cell harvesting and preservation, increasing the 
success of islet cell transplantation. 
4.3 PYY within the brainstem 
PYY expression has also been reported in the brainstem neurones. PYY-immunoreactive 
cell bodies have been localized exclusively to the gigantocellular reticular nucleus of the 
rostral medulla in the mouse, rat, and monkey (Glavas et al. 2008). PYY-immunoreactive 
fibres from these neurones extend to the nucleus of the solitary tract and the dorsal motor 
nucleus of the vagus (Glavas et al. 2008). These brainstem regions have been implicated in 
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the regulation of food intake. Within the gigantocellular reticular nucleus, orexigenic orexin 
and melanin concentrating hormone (MCH) fibres have been shown to make close 
appositions with PYY cell bodies (Glavas et al. 2008). Peripheral administration of DT most 
likely ablates PYY-expressing neurones in the brainstem as well as in the GI tract and 
pancreas. However, the development of diabetes following systemic administration of DT 
makes it difficult to determine the physiological consequences of the loss of PYY in the 
brainstem. It may be possible to selectively ablate PYY-expressing neurons by local 
stereotactic administration of DT into the brainstem. The transgenic DTR-BAC mice may 
therefore be used to explore the physiological role of PYY-expressing neurons in the 
brainstem. 
In summary, I have investigated the effects of ablation of PYY-expressing cells in adult mice. 
This work has provided insight into a previously unknown function of pancreatic PYY-
expressing cells in maintaining beta cell viability.  This has important implications for 
identifying new treatments for prevention and treatment of beta cell loss in diabetes mellitus. 
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0.01M Citrate buffer 
   Add 2.1g citric acid to distilled water: total volume of 1L. Add NaOH to pH 6. 
 
Dextran coated charcoal: 
Add 2.4g of charcoal and 0.24g of dextran to 100ml of phosphate buffer with 
gelatine, and mix for twenty minutes at 20°C. 
 
DNA loading buffer: 
Mix 3.125ml 80% glycerol, 50µl 0.5M EDTA, and 10mg orange G in 6.075ml 
of autoclaved distilled water. 
 
dNTP mix for PCR and reverse transcription: 
Mix 10μl each of the 100mM dGTP, dCTP, dATP, and dTTP in 60μl of 
autoclaved distilled water and aliquot into 20μl batches. 
 
0.5M ethylenediaminetetra-acetic acid (EDTA): 
Dissolve 186.1g C10H14H2O8Na2.2H2O (EDTA) in 800ml autoclaved distilled 
water and adjust to pH 8.0 with 1M NaOH.  Make up to 1l with water. 
 
0.01M phosphate buffered saline (PBS): 
Dissolve 8.7g NaCl, 0.272g KH2PO4, and 1.41g Na2HPO42H20 in 800ml of 
distilled water. Adjust to pH 7.5 and make up to 1l.  
 
0.01M PBS/0.1% NaN3/ 0.1% BSA: 
 Dissolve 1g NaN3 (sodium azide) and 1g of BSA in 100ml of 0.01M PBS, then 
make up to 1l. 
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PBS/0.05%Tween: 
 Add 250µl Tween 20 to 500ml 0.01M PBS. 
 
Phosphate buffer (RIA buffer): 
48g of Na2HPO4.2H2O, 4.13g KH2PO4, 18.61g EDTA, 2.5g NaN3 were 
dissolved in 5l of distilled water that had been boiled and allowed to cool, the 
pH was measured to confirm it was 7.4 ± 0.1 and the buffer was stored at 
4oC. 
 
Phosphate buffer with gelatin: 
The buffer was produced as above with 12.5g of gelatin dissolved in the 
boiling water then cooled before the addition of the other reagents 
 
20mg/ml proteinase K: 
Dissolve 20mg for every 1ml of autoclaved distilled water and store at -20oC. 
 
50x TAE: 
Dissolve 242g Trizma base in 843ml distilled water. Add 57ml glacial acetic 
acid and 100ml 0.5M EDTA and mix. 
 
0.05M TRIS/HCl buffer 
Dissolve 6.05g Trizma base in 1 L distilled water, Add HCl to pH 7.6 
 
 
 
